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1. Respiratory infections in turkeys 
1.1. Pathogens responsible for respiratory infections  
Viral and bacterial infections of the respiratory tract often affect turkeys during the 
production round, resulting in economic losses due to an increased mortality and feed 
conversion rate, a reduction in growth rate and high medical costs (van Empel and Hafez, 
1999). Besides viral and bacterial causes, respiratory disease in poultry is often a 
multifactorial problem and is frequently triggered by non-infectious factors such as poor 
management or housing conditions (temperature, ventilation, humidity, atmospheric 
ammonia and dust). These environmental factors may facilitate the pathogenic action of the 
pathogen, resulting in clinical symptoms (Glisson, 1998, 2013; Kleven, 1998).  
 
Several avian viruses, including Newcastle disease virus, other avian paramyxoviruses (type 
2, 4 and 6) and aviary influenza, infect the respiratory tract as well as other organs, whereas 
avian metapneumovirus (APV) and infectious laryngotracheitis virus only invade respiratory 
tissues (Villegas, 1998; Warke et al., 2008). APV, which belongs to the genus 
Metapneumovirus, is widely spread in the poultry industry, and is well known as turkey 
rhinotracheitis (Fig. 1) or “swollen head syndrome” in chickens, with swelling of the 
infraorbital sinuses being the most clearly visible symptom. Infection is reported in turkeys 
and chickens of all ages, but the most severe clinical signs are seen in young turkeys, broilers 
and heavy breeders during 
production. Vaccines are used 
to control the disease in 
chickens and turkeys (Villegas, 
1998). The morbidity rate of 
APV is high (up to 100%) and 
the mortality rate depends on 
the age of the birds and the 
presence of concomitant 
infections with other 
Figure 1. Clinical symptoms of avian metapneumovirus in turkey 
poults, with swollen infraorbital sinuses, nasal and ocular 
discharge, which can be mucopurulent in case of bacterial co-
infection. 
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(secondary) agents, such as Escherichia coli, Mycoplasma spp., or Ornithobacterium 
rhinotracheale (Naylor et al., 1992; Hafez, 1998). These co-infections may bring increased 
condemnation.   
 
Next to viruses, many bacterial pathogens are involved in respiratory diseases. Pasteurella 
multocida causes fowl cholera. Although the bacterium induces purulent exudative lesions in 
multiple organ systems, the respiratory pathology is the most important aspect of the 
disease (Glisson, 1998). Infectious coryza is caused by Avibacterium paragallinarum and 
infects the upper respiratory tract of chickens with symptoms of swollen infraorbital sinuses, 
nasal discharge and depression (Glisson, 1998). To prevent fowl cholera and infectious 
coryza, vaccines are available. Bordetellosis (Bordetella avium) is referred to as turkey 
coryza, as the clinical signs are similar to infectious coryza in chickens. However, the disease 
is more severe in turkeys compared to chickens. Young turkeys show sneezing, oculonasal 
discharge, mouth breathing, tracheal collapse and reduced growth. Both vaccination and 
antimicrobial treatment have limited success (Glisson, 1998). E. coli is an ubiquitous 
bacterium in the gastro-intestinal tract of poultry, although it can give rise to secondary 
respiratory infections subsequent to viral or bacterial infections or environmental insult. 
Colibacillosis lesions are present in respiratory tissue, but also in pericardial sac and 
peritoneal cavities. Mycoplasmas cause respiratory disease in avian species. They tend to be 
host-specific, like M. meleagridis only infects turkey and M. gallisepticum may infect many 
species of birds, but these are not known to infect mammalian or other species (Kleven, 
1998). In chickens, Mycoplasmas cause a chronic respiratory disease and in turkeys an 
infectious sinusitis (Chin, 2013; Raviv and Ley, 2013). Many studies proved the interaction 
between Mycoplasmas and other respiratory viruses and bacteria (Naylor et al., 1992; 
Kleven, 1998; Marien, 2007). Also Chlamydia psittaci is associated with respiratory distress in 
turkeys, alone or in combination with other pathogens (Vanrompay et al., 1997; Van Loock 
et al., 2005). Beside E. coli, O. rhinotracheale is another highly prevalent bacterium which 
causes secondary respiratory problems in turkey poults, with a high economic impact due to 
high medical costs, increased mortality and carcass condemnation rates or decreased 
growth and hatchability or drops in egg production. Therefore, this pathogen will be 
described more in detail in the following paragraph. 
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1.2. Ornithobacterium rhinotracheale infection  
1.2.1. Characteristics of Ornithobacterium rhinotracheale 
O. rhinotracheale is a Gram-negative, nonmotile, pleomorphic, rod-shaped, nonsporulating 
bacterium (Chin et al., 2013). It was characterized in 1991 from isolates of turkey, chicken 
and rook out of Europe and South Africa (van Beek et al., 1994; Vandamme et al., 1994). 
Nowadays this bacterium can be found worldwide in different avian species, including 
chicken, duck, falcon, goose, guinea fowl, gull, ostrich, partridge, pheasant, pigeon, quail, 
rook and turkey. Between those different isolates of O. rhinotracheale, pathogenicity 
differences exist (Chin et al., 2013). 
O. rhinotracheale develops pin-point colonies (1-2 mm after 48h of incubation), which are 
grey to grey-white, circular and convex with an entire edge. In vitro, the bacterium grows on 
a common, nonselective blood agar, in air enriched with 5 – 10% CO2 (Chin et al., 2013). To 
date, 18 serotypes of O. rhinotracheale are determined (serotype A to R). Host specificity of 
the serotypes has not been described, but 61% of the isolates in turkeys belong to serotype 
A (Chin et al., 2013). Also small-colony variants of O. rhinotracheale exist. They are 
characterized by low growth rates, an atypical colony morphology (Zahra et al., 2013). 
O. rhinotracheale can spread by horizontal transmission, direct or indirect through aerosol 
and drinking water, and by vertical transmission, in ovo (van Empel and Hafez, 1999, Chin et 
al., 2013). This rapid transmission in combination with the difficulty to eradicate has led to 
an endemic infection of O. rhinotracheale worldwide, especially in countries with intensive 
poultry production (Hafez, 2002; Gornatti Churria et al., 2012). In Belgium, 40 commercial 
layer hen flocks were all positive for O. rhinotracheale and with high titers of the individual 
birds (Vandekerckhove et al., 2004). Also in hobby poultry, the seroprevalence of O. 
rhinotrachele is very high. In a study of Haesendonck et al. (2014), all of 56 tested flocks 
were positive. 
Notwithstanding many studies about O. rhinotracheale infections in poultry have already 
been performed, very little is known about interactions with avian hosts. Tabatabai et al. 
(2010) observed that the majority of the North American field isolates of O. rhinotracheale 
showed β-hemolytic reactions. This haemolytic activity may contribute to the virulence of 
the bacterium. Another virulence factor that is characterised in O. rhinotracheale is 
neuraminidase enzymatic activity. This NanO neuraminidase can liberate sialic acid from 
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Figure 2. Severe lung inflammation, caused 
by Ornithobacterium rhinotrachelae (Hafez, 
2014). 
poultry glycoproteins. But it is not known whether NanO of O. rhinotracheale has a role in 
host tissue colonization or inflammation (Kastelic et al., 2013). A lot of pathogens use iron 
acquisition mechanisms to conquer the host's capacity to limit available iron during the 
infection process. O. rhinotracheale also has this mechanism and this occurs via the iron-
bound protein pathway rather than through the siderophore secretion pathway (Tabatabai 
et al., 2008).  
 
1.2.2. Clinical symptoms  
Clinical signs occur at 2 to 4 days post infection (Van Empel et al., 1996). At this early stage, 
the bacterium is attached to cilia of the epithelium on the respiratory side of the air sacs. 
Later, bacterial cells and cell fragments can be found in macrophages in the airsacs and lungs 
(van Empel and Hafez, 1999). 
The severity, duration and mortality of an O. rhinotracheale infection are variable and 
depend on the strain, co-infection and environmental factors. In turkeys, an age difference 
has been reported, where older turkeys have a higher severity of clinical signs and mortality 
(Roepke et al., 1998). Although, mostly young poults of 2 to 8 weeks of age are infected 
(Chin et al., 2013). Mild symptoms are coughing, 
sneezing and nasal discharge and these can be 
followed by severe respiratory distress, dyspnea 
and sinusitis, resulting in reduction of feed and 
water consumption. Oedema, consolidation of the 
lungs with fibrinous exudates on the pleura (Fig. 
2), airsacculitis, pericarditis, peritonitis and mild 
tracheitis are gross lesions that can be seen (Chin 
et al., 2013). 
 
The bacterium can also distribute to other sites of the body resulting in local pathology, such 
as hepatitis, meningitis and joint-infections (Back et al., 1998; Zbikowski et al., 2013).           
O. rhinotracheale has a preference for the tibio-tarsal joint, resulting in lameness. In the 
field, this is a common problem, sometimes more visible than the respiratory signs. 
Lameness is more observed in male turkeys, due to their higher body weight.  
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1.2.3. Diagnosis and identification 
Diagnosis of an O. rhinotracheale infection based on the clinical signs is difficult as there are 
a lot of agents, viruses and bacteria, resulting in a similar symptomatology. The differential 
diagnosis for O. rhinotracheale are other bacterial pathogens which cause respiratory 
lesions, such as E. coli, P. multocida, A. paragallinarium and C. psittaci (Chin et al., 2013). 
Isolation and identification of the causative pathogen are crucial for a correct diagnosis. 
Trachea, lungs and air sacs are the best tissues in the respiratory tract to isolate O. 
rhinotracheale. But also swabs from the tibio-tarsal joint can be used for bacterial isolation. 
Due to overgrowth of other bacteria, O. rhinotracheale can be masked in samples of the 
infraorbital sinus and nasal cavity. To specify the growth on blood agar, gentamicin and/or 
polymyxin B can be added to the medium to inhibit overgrowth of fast-growing bacteria, 
such as E. coli, Proteus spp., Pseudomonas spp. (Garmyn et al., 2009). For identification of 
the bacterial strains, biochemical tests can be conducted. A combination of the agar gel 
precipitation test and the API-20NE identification strip (bioMérieux, France) is reliable to 
indentify O. rhinotracheale. These API strips give accurate identifications based on extensive 
databases and are standardized, easy-to-use test systems. The biochemical characteristics 
for O. rhinotracheale are: positive for oxidase, urease, β-galactosidase, arginine dehydrolase, 
alkaline phosphatase, esterase lipase, leucine arylamidase, cystine arylamidase, acid 
phosphatase, phosphohydrolase, α-glucosidase, N-acetyl-β-glucosaminidase, and acid 
production from glucose, fructose, lactose and galactose. The bacterium is negative for 
nitrate reduction, catalase, growth on McConkey agar, motility, lysine decarboxylase, indole 
production, gelatinase, esterase, lipase, chymotrypsin, β-glucuronidase, β-glucosidase, α-
mannosidase, α-fucosidase, and acid production from maltose, sucrose, fructose and ribose 
(van Empel and Hafez, 1999). 
Furthermore, serology is very useful for flock monitoring. A drawback with this technique is 
the occurrence of positive samples due to maternal antibodies, which cannot be 
distinguished from antibodies derived from an infection. Commercial ELISAs have been 
developed using different serotypes and antigens of O. rhinotracheale, allowing the 
detection of several serotypes (Chin et al., 2013).  
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Antigen detection, by immunofluorescence antibody testing or immunohistochemical 
staining, or detection of a specific genome sequence by PCR can be conducted for the 
identification of O. rhinotracheale. These procedures are able to identify a higher percentage 
of O. rhinotracheale infected animals compared to serology and bacteriology (Chin et al., 
2013). 
 
Also the resistance of an O. rhinotracheale strain can be determined with the above-
mentioned techniques. Diffusion-based (with disk diffiusion or gradient strips) or dilution- 
based gives a direct result to what extent the pathogen is resistant or susceptible for the 
tested antimicrobials. The occurrence of resistance genes, investigated by PCR, can give 
more information about the resistance mechanism. 
 
1.2.4. Treatment and control 
1.2.4.1. Management and housing conditions 
To control O. rhinotracheale infections in poultry-rearing, a strict biosecurity level is required 
as O. rhinotracheale appears to spread by direct and indirect contact through aerosols and 
drinking water (Chin et al., 2013). Moreover, environmental factors, such as poor 
management, inadequate ventilation, poor hygiene, high flock density, high ammonia level, 
incorrect temperature and relative humidity, can exert the pathogenic action of O. 
rhinotracheale (van Empel and Hafez, 1999). Consequently, optimal environmental 
conditions are necessary. 
 
1.2.4.2. Antimicrobial treatment 
Despite antimicrobials are frequently applied during O. rhinotracheale outbreaks, 
consideration about the choice of the antimicrobial agent is important as a high resistance 
level against a wide range of antimicrobial classes employed to treat O. rhinotracheale has 
been reported (van Veen et al., 2001; Soriano et al., 2003; Zaini et al., 2008). A standard 
procedure for susceptibility testing for O. rhinotracheale has not been established by the 
Clinical Laboratory Standard Institute (CLSI). However, several in vitro studies have been 
performed to investigate the susceptibility or resistance of O. rhinotracheale against many 
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antimicrobials. The used testing methods and criteria for susceptibility and resistance may 
differ among reports. 
All strains were resistant to the aminoside antibiotics neomycin and gentamicin, but if this 
resistance is intrinsic is not known (Ak and Turan, 2001; van Veen et al., 2001; Banani et al., 
2004). For the tetracyclines oxytetracycline and doxycycline and several fluoroquinolones 
(enrofloxacin, danofloxacin, flumequin), the susceptibility was strain dependent (Devriese et 
al., 1995; Ak and Turan, 2001; Devriese et al., 2001; Banini et al., 2004). The susceptibility of 
O. rhinotracheale against amoxicillin decreased (van Veen et al., 2001), whereas there was 
resistance against other β-lactam antibiotics (namely ampicillin, ceftiofur) (Devriese et al., 
2001). Data about the first generation macrolides, like erythromycin and tylosin, show 
resistance against O. rhinotracheale strains (Devriese et al., 1995; Ak and Turan, 2001; van 
Veen et al., 2001; Banini et al., 2004). Accordingly, the sensitivity of O. rhinotracheale to 
above mentioned antimicrobial drugs is very inconsistent and strain-dependent. However, 
more recently introduced antibiotics, such as the newer macrolides, might have higher 
sensitivity to O. rhinotracheale. 
According to the antibiotic guide to promote well-considered usage of antibiotics in poultry, 
published by the Belgian Institute of Antimicrobial Consumption and Resistance in Animals 
(AMCRA), the combination of trimethoprim and sulphonamides is the first choice to treat an 
infection with O. rhinotracheale (AMCRA, 2013). However, several studies confirmed the 
high resistance of O. rhinotracheale, isolated from farm, backyard and wild birds, against 
potentiated sulphonamides (Malik et al., 2003; Soriano et al., 2003; Szabo et al., 2015). Also 
tetracyclins (e.g. doxycycline and chlortetracycline) and amoxicillin can be administered, but 
as already mentioned, high levels of resistance against these antimicrobials have been 
reported too. Within the group of tetracyclines, doxycycline is preferable because of the 
higher oral bioavailability compared to chlortetracycline (AMCRA, 2013). 
 
Only a few studies evaluated the efficacy of antimicrobial drugs administered in an in vivo 
infection model against O. rhinotracheale in turkeys. Marien et al. (2006) concluded that 
continuous drinking water medication with enrofloxacin (10 mg/kg body weight, BW) was 
the most successful drug, followed by florfenicol (FF, 20 mg/kg BW), whereas amoxicillin (20 
mg/kg BW) was ineffective. Other studies investigated the efficacy of different enrofloxacin 
treatment regimens, in which the treatment of 10 mg/kg during 5 days gave the best results 
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(Garmyn et al., 2009a,b). To the author’s knowledge, no other in vivo efficacy studies with O. 
rhinotracheale in turkeys have been performed. 
 
1.2.4.3. Vaccination 
To reduce treatment of infections by antimicrobials, vaccines can be administered to provide 
the host a complete or partial protection. For infections with O. rhintracheale, this is 
probably the best option as infections are endemic and difficult to eradicate, and the 
resistance level against several antimicrobials is high.  
Despite these arguments, there is currently only one commercial vaccine against O. 
rhinotracheale registered in Europe, namely Nobilis OR Inac. This vaccine contains an 
inactivated whole cell suspension of O. rhinotracheale serotype A, strain B3263/91 (EMA, 
2008a). It is used to vaccinate female chickens that are being used for breeding broilers, 
resulting in immunity of the progeny, which is a passive immunization. The vaccination 
scheme is as follows: a first injection (0.25 mL) at the age of 6 to 12 weeks and a second 
injection (2.5 mL) at least six weeks later (at the age of 14-18 weeks). The breeders can 
transfer the immunity to their offspring untill 43 weeks after the last vaccination. However, 
the administration of this vaccine to turkeys is off-label. 
 
A lot of studies has been performed with a wide range of vaccines, such as bacterins, live 
vaccines and subunit recombinant vaccines, with variable results (Churria et al., 2013). 
After immunization with the commercial monovalent vaccine Nobilis OR Inac, the 
performances of the chickens was better, with lower mortality and a higher production 
index (Cauwaerts et al., 2002; Bisschop et al., 2004; De Herdt et al., 2012). The inactivated 
vaccines are mostly serotype specific. Consequently, they are not effective as most 
outbreaks involve a mix of serotypes (van Empel and Hafez, 1999; Salmon and Watts, 2000; 
Schuijffel et al., 2006; Murthy et al., 2007). Therefore, an immunization strategy that 
protects birds from infections with heterologous serotypes is needed. Erganiᶊ et al. (2010) 
prepared a bivalent bacterin with both serotype A and B. They observed an increased weight 
gain, better feed conversion ratio and lower morbidity and mortality of the vaccinated 
turkeys compared to non-vaccinated turkeys. 
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Vaccination with live vaccines of O. rhinotracheale is controversial because of the severity of 
an O. rhinotracheale infection, but is generally of higher quality than vaccination with killed 
whole-cell vaccines. Lopes et al. (2002) developed a live vaccine based on a temperature 
sensitive mutant strain of O. rhinotracheale, which is inactive at a temperature of 41 °C. This 
strain has the ability to colonize and persist in the upper respiratory tract, where it simulates 
the local immunity. As a result, the severity of an infection with O. rhinotracheale minimizes. 
Also the combination of a live vaccine and a bacterin would be efficacious to reduce 
symptoms induced by the live vaccine (van Empel and van den Bosch, 1998).  
A subunit recombinant vaccine with recombinant proteins of a serotype G strain, gives cross-
protection against A, B and G (Schuijffel et al., 2005; 2006).  
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2. Drug administration in poultry 
2.1. Antimicrobial use in poultry 
Antimicrobial agents are of great importance in the poultry industry and they are used 
prophylactic, metaphylactic and therapeutic. A controversial use of antimicrobials in poultry 
is the subtherapeutic use of antimicrobials as growth promoters. This category is banned in 
Europe since 2006 (EU, 2006), but is still permitted in the United States and Canada (such as 
flavophospholipol, virginiamycin). Also prophylactic use of antimicrobials is under discussion 
nowadays (BEUC, 2015). 
 
The preventive or prophylactic administration of antimicrobials takes place prior to the 
appearance of clinical signs of disease. The route of administration of prophylactic drugs 
depends on the age of the bird. The drug can be given in ovo or subcutaneously in 1-day-old 
chicks. For older animals, it can also be administered through the drinking water or feed. In 
contrast, the therapeutic use is intended to cure the birds from clinical disease. These drugs 
are mainly administered via the drinking water, as sick birds may refuse to eat but still drink. 
However, the boundary between prophylaxis and treatment is very narrow, as poultry are 
mainly treated on flock level. Since a house can contain more than 40,000 birds, a disease 
can spread very quickly. As a result, the preferred method to treat is group medication, in 
which all sick individuals and those in contact and at high risk of exposure (the entire flock) 
are treated (metaphylactic treatment) (Vermeulen et al., 2002; Hofacre et al., 2013). In case 
of infection, the veterinarian has to decide whether the birds can be treated with an 
antimicrobial, and, if so, which antimicrobial and by what route of administration (Hofacre, 
2002). The veterinarian has to consider several factors including effectiveness against the 
pathogen, pharmacokinetic/pharmacodynamic (PK/PD) properties of the drug, withdrawal 
times, economics/cost-benefit, animal welfare and impact on the ability to market the final 
product (Hofacre et al., 2013). For the PK/PD properties, it should be mentioned that the 
susceptibility testing is usually performed on only one isolate of the pathogen, whereas 
poultry are often affected by several isolates of the same bacterial species, with a wide 
range of minimum inhibitory concentration (MIC) values. Moreover, these values are not 
uniform worldwide and have geographic variations (Salmon and Watts, 2000). Therefore, an 
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empirical treatment can be started, prior to the results of bacterial culture and susceptibility 
testing. 
The reduction of the emergence of antimicrobial resistance implies a reduction in the 
inappropriate and excessive use and also the selection of the optimal drug, dose and 
duration of treatment (Landoni and Albarellos, 2015). Therefore, PK/PD studies are essential 
to realize this goal.  
 
The AMCRA 2020 vision statement defines the guidelines of the policy relating to the use of 
antibiotics and to antibiotic resistance among animals in Belgium (AMCRA, 2015). The three 
main objectives about the consumption of antimicrobials are 1) a 50% reduction in  
antimicrobial use by 2020, 2) a 75% lower use of the most critical antimicrobials 
(cephalosporins and fluoroquinolones) by 2020 and 3) a 50% reduction in use of feed 
medicated with antibiotics by 2017. Also the poultry industry has to contribute to achieve 
these objectives. 
 
As mentioned above, the preferred route of administration is oral treatment via feed or 
drinking water. Consequently, as little as 1% of the total pharmacotherapy of birds involves 
parental administration, which can be performed subcutaneaously (SC) at the neck or axilla 
and intramuscularly (IM) in the pectoral or leg muscle (Vermeulen et al., 2002). However, 
this method is very time consuming, stressful for the birds (individual handling) and can give 
rise to residues in edible tissues in case of off-label use. Some formulations result in a slow 
release with undesirable absorption patterns and possibly prolonged withdrawal times. 
Furthermore, IM administration can give rise to muscular damage, with economic losses. A 
comparison between oral (flock) and parenteral (individual) administered drugs is given in 
Table 1. 
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Table 1. Comparison between individual or flock treatment (adapted from Vermeulen et al., 2002). 
Parenteral - individual Oral - flock treatment 
Advantages: 
- correct dosage 
- each bird 
- only sick animals 
Advantages: 
- easy to perform 
- no tissue damage 
- better animal welfare 
Disadvantages: 
- time and labour consuming 
- tissue necrosis and residues 
- less animal welfare (stressful) 
Disadvantages: 
- global dosage 
- depends on feed and water intake 
- sick animals not always treated 
 
 
2.2. Medication through drinking water and feed 
As stated before, medication through drinking water and feed is most commonly applied in 
intensively reared poultry. Since an individual bird has a low economic value, parenteral 
administration is practically impossible. Sick birds show a significant reduction in their water 
and feed consumption, but the decline in drinking water uptake is usually less compared to 
feed. 
To calculate the most accurate dose in medicated water or feed, the total body weight of 
birds in a flock should be taken into account. That dose should be included in the volume of 
water or feed the birds are expected to consume each dosing interval (Hofacre et al., 2013).  
 
Drinking water medication offers several advantages but also some disadvantages. The low 
cost organization, the low work load and the ease of administration are very important 
factors for the farmer. An instant therapeutic effect and the possibility of a quick change of 
drug and/or dose have an influence on the birds’ health (Vermeulen et al., 2002). On the 
other hand, a great disadvantage is the variability of drug intake, as a result of the individual 
animal (grade of sickness, pecking order), the individual farmer (unprofessional use or 
preparation of the solution), the drug properties (stability, solubility) and/or the drinking 
water quality (pH, hardness, nitrite and iron concentration, bacterial contamination, see 
Table 2). Medicated solutions should generally be replaced every 24 hours, although for 
some drugs, like β-lactam antimicrobials, this interval is shorter, depending on their stability. 
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A drug formulation needs to be physically and chemically stable over a sufficient period of 
time to allow a homogenous dose administration and consequently an efficient therapy. 
Therefore, an adapted formulation of the active substance is essential for medication 
through drinking water to help to improve solubility and stability of the drug. Beside a 
continuous administration, also a pulsed administration of medicated drinking water can be 
used, this for a limited period between 4 and 12 h, followed by administration of 
unmedicated water (Charleston et al., 1998). Drinking water medication is usually 
administered using a bulk tank, in which the entire volume of the water tank is filled with 
medicated water at the appropriate concentration. Another method is the water 
proportioner, which is a device that meters the drug from a highly concentrated stock 
solution to the drinking water, achieving the correct concentration (Hofacre et al., 2013). 
This concentrated solution may mount up to 100 fold the therapeutic concentration. This 
poses real challenges from a pharmaceutical technical point of view, in order to keep 
optimal solubility and dissolution of the concentrated drug. 
 
Table 2. Standards for water quality for poultry in Belgium (adapted from Dierengezondheidszorg 
Vlaanderen, 2014) and results of water quality in poultry stable of Faculty of Veterinary Medicine. 
Chemical Allowance in Belgium Belplume Faculty of Veterinary 
Medicine 
Physical aspect 
Clear, colour- and 
odorless 
Clear, colour- and 
odorless 
Clear, colour- and 
odorless 
pH 3.5 – 9 4 – 9 ND 
Total hardness - ≤ 20°D 32.2°D 
Nitrite ≤ 1.0 mg/L ≤ 1.0 mg/L < 0.1 mg/L 
Total iron ≤ 2.5 mg/L ≤ 2.5 mg/L < 0.025 mg/L 
Bacteriological Allowance in Belgium Belplume Faculty of Veterinary 
Medicine 
Total plate count 22°C ≤ 1.106 cfu/mL ≤ 1.106 cfu/mL 480 cfu/mL 
Total plate count 37°C - ≤ 1.106 cfu/mL ND 
E.coli ≤ 1000 cfu/mL ≤ 100 cfu/mL < 1 cfu/100 mL 
Intestinal enterococci ≤ 1000 cfu/mL < 1 cfu/100 mL < 1 cfu/ 100 mL 
Allowance in Belgium: according to KB 17 June 2013; Belplume is a quality system within the Belgian broiler 
chain 
- : not specified; ND: not determined 
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Feed medication can be applied as a therapeutic as well as meta- or prophylactic treatment. 
In case of long term therapy of more than 5-7 days, feed medication is recommended since 
the flock begins to recover, resulting in more appetite. A major advantage of feed 
medication is the cost, since feed-grade antimicrobials are mostly less expensive than the 
water soluble alternatives (Hofacre et al., 2013). Medicated feed is manufactured by mixing 
feed with a premix formulation of a drug, resulting in ideally a stable and homogeneously 
distributed active substance. A high risk in the production of medicated feed is cross-
contamination, with contamination of drugs to the next batch of feed. To reduce this cross-
contamination with antimicrobials, mixing the premix at the end of the production process 
or using a fine dosage system during unloading at the farm, is obligatory in Belgium since 
2014 (FAVV, 2013). Turkeys are often fed by pellets, and it is complicated to obtain a 
homogenous and thermostable product between the pellets and a premix. Other 
disadvantages of medicated feed are a limited flexibility in dosing, possibility of segregation 
and separation during transport, cross-contamination at the farm level, not advisable as 
start-up therapy, not very suitable for concentration-dependent antimicrobial products 
(such as aminoglycosides and fluoroquinolones). These properties can give rise to selection 
of antimicrobial resistance. Moreover, the oral bioavailability can be reduced as a result of 
interactions between the veterinary drug and some components of the feed, such as 
mycotoxin binders (Devreese et al., 2012; De Mil et al., 2015). As already reported, the aim is 
to reduce the use of medicated feed with 50% by 2017 (AMCRA, 2015).  
 
 
2.3. Influence of environmental conditions 
Since poultry are intensively reared, good husbandry practices are necessary for the poultry 
industry. To prevent sickness, the house environment is of great importance for animal 
health. Moreover, several environmental factors, such as water quality, photoperiod, 
ambient temperature and type of diet, can influence the treatment regime as they affect the 
water and feed consumption. 
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In general, the drinking water should be clean, cool and neutral in taste. The pH is an 
important parameter. The optimum pH of drinking water should range between 5 and 7. 
With a pH value below 5, the water consumption will decrease and it may lead to parasitic 
infestations (Vermeulen et al., 2002). However, the stability and solubility of certain 
antimicrobials like tetracyclines are optimal in water with a low pH (3-5). Santos et al. (1997) 
observed that the palatability of medicated water containing doxycycline and citric acid was 
good, as the water consumption of turkeys did not change significantly compared to non-
medicated tap water. On the other hand, higher pH values may indicate possible 
contamination with salts (e.g. sodium bicarbonate), resulting in a lower utilization of dietary 
minerals, such as calcium, magnesium, phosphorus and potassium (Vermeulen et al., 2002). 
The combination of different drugs or the co-administration of a disinfecting product can 
result in incompatibilities and precipitation (Esmail, 1996). Also the water temperature is of 
importance as it determines the drug solubility and stability, especially for poor soluble 
drugs (Vermeulen et al., 2002). 
Furthermore, the ambient temperature is related to the water intake. For broilers, the water 
consumption increases with 7% for every 1 °C above 21 °C. However, under extremely hot 
conditions, the water intake decreases as a result of the reduced activity of the birds 
(Vermeulen et al., 2002).  
In addition, the eating and drinking patterns may alter depending on the light scheme 
(Classen et al., 1994), which can have a huge influence on the uptake of medicated drinking 
water. For time-dependent antibiotics, such as FF and gamithromycin (GAM) (Hesje et al., 
2007), it is important to have a frequent drug-intake to obtain a time above the MIC (T>MIC) 
of minimum 40%. Birds exposed to a very short photoperiod (< 6 h light) as well as a 
continuous photoperiod seemed to have a reduced feed intake. The former can be due to a 
too short photoperiod for the higher diurnal rate of feeding to compensate for the reduced 
nocturnal feeding rate. The latter could be due to the absence of the need to store feed for a 
dark period (Lewis et al., 2009). Nowadays, a minimum of 6 h of light is required in poultry-
rearing (Anonymous, 2007). Studies in chickens and turkeys have already related extreme 
photoperiods with a change in feeding cycles (Newberry, 1992; Brown et al., 2008; Lewis et 
al., 2009). Since feeding uptake in birds is strongly connected with water uptake, changes in 
photoperiod can also easily affect the drinking water uptake. 
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Finally, also the composition of the diet affects the water intake. Some protein sources, like 
soybeans, and a high content of fibers are positively correlated with the amount of water 
consumption, whereas a high energy diet requires less water uptake (Esmail, 1996).  
 
In general, the environment might influence the feed and water uptake, and consequently 
also the drug intake, resulting in unexpected plasma concentrations and altered therapeutic 
outcome. 
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3. Principles of pharmacokinetics and pharmacodynamics of 
antimicrobials 
To understand and control the efficacy of drugs in animals, one must know how much drug 
will reach the biophase and when this will occur. Especially for microbial infections, it is of 
great importance to rapidly reach effective concentrations of the antimicrobial drug at the 
site of infection, for an adequate duration (Baggott and Giguère, 2013).  
Pharmacokinetics is a quantitative analysis of how man and animal handle xenobiotics, in 
other words what the body does to the drug (Mahmood, 2005). It includes absorption, 
distribution, metabolism and excretion of a drug in the body (ADME). The PD properties 
refer to the action of the drug in the body, including the therapeutic effects (Andes et al., 
2004). Hence, the PK/PD approach gives an insight into the therapeutic action of 
antimicrobial drugs. 
 
 
3.1. PK/PD indices 
PK/PD-modeling combines two research fields in pharmacology and describes the effect-
time course resulting from the administration of a certain dose of drug (Fig. 3). Furthermore, 
it can be used as a basis to predict the dose, dosing frequency and duration of drug 
administration (Martinez et al., 2013). 
 
 
Figure 3. The relationship between pharmacokinetics (PK) and pharmacodynamics (PD), resulting in 
PK/PD-modelling (adapted from Meibohm and Derendorf, 1997). 
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Figure 4 shows the most widely used PK/PD indices for antimicrobial agents, which rely on 
plasma concentrations as PK parameter and the MIC as PD parameter (Giguère and 
Tessman, 2011). The efficacy of concentration-dependent antimicrobials, such as 
aminoglycosides, fluoroquinolones and metronidazole, is best predicted by correlating the 
maximum plasma concentration to the MIC (Cmax/MIC ratio). β-lactams, macrolides and FF 
are examples of time-dependent antimicrobial agents. The efficacy of these drugs is 
associated with the time, expressed as a percentage of the dosage interval or maximum 24 
h, that the concentration remains above the MIC (T>MIC). For antibiotics which are both 
concentration- and time-dependent, like azalides and tetracyclines, the ratio of the area 
under the curve (AUC) of a 24 h interval to MIC (AUC24h/MIC) best predicts their efficacy 
(Giguère and Tessman, 2011; Mouton et al., 2012). Also for time-dependent drugs with a 
long post antibiotic effect, such as β-lactams and macrolides, AUC/MIC is the most 
appropriate PK/PD index (Munckhof et al., 1997; Martinez et al., 2013). 
 
 
Figure 4. Pharmacokinetic (PK)-pharmacodynamic (PD) indices for antimicrobial drugs, with Cmax, 
maximum plasma concentration; MIC, minimum inhibitory concentration of an antimicrobial; AUC, 
area under the plasma concentration-time curve; T>MIC, time the plasma concentration is above the 
MIC. For concentration-dependent antimicrobials, Cmax/MIC is used to predict the efficacy, while 
T>MIC is associated with time-dependent antimicrobials. For antimicrobials which are both 
concentration-dependent and time-dependent, AUC/MIC is the most appropriate predictor for the 
efficacy. 
 
 
3.2. Clinical breakpoints  
It is generally assumed that effective antimicrobial therapy requires sustained blood or 
tissue concentrations above the MIC (Prescott and Baggott, 1994). Clinical breakpoints, 
established by the CLSI and the European Committee on Antimicrobial Susceptibility Testing 
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(EUCAST), are being compared with the acquired MIC values. These are indicators for the 
development of resistance and bacterial isolates can be categorized as susceptible, 
intermediate or resistant. CLSI and EUCAST define a microorganism as susceptible by a level 
of antimicrobial activity associated with a high likelihood of therapeutic success. A 
susceptible isolate of an infecting microorganism has a high chance to be successfully 
treated with the recommended dosage regimen of an antimicrobial agent. The term 
intermediate implies that an infection by the isolate can be treated at body sites where the 
drug is physiologically concentrated or when a high dosage is used. When an infecting isolate 
cannot be inhibited by typically achieved concentrations of an antimicrobial with normal 
dosage regimens and/or when clinical efficacy has not been reliable in field studies, the 
isolate can be considered as resistant (EUCAST, 2014). This classification can be used by 
clinicians to establish a treatment with an antimicrobial against the corresponding pathogen. 
The CLSI has already published some veterinary breakpoints, but to date, no clinical 
breakpoints for O. rhinotracheale in poultry have been determined yet. 
An important consideration about the clinical outcome is the correlation between MIC, 
exposure and efficacy. The efficacy of an antimicrobial depends on the MIC against the 
pathogen and the exposure of that pathogen in the patient. In addition, the dose and the PK 
properties of a drug determine the exposure of the pathogen to the antimicrobial (Mouton 
et al., 2012). 
 
 
3.3. Cut-off values 
To determine clinical breakpoints, it is important to establish cut-off values. Turnidge et al. 
(2007) proposed that the term “cut-off” is more widely and describe the three types of 
“breakpoints”. On the other hand, the term “breakpoint” should be reserved for the final 
selected value to be applied in the clinical laboratory. In contrast with clinical breakpoints, 
cut-off values are no indicators for the development of resistance. The establishment of the 
clinical breakpoint can be based on three cut-off values, namely the epidemiological, the 
PK/PD and the clinical cut-off values. 
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First, the epidemiological cut-off values (COWT) are determined on the distribution of the 
MIC for an antimicrobial and a bacterium. When a population is clearly separated of the 
wild-type population, it can be categorized as non-wild type. The latter population consists 
of isolates with an acquired resistance mechanism to the drug (EUCAST, 2014). The 
epidemiological cut-off is set at the upper MIC value of the wild type distribution (Fig. 5). 
However, this parameter does not take into account the results of clinical efficacy studies, 
dosage and route of administration of the antimicrobial agent, or PK/PD indices in the 
animal species concerned (Silley, 2012). 
 
 
Figure 5. Epidemiological cut-off value. Results of a MIC determination of an antimicrobial agent “X” 
for several isolates of one bacterial species, with indication of the epidemiological cut-off value 
(adapted from Boyen et al., 2012). 
 
 
Second, PK/PD cut-off values (COPK/PD) are based on the PK/PD indices T>MIC, AUC/MIC or 
Cmax/MIC. Selecting the best suitable PK/PD index is essential to obtain PK/PD cut-offs. Table 
3 gives an overview of several antimicrobial agents and their appropriate PK/PD indices. 
There are absolute PK/PD cut-off values established for Gram-negative bacteria. These are a 
T>MIC of 40-50%, expressed for the dosage interval or a period of 24 h, an AUC/MIC of 125, 
based on a 24 h period in plasma in steady state condition, and a Cmax/MIC between 8 and 
10. For Gram-positive bacteria these cut-off values are determined at 40-50% and 30-50 for 
T>MIC and AUC/MIC, respectively (Hesje et al., 2007; Lees et al., 2008). However, for slowly 
eliminating antimicrobials or when no steady state situation is achieved, these cut-offs have 
no value. Martinez et al. (2013) suggested that the interval for T>MIC of these antibiotics 
may extend 24 h and the AUCinf may be taken into account for plasma PK/PD correlations. 
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Table 3. Classification of antimicrobials according to type of killing action and their PK/PD indices 
(adapted from Lees et al., 2008). 
Action types Chemical groups Drug examples 
Integrated PK/PD 
variables 
correlating with 
bacteriological 
effect 
Concentration-dependent 
killing, usually exerting 
significant post-antibiotic 
effect 
Fluoroquinolones 
 
 
Aminoglycosides 
 
Nitroimidazoles 
Polymixins 
Enrofloxacin, Danofloxacin, 
Marbofloxacin, Difloxacin, 
Ibafloxacin 
Streptomycin, Neomycin, 
Gentamicin, Amikacin, Tobramycin 
Metronidazole 
Colistin 
AUC/MIC;Cmax/MIC 
 
 
Cmax/MIC  
 
AUC/MIC;Cmax/MIC  
AUC/MIC 
Time-dependent killing 
with either no or limited 
post-antibiotic effect 
Penicillins 
 
Cephalosporins 
Macrolides and 
triamilides 
Lincosamides 
Phenicols 
Sulfonamides 
Diaminopyrimidines 
Benzylpenicillin, Cloxacillin, 
Ampicillin, Amoxicillin, Carbenicillin 
Ceftiofur, Cefalexin, Cefapirin 
Aivlosin, Tylosin, Erythromycin, 
Tilmicosin, Tulathromycin 
Clindamycin 
Chloramphenicol, Florfenicol 
Sulfadoxine, Sulfadiazine 
Trimethoprim 
T>MIC 
 
T>MIC 
T>MIC
a 
 
T>MIC 
T>MIC 
T>MIC 
T>MIC 
Co-dependent killing, that 
is killing action dependent 
on both duration of 
exposure and maintained 
drug concentration 
Tetracyclines 
 
Ketolides 
Glycopeptides 
Oxytetracycline, Chlortetracycline, 
Doxycycline 
Azithromycin, Clarithromycin 
Vancomycin 
AUC/MIC 
 
AUC/MIC 
AUC/MIC 
a For some macrolide and triamilide drugs, AUC/MIC best correlates with efficacy; for others no correlations 
have been established. 
 
The afore-mentioned general PK/PD cut-offs are not specific for a particular pathogen-drug 
interaction. Therefore, VetCAST has proposed a step-wise calculation of this parameter. The 
first step to determine COPK/PD is selecting the best suitable PK/PD index (Table 3). The 
second step is the determination of the critical value of the selected PK/PD index. This can 
be done by for example killing curve assay. The last step is the computation of the 
percentage of animals which are able to achieve the critical value of the selected PK/PD 
index, and this for a given animal species and for all possible MIC values. This can be 
executed by Monte Carlo simulations. The result of such simulations is the determination of 
the population distribution of doses that are able to achieve the critical value of the PK/PD 
index in the population taking into account the actual MIC distribution (Mouton et al., 2012; 
Toutain, 2015). 
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Both host and pathogen factors can affect the PK/PD results. In case of a normal immune 
system, an antimicrobial has to assist the animal to cure from the pathogen. Therefore, 
lower in vivo drug concentrations compared to MIC could still achieve recovery. Moreover, 
the site of infection can influence the drug efficacy. The current PK/PD indices are limited to 
plasma concentrations. However, drug concentration at the site of action can be quite 
different compared to plasma concentration, as demonstrated for the newer macrolides and 
quinolones. Therefore, PK results at the site of action, such as tissue homogenates, are more 
clinically relevant (Andes et al., 2004; Barbour et al., 2010; Giguère and Tessman, 2011). In 
contrast, Andes et al. (2004) stated that tissue homogenates may underestimate or 
overestimate the concentration in the interstitial space, because they contain the interstitial, 
intracellular and vascular compartments. Also the PD parameter can be influenced by the 
medium in which it is determined. The value of the MIC can be lower (for macrolides) or 
higher (tetracyclines) when measured in medium with serum, compared to artificial medium 
(Bruyck et al., 2012; Mitchell et al., 2013). 
Furthermore, adapted cut-off values could be considered for some drugs as lung tissue and 
pulmonary epithelial lining fluid (PELF) concentrations of macrolides tend to be higher than 
plasma concentrations. Indeed, low plasma AUC/MIC ratios are still correlated with a good 
efficacy for telithromycin and azithromycin of only 3.38 and 5, respectively (Craig, 2001; 
Lodise et al., 2005; Martinez et al., 2013).  
 
At last, the clinical cut-off values (COCL) reflect the upper limit of the MIC associated with a 
high likelihood of clinical success or the probability to cure. It is based upon the collection of 
isolates obtained during clinical effectiveness studies and there is no set method for 
establishing the COCL (Toutain, 2015).  
 
To establish clinical breakpoints (susceptible, intermediate or resistant) out of these three 
cut-off values, a decision tree can be used (Fig. 6). 
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Figure 6. Decision tree to select a breakpoint from the three cut-off values, with COWT, 
epidemiological cut-off value;  COCL, clinical cut-off value; COPK/PD, PK/PD cut-off value; S, clinical 
breakpoint set as susceptible (adapted from Toutain, 2015). 
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4. Antimicrobial drugs 
Antimicrobial drug resistance is a major concern worldwide. Also in the poultry industry, it is 
of great importance to apply antimicrobial agents prudently, concerning public health and 
food safety  (Agunos et al., 2014). In this respect, fluoroquinolones have already been 
withdrawn for use in poultry in the United States (FDA, 2005; Nelson et al., 2007). Therefore, 
the use of antimicrobials which are not registered in human medicine is preferred. 
Florfenicol and the new generation macrolide GAM are only used in veterinary medicine and 
are used to treat respiratory infections in swine and cattle, suggesting a possible therapeutic 
effect against an O. rhinotracheale infection in turkeys.  
O. rhinotracheale has the ability to invade the respiratory tract of turkey poults. Therefore, 
an antimicrobial drug with a high distribution to lung tissue is preferred. Florfenicol and 
GAM may be of interest, due to their interesting PK characteristics. In order to gain insight 
into the distribution to the respiratory tissue and PK properties of those drugs, the 
concentration should be determined in the target tissues, and not only in plasma. In turkeys, 
there are no PK studies of antimicrobials in respiratory tissue performed. 
 
 
4.1. Florfenicol 
4.1.1. Structure and physicochemical properties 
Florfenicol is a structural analogue of chloramphenicol (CAP). The latter is obtained from the 
bacterium Streptomyces venezuelae. Since CAP has severe adverse effects in humans, the 
most important being bone marrow depression, the administration of the drug is only 
allowed in special cases. In veterinary medicine, the use of CAP is forbidden in food-
producing animals (EU 37/2010). Therefore, two structure analogues have been developed, 
namely thiamphenicol (TAP) and FF. TAP differs from CAP by the replacement of the nitro 
group by a sulfomethyl group. FF lacks the nitro group as well, but has a fluorine atom at the 
3’ carbon position (Fig. 7). This replacement enhances the antibacterial activity, broadens its 
spectrum, as well as enhancing its bioavailability. 
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Figure 7. Chemical structures of chloramphenicol (A), thiamphenicol (B) and florfenicol (C). 
Thiamphenicol and florfenicol have a sulfomethyl group instead of the nitro group (green circle). 
Florfenicol has a fluorine atom at the 3’ carbon position (red circle). 
 
The molecular formula of FF is C12H14Cl2FNO4S, with a molecular mass of 358.21 g/mol. FF 
has a low log P value of -0.12, which corresponds with rather hydrophilic molecules, 
although FF is poorly soluble in aqueous solutions. With a pKa value of 9.03, FF is unionized 
in a pH range from 3 to 9. Due to its lipophilicity and unionized part at physiological pH of 
7.4, FF shows a good tissue penetration (Schwarz et al., 2004). 
 
4.1.2. Mechanism of action and spectrum 
The phenicols inhibit the growth of bacteria by preventing bacterial protein synthesis, in 
particular the process of transpeptidation at the 23S ribosomal RNA in the 50S subunit of 
ribosomes. These drugs bind irreversible to different bases of the peptidyl transferase center 
and prevent protein elongation (Fig. 8) (Dowling, 2013). 
 
Comparable with CAP, FF has a broad spectrum activity with a slightly wider range, including 
Gram-positive and Gram-negative, aerobic and anaerobic bacteria, chlamydiae, 
mycoplasmas and rickettsiae. It Is highly active against bacterial pathogens which are 
involved in respiratory diseases. Approved clinical breakpoints for FF are available for 
pathogens related with swine (SRD) as well as bovine (BRD) respiratory disease, such as 
Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica and 
Mycoplasma hyopneumoniae for SRD and P. multocida, Mannheimia hemolytica, Histophilus 
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somni and M. bovis for BRD. The MIC clinical breakpoints of the above mentioned bacterial 
species for susceptibility to FF are all set at 2 µg/mL (CLSI, 2013). FF is also registered for the 
treatment of pododermatitis in cattle caused by Fusobacterium necrophorum and 
Bacteroides melaninogenicus (Schwarz et al., 2004). Furthermore, FF has been approved in 
Europe as treatment for fish and chickens (EMA, 2002). In turkeys, FF can be applied against 
respiratory infections with O. rhinotracheale (Marien et al., 2007). Also for Mycoplasma 
gallisepticum, the MIC50 of FF was low, 1 and 0.5 µg/mL (Gharaibeh and Al-Rashdan, 2011). 
Enterobacteriaceae are less susceptible, for example the MIC50 and MIC90 against Salmonella 
enterica isolates was 8 and 16 µg/mL, respectively, and the MIC90 for Salmonella Dublin was 
32 µg/mL (Clemente et al., 2013; Dowling, 2013). Salmon and Watts (2000) reported a MIC50 
and MIC90 for FF against E. coli of 4 and 8 µg/mL, respectively. Notwithstanding, Gregova et 
al. (2012) and Kashoma et al. (2014) found a high susceptibility of FF against E. coli and 
Campylobacter spp.  
Because there are no clinical breakpoints of FF for avian pathogens, the above-mentioned 
MIC values have to be critically interpreted. These values depend not only on the pathogen-
drug interaction but also on the used population of strains of the pathogen, and the method 
of determination. Moreover, these values have to be compared with the PK of the 
antimicrobial and the clinical outcome in field studies. 
 
 
Figure 8. Diagram of the mechanism of action of florfenicol, which inhibits the transpeptidation of 
the growing peptide chain, during the bacterial protein synthesis (adapted from Rang et al., 2003). 
This reaction, which occurs between the aminoacyl acceptor (A) site and the peptidyl (P) donor site, 
is catalysed by the enzyme peptidyl transferase. 
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4.1.3. Mechanism of resistance 
Chloramphenicol acetyltransferases (CATs) are responsible for the enzymatic inactivation of 
CAP by acetylation of the hydroxyl groups. This results in preventing the drug to bind to the 
50S ribosomal subunit. Although CATs are responsible for the first and most frequently 
encountered mechanism of resistance for CAP, FF doesn’t have this mechanism due to the 
replacement of the hydroxyl group by a fluorine atom. Consequently, CAP-resistant strains, 
in which resistance is based on the activity of CAT, are still susceptible to FF (Schwarz et al., 
2004; Dowling, 2013). The genes coding for CATs or specific transporters are often present 
on mobile genetic elements, such as plasmids, transposons or gene cassettes (Dowling, 
2013). 
Another mechanism of resistance is the efflux of phenicols by efflux proteins on the bacterial 
cell wall. Both CAP and FF can be exported from the bacterial cell by specific transporters or 
multidrug transporters belonging to the Major Facilitator Superfamily (MFS). Specific 
transporters, which have a narrow substrate spectrum, lead to higher levels of resistance as 
compared to the multidrug transporters. The latter are involved in the efflux of a wide range 
of unrelated substances (Schwarz et al., 2004).  
FloR genes are associated with multiresistance gene clusters and are detected in avian 
pathogenic E. coli  and Salmonella enterica (Keyes et al., 2000; Ahmed et al., 2007; Ahmed et 
al., 2013).  
 
4.1.4. Toxicity and interactions 
The use of CAP has been restricted due to severe adverse effects in humans such as dose-
independent irreversible aplastic anemia and dose-dependent bone marrow suppression 
(Schwarz et al., 2004). Therefore, FF was developed and registered solely for veterinary use. 
The nitro-group, which was considered to be responsible for the bone marrow suppression, 
has been replaced by a sulfomethyl group (Fig. 7). Nevertheless, FF might exert less life-
threatening side effects, such as transient diarrhea, feed refusal, peri-anal inflammation or 
rectal eversion. These symptoms were described in cattle and swine and should resolve 
within a few days of discontinuing treatment (Dowling, 2013). 
Phenicols should not be used concurrent with macrolides as they both bind at the 50S 
ribosomal site and act as competitors. Phenicols have an antagonistic action to 
fluoroquinolones due to the mode of action of the phenicols. The latter inhibit protein 
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synthesis, resulting in a deficiency of production of autolysins, which are necessary for cell 
lysis after fluoroquinolone interference with bacterial DNA. Furthermore, phenicols inhibit 
microsomal enzyme activity, leading to a delayed hepatic biotransformation. Consequently, 
the pharmacological effect of drugs that are dependent on these enzymes for their 
biotransformation, like barbiturates, can be prolonged (Dowling, 2013). Moreover, 
simultaneous administration of FF and inhibitors of P-glycoprotein or cytochrome P450 
enzyme complex (CYP450) 3A may lead to increased AUC values and decreased elimination 
of FF in rabbits (Liu et al., 2012). 
 
4.1.5. Pharmacokinetic properties 
The plasma PK of FF has been described in many animal species, including mammals, birds 
and fish.  Tables 4 and 5 give an overview of the PK parameters in several animal species.  
In general, FF is absorbed very rapidly after both IM and oral (PO) administration. For oral 
administration, it is important to know if the absorption depends on the prandial status of 
the animal. Jiang et al. (2006) found no significant effect of prior feeding on the 
bioavailability of the drug in pigs. In birds, the bioavailability after IM and PO administration 
is generally high (> 75%, El-Banna, 1998; Shen et al., 2003; Switala et al., 2007; Ismail and El-
Kattan, 2009; Koc et al., 2009b). One study demonstrated a lower oral bioavailability of 55% 
in broiler chickens (Afifi and Abo El-Sooud, 1997). This could be attributed to the fed status 
of the chickens or a partial absorption from the gastro-intestinal tract. In Leghorn chickens 
and Taiwan native chickens, the Cmax was much higher and the time to Cmax (tmax) shorter 
compared to the other avian species.  
The plasma protein binding is low, around 20% in chickens as well as in healthy and 
Pasteurella infected ducks (Afifi and Abo El-Sooud, 1997; El-Banna, 1998; Chang et al., 2010). 
Accordingly, FF distributes well among tissues, such as lung, muscle, bile and kidney 
(Dowling, 2013), resulting in a moderate volume of distribution (Vd) in avian species and 
rabbits (≥1 L/kg). However, in sheep, goats and camels the Vd was below 1 L/kg. Liu et al. 
(2003) described a rapid and extensive penetration into the respiratory tract in pigs infected 
with A. pleuropneumoniae. In mammals as well as in avian species, FF concentrates in 
kidney, intestine, lung and bile (Adams et al., 1987; Afifi and Abo El-Sooud, 1997; Chang et 
al., 2010), but no further PK parameters are known. 
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In chickens and Japanese quails the total body clearance (Cl) is similar, around 1.5 L/kg/h, 
while it seems to be higher for pigeons and quails, 3.9 and 5.3 L/kg/h, respectively. On the 
contrary, turkeys have a Cl which is comparable to that of mammals, <0.5 L/kg/h. The half-
life of elimination (t1/2el) in turkeys, broiler chickens, quails and pigeons was comparable 
after either intraveneous (IV), IM or PO administration (range from 1.16 to 3.76 h). The 
elimination of FF was remarkably longer in ducks, Leghorn chickens and Taiwan native 
chickens, with a t1/2el of 7.42, 10.96 and 10.19 h respectively. Also in mammals, there is a 
wide range of t1/2el. In goats, camels and rabbits this value is similar to turkeys and chickens, 
whereas pigs and cattle have much longer t1/2el. A flip-flop phenomenon can occur as the 
commercial injectable formulation of FF is long-acting, leading to a prolonged elimination 
due to the slow absorption from the injection site (IM or SC) (Dowling, 2013). 
Florfenicol amine is the most important metabolite. Since its depletion from the liver is very 
slow, it is used as a marker residue for the determination of maximum residue levels (MRLs) 
(EU 37/2010; Dowling, 2013). Excretion of FF and its metabolites occurs mainly via urine 
(EMA, 1999). 
As described above, and can be seen in Tables 4 and 5, the PK properties vary enormously 
between different mammal and avian species. Also Baert and De Backer (2003) 
demonstrated differences in PK properties of non-steroidal inflammatory drugs between 
avian species. Rivière et al. (1997) performed an interspecies allometric analysis of the PK of 
44 drugs. However, this approach seemed not suitable for CAP. Therefore, it is of great 
importance to study the PK in the species of interest and not to extrapolate from other 
animal species. Furthermore, in case of sickness and fever, enhanced extravascular 
distribution occurs, resulting in reduced circulating plasma concentrations (El-Banna, 1998). 
Consequently, the PK can differ depending on the health status of the animals. 
 
4.1.6. Pharmacodynamic properties 
The main purpose of FF is its antibacterial action against several pathogens which are 
responsible for respiratory tract infections, urinary and gastrointestinal tract infections. FF is 
considered to be mainly a time dependent drug, in which the T>MIC in plasma must be at 
least 40% of a 24 h dosing interval (Hesje et al., 2007).  
An excellent response of FF in BRD and SRD can be attributed to the low resistance of cattle 
and swine pathogens like M. haemolytica, P. multocida, A. pleuropneumoniae, which all have 
General Introduction 
38 
a MIC90 below 1 µg/mL (Shin et al., 2005). T>MIC of FF against M. haemolytica and P. 
multocida was longer than 75 h (Sidhu et al., 2014). After an oral bolus administration of 30 
mg/kg BW FF to chickens, the plasma concentration remained for 11 h above a therapeutic 
concentration of 2 µg/mL (Shen et al., 2003). 
Salmon and Watts (2000) evaluated the sensitivity of several bacterial pathogens for FF. The 
authors observed a MIC50 and MIC90 against E. coli of 4 and 8 µg/mL, respectively. Other 
Gram-negative bacteria showed similar values, except for Pseudomonas spp., which have a 
MIC50 as well as a MIC90 of >64 µg/mL. The MIC90 of Gram-positive organisms, such as 
Staphylococci, Streptococci and Enterococci, was 4 µg/mL. The authors reported also 
geographic differences for several antibiotics, but not for FF. In turkeys, FF administered in 
drinking water at a dose of 20 mg/kg BW was reported a good therapy to cure from an O. 
rhinotracheale infection (Marien et al., 2006). In this study, both the clinical symptoms and 
the bacterial titres were reduced during and after treatment, but no correlation was made 
between PK and PD.  
  
  
 
Table 4. Plasma pharmacokinetic properties of florfenicol in different avian species. 
 ROA Dose 
mg/kg BW 
AUCinf 
µg.h/mL 
t1/2el 
h 
tmax 
h 
Cmax 
µg/mL 
Vd 
L/kg 
Cl 
mL/kg/h 
F 
% 
References 
Broiler chicken IV 
IM 
PO 
IV 
IM 
IV 
IM 
PO 
30 
30 
30 
30 
30 
30 
30 
30 
19.00 
18.33 
10.50 
18.00 
17.84 
29.45 
28.75 
27.59 
2.89 
3.40 
1.78 
3.21 
3.24 
3.02 
2.38 
2.25 
- 
1.67 
1.05 
- 
1.50 
- 
0.73 
1.35 
- 
3.82 
3.20 
- 
4.50 
- 
6.79 
5.82 
6.47 
ND 
ND 
5.33 
ND 
1.15 
ND 
ND 
1.61 
ND 
ND 
1.63 
ND 
1.02 
ND 
ND 
- 
97 
55 
- 
99 
- 
98 
94 
Afifi and Abo El-Sooud, 1997 
Afifi and Abo El-Sooud, 1997 
Afifi and Abo El-Sooud, 1997 
Ismail and El-Kattan, 2009 
Ismail and El-Kattan, 2009 
Shen et al., 2003 
Shen et al., 2003 
Shen et al., 2003 
Leghorn 
chicken 
PO 30 38.49 10.96 0.53 9.42 ND ND ND Chang et al., 2010 
Taiwan native 
chicken 
PO 30 26.07 10.19 0.30 10.42 ND ND ND Chang et al., 2010 
Duck IV 
IM 
30 
30 
- 
- 
7.17 
7.42 
- 
1.15 
- 
2.99 
5.15 
ND 
0.61 
ND 
- 
77 
El-Banna, 1998 
El-Banna, 1998 
Pigeon IV 
IM 
30 
30 
7.54 
7.55 
1.82 
2.00 
- 
1.50 
- 
2.90 
5.76 
ND 
3.88 
ND 
- 
100 
Ismail and El-Kattan, 2009 
Ismail and El-Kattan, 2009 
Quail IV 
IM 
30 
30 
5.00 
4.91 
1.24 
1.16 
- 
1.50 
- 
2.10 
4.70 
ND 
5.30 
ND 
- 
97 
Ismail and El-Kattan, 2009 
Ismail and El-Kattan, 2009 
Japanese quail IV 
IM 
30 
30 
23.00 
12.30 
ND 
ND 
- 
ND 
- 
ND 
8.70 
ND 
1.30 
ND 
- 
79 
Koc et al., 2009b 
Koc et al., 2009b 
Turkey IV 
PO 
30 
30 
97.06 
77.62 
2.34 
3.76 
- 
2.00 
- 
12.25 
1.06 
ND 
0.32 
ND 
- 
82 
Switala et al., 2007 
Switala et al., 2007 
ROA, route of administration; AUCinf, area under the plasma concentration-time curve from time 0 to infinity; t1/2el , half-life of elimination; tmax, time to maximum plasma 
concentration; Cmax,  maximum plasma concentration; Vd, volume of distribution; Cl, total body clearance; F, absolute bioavailability. 
IV, intravenous; IM, intramuscular; SC, subcutaneous; PO, per oral; ND, not determined; -, not possible to determine due to the ROA 
  
 
Table 5. Plasma pharmacokinetic properties of florfenicol in different mammal species. 
 ROA Dose 
mg/kg BW 
AUCinf 
µg.h/mL 
t1/2el 
h 
tmax 
h 
Cmax 
µg/mL 
Vd 
L/kg 
Cl 
mL/kg/h 
F 
% 
References 
Camel IV 
IM 
20 
20 
60.61 
41.93 
1.44 
2.52 
- 
1.51 
- 
0.84 
0.89 
ND 
0.33 
ND 
- 
69 
Ali et al., 2003 
Ali et al., 2003 
Cattle SC 40 175.10 27.54 2.96 6.04 ND 0.23* ND Sidhu et al., 2014 
Goat IV 
IM 
20 
20 
74.07 
58.73 
1.19 
2.12 
- 
1.13 
- 
1.21 
0.57 
ND 
0.27 
ND 
- 
61 
Ali et al., 2003 
Ali et al., 2003 
Pig IV 
IM 
PO 
20 
20 
20 
90.10 
84.30 
132.10 
6.70 
17.20 
10.00 
- 
1.00 
1.50 
- 
3.50 
9.90 
1.50 
ND 
ND 
0.23 
ND 
ND 
- 
97 
149 
Jiang et al., 2006 
Jiang et al., 2006 
Jiang et al., 2006 
Rabbit IV 
IM 
25 
25 
44.59 
39.10 
1.21 
1.49 
- 
1.56 
- 
8.65 
0.98 
ND 
0.56 
ND 
- 
89 
Koc et al., 2009a 
Koc et al., 2009a 
Sheep IV 
IM 
IV 
IM 
30 
30 
20 
20 
119.21 
101.95 
62.45 
49.56 
18.71 
9.57 
1.31 
2.28 
- 
1.34 
- 
1.44 
- 
7.01 
- 
1.04 
1.86 
ND 
0.69 
ND 
0.25 
ND 
0.30 
ND 
- 
86 
- 
66 
Shen et al., 2004 
Shen et al., 2004 
Ali et al., 2003 
Ali et al., 2003 
ROA, route of administration; AUCinf, area under the plasma concentration-time curve from time 0 to infinity; t1/2el , half-life of elimination; tmax, time to maximum plasma 
concentration; Cmax,  maximum plasma concentration; Vd, volume of distribution; Cl, total body clearance; F, absolute bioavailability. 
IV, intravenous; IM, intramuscular; SC, subcutaneous; PO, per oral; ND, not determined; -, not possible to determine due to the ROA 
* Cl/F, clearance scaled by bioavailability
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Macrolides 
13-C 
Semisynthetic 
Tulathromycin 
(10%) 
14-C 
Natural 
Erythromycin 
Oleandomycin 
Semisynthetic 
Clarithromycin 
Roxithromycin 
Dirithromycin 
Fluorithromycin 
15-C 
Semisynthetic 
Azithromycin 
Gamithromycin 
Tulathromycin 
(90%) 
16-C 
Natural 
Spiramycin 
Tylosin   
Josamycin 
Midecamycin  
Semisynthetic 
Tilmicosin 
Tildipirosin 
Tylvalosin 
Miokamycin 
Rokitamycin 
4.2. Gamithromycin 
4.2.1. Structure and physicochemical properties 
Gamithromycin is an antimicrobial agent belonging to the group of macrolides. These 
antibiotics have three common structural characteristics, a large lactone ring (macro 
meaning large, olide meaning lactone), a ketone group and a glycosidically linked amino 
sugar (Fig. 10) (Martin, 1998; Giguère, 2013). According to the number of atoms in the 
lactone ring, the macrolides are classified in a 12- (which is no longer used in clinical 
practice), 13-, 14-, 15- and 16-membered subgroup (Fig. 9).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Classification of macrolide antimicrobial agents, according to their nature (natural or 
semisynthetic) and to the size of the lactone ring (adapted from Giguère, 2013). 
 
Most of the macrolides are produced by Streptomyces spp., with erythromycin (Fig. 10) as 
the prominent molecule, originating from the organism Streptomyces erythreus. However, 
the use of these natural compounds is limited because of their instability in gastric acid and, 
consequently, poor oral bioavailability. Therefore, semisynthetic derivates have been 
developed through esterification, salt formation or structural modification (Kirst, 1991; 
Papich and Rivière, 2009).  
The macrolides are weak bases with a dimethylamine group, which results in a pKa that 
varies between 6 and 9 (Babić et al., 2007; Papich and Rivière, 2009; Beale, 2011). Older 
macrolides contain just one functional group with associated pKa value, such as 8.88 and 
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7.73 for erythromycin and tylosin, respectively (McFarland et al., 1997). On the other hand, 
the new generation macrolides, such as azithromycin, tilmicosin and tulathromycin, can be 
di-basic or even tri-basic (McFarland et al., 1997; Douthwaite et al., 2011; Reeves, 2012). 
GAM is a 15-membered erythromycin derivate, with a uniquely positioned alkylated nitrogen 
at the 7a carbon of the lactone ring, which is typical for azalides (Fig. 10). This structure 
appears to prevent the gastric degradation, increases the antibacterial activity, improves 
tissue penetration and prolongs t1/2 el (Peters et al., 1992; Piscitelli et al., 1992). 
 
                     
Figure 10. Chemical structures of (A) erythromycin, a 14-membered lactone ring with 2 sugars, 
clandinose and desosamine, and (B) gamithromycin, a 15-membered lactone ring with the same 
sugars as erythromycin and additional an alkylated nitrogen at the 7a carbon of the lactone ring. The 
red circle indicates the groups responsible for the pKa values: 8.88 for erythromycin, 8.88 and 9.78 
for gamithromycin. 
 
The molecular formula of GAM is C40H76N2O12, with a molecular mass of 777.04 g/mol. A log 
P value of 4.69 indicates that GAM is lipophilic and according to the law of Fick, results in a 
rapid diffusion through cell membranes.  GAM is a dibasic molecule, with two pKa values, 
8.88 and 9.78. The pKa1 is situated on the basic dimethylamine group, which is the same for 
all macrolides (Babić et al., 2007). The alkylated nitrogen, which is specific for GAM, results 
in a pKa2. In contrast with the neutral form, the ionized form is more water soluble. GAM is 
completely ionized at pH <7, resulting in ion trapping in macrophages (pH 4.8), where 
macrolides preferentially concentrate. 
 
A B 
General Introduction 
43 
4.2.2. Mechanism of action and spectrum 
Macrolides have the same mode of action as FF. These compounds bind irreversible to a 
receptor site on the 50S subunit of the bacterial ribosome, inhibiting the translocation 
process. Subsequently, they prevent the amino acid transfer to the growing peptide chain 
and thus inhibit protein formation (Fig. 11) (Cobos-Trigueros et al., 2009). 
 
 
Figure 11. Diagram of the mechanism of action of GAM, which inhibits the translocation from the 
aminoacyl acceptor (A) site and the peptidyl (P) donor site, during the bacterial protein synthesis 
(adapted from Rang et al., 2003). 
 
In general, macrolides act bacteriostatic, but at higher doses they can also be bactericidal. It 
is known that the 14- and 15-membered macrolides have a time-dependent action 
(Tamaoki, 2004). 
The spectrum of activity of the macrolides is mainly against Gram-positive micro-organisms 
and also against many intracellular bacteria. For humans, clinical indications of macrolides 
include Mycoplasma pneumoniae, infections of the respiratoy tract, skin and soft tissues 
with Steptococcus spp. and Staphylococcus spp., diphtheria, gastroenteritis caused by 
Campylobacter jejuni and urethritis/cervicitis caused by Chlamydophila trachomatis, 
Neisseria gonorrhoeae or Uroplasma urelyticum (Anadon and Reeve-Johnson, 1999). In 
veterinary medicine, these drugs are used to treat pneumonia and mastitis. In particular, the 
azalides have a similar spectrum to that observed for erythromycin, but with some 
differences. Azithromycin is less active against Gram-positive bacteria, although it has more 
potency against Gram-negative bacteria (Beale, 2011). Also GAM has activity against both 
A P 
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Gram-positive and -negative bacteria, such as M. haemolytica, P. multocida, H. somni, M. 
bovis, M. mycoides subspecies mycoides, Streptococcus equi subspecies zooepidemicus, 
Rhodococcus equi, Bacteroides melaninogenicus, Treponema spp. and Dichelobacter nodosus 
(Bagott et al., 2011; Forbes et al., 2011; Sargison and Scott, 2011; Evans et al., 2012; Giguère, 
2013; Mitchell et al., 2013, Forbes et al., 2014; Strobel et al., 2014; Hildebrand et al., 2015). 
At this time, GAM is only registered to treat BRD, but is used off-label against other bacterial 
infections in sheep and foal (Sargison and Scott, 2011; Hildebrand et al., 2015). Just recently, 
the manufacturer has intentions to register the product for treatment of SRD and MRLs have 
been established for porcine species (EMA, 2015). 
 
4.2.3. Mechanism of resistance 
Resistance against macrolides can occur through different mechanisms. The first mechanism 
is the ribosomal target modification due to rRNA methylation. This methylation, most often 
at the 23S rRNA changes the conformation of the ribosome, preventing the antimicrobial 
from binding to the bacterial ribosome (Zhanel et al., 2001). Ribosomal methylation results 
in a high level of resistance and is, in addition, responsible for cross-resistance between the 
macrolides, lincosamides and streptogramin, the so-called MLS resistance (Zhanel et al., 
2001). The mechanism of ribosomal target modification is encoded by the erythromycin-
resistant methylase (erm) genes. These genes are widely distributed in Gram-positive as well 
as Gram-negative bacteria and can be located on plasmids or transposons (Giguère, 2013). 
The expression of the erm genes can be inducible or constitutive. The constitutive form, 
when erm mRNA is always active, is related to the MLS resistance. On the other hand, the 
inducible erm genes are synthesized in an inactive form and become active in the presence 
of inducing macrolides. The latter are 14- and 15-membered macrolides, while lincosamides 
and 16-membered macrolides are weaker inducers of resistance (Zhanel et al., 2001; 
Giguère, 2013).  
Secondly, the presence of efflux pumps in the cell or cell membrane results in macrolide 
resistance. There is a wide range of efflux genes (mef genes), whereby some only interfere 
with 14- and 15-members, whereas other genes lead to MLS resistance (Giguère, 2013). 
These efflux pumps have a role in the acquired resistance, as in some Gram-positive 
bacteria, as well as in the natural resistance of Gram-negative bacteria such as 
Enterobacteriaceae (Zhanel et al., 2001; Bozdogan and Appelbaum, 2004).  
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A less common mechanism of resistance is caused by enzymatic inactivation. The 
inactivating enzymes are esterases and phosphorylases (Giguère, 2013). 
Mutation in ribosomal proteins is also a rare cause of macrolide resistance. These mutations 
appear in the 23S rRNA and/or ribosomal protein genes (Zhanel et al., 2001; Giguère, 2013). 
Moreover, a macrolide efflux pump and a macrolide-inactivating phosphotransferase are 
involved in GAM resistance for several isolates of M. haemolytica and P. multocida (Michael 
et al., 2012; Rose et al., 2012; Olsen et al., 2015).  
 
4.2.4. Toxicity and interactions 
Macrolides have in general low adverse effects in man and animal species. An important side 
effect for all macrolides is their irritating nature (irritation can be pharmacological in nature 
or can be due to the poor solubility of macrolides), which leads to pain at the site of injection 
(IM, SC), thrombophlebitis and periphlebitis (IV) and inflammation after intramammary 
administration (Giguère, 2013, Wyns et al., 2015). Erythromycin has dose-related 
gastrointestinal inconveniences in most animal species, such as nausea, vomiting, diarrhea 
and intestinal pain. Besides the disruption of the intestinal microbiota, erythromycin binds to 
motilin receptors resulting in stimulatory effects on smooth muscle. The newer macrolides, 
like GAM have no serious adverse events, only those mainly associated with the injection, 
such as pain, swelling and redness (Giguère, 2013; Wyns et al., 2014). 
 
Many macrolides inhibit CYP450 isoenzymes in liver microsomes and enterocytes, especially 
CYP3A4/5. Hence, macrolides in combination with drugs which depend on CYP450 mediated 
biotransformation result in an increased concentration of these drugs. For example, 
ionophoric antibiotics, which have a CYP450 dependent biotransformation, in combination 
with macrolides (except tylosin, tilmicosin, azithromycin, spiramycin, josamycin and 
midecamycin) can cause anorexia, depression and myopathy of cardiac and skeletal muscles 
(Anadon and Reeve-Johnson, 1999). The combination with the ionophoric coccidiostat 
lasalocid is more safe (Lodge et al., 1988; Islam et al., 2009). Some macrolides (erythromycin, 
clarithromycin, but not azithromycin) are inhibitors of the intestinal P-glycoprotein 
(multidrug resistance protein, MDR1), resulting in interactions at the intestinal absorption 
level. In humans, a prolongation of the QT interval with risk of cardiac arrhythmias has been 
described when co-administrating macrolides with quinolones (Cascorbi, 2012). 
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4.2.5. Pharmacokinetic properties 
The oral bioavailability of macrolides is low to moderate (30 – 50%). However, salt- or ester-
forms show an enhanced oral absorption up to 80% (Zhanel et al., 2001). Despite this 
incomplete absorption, the low concentration should guarantee a good efficacy of the drug 
in target tissue (Kowalski et al., 2002). Due to their lipophilic nature, macrolides distribute 
very well into different tissues, such as the lung, liver, kidney, spleen and the reproductive 
tract (Anadon and Reeve-Johnson, 1999). Consequently, these PK properties correspond 
with a two-compartment model and drug plasma concentrations are consistently lower than 
at the site of action.  The t1/2el varies among different macrolides. For instance, in chickens 
the t1/2el of erythromycin and tylosin after PO administration is short (4.1 h and 2.07 h, 
respectively) compared to tilmicosin (45 h) (Kowalski et al., 2002; Goudah et al., 2004; Abu-
Basha et al., 2007). 
 
Only a few studies reported PK properties of GAM in plasma, lung tissue and PELF of 
different animal species (Table 6). GAM is fully and rapidly absorbed into the systemic 
circulation after SC or IM administration, with a Cmax that shows discrepancy between 
species. After the administration of the same dose, foals and pigs have much lower plasma 
concentrations compared to cattle and chickens. In cattle as well as in pigs and chickens, a 
complete bioavailability was demonstrated after SC administration. The plasma Cl varies 
among species, with increasing Cl from cattle towards pigs and chicken (Table 6). As stated 
above, smaller species will eliminate drugs more rapidly compared to large animals. While 
the Vd remains constant, this results in a decreased t1/2el (Huang et al., 2010; Berghaus et al., 
2011; Watteyn et al., 2013a; Wyns et al., 2014). The low plasma protein binding, namely 
26.0%, 23.1%, 21.8% and 21.5% in cattle, swine, rat and dog plasma, respectively, is also 
responsible for the very high Vd (> 20 L/kg) (EMA, 2008b). As already mentioned in general, 
plasma is not the most accurate matrix to predict the in vivo efficacy of macrolides. 
Therefore, studies of the PK of GAM in the target tissue are even more important. In 
comparison with plasma, the concentrations in lung tissue and PELF are much higher, due to 
the accumulation of GAM in the respiratory tract. These high concentrations, combined with 
the slow elimination of the drug from the target site results in sustained drug concentrations 
for days following a single injection (Berghaus et al., 2011; Giguère et al., 2011). 
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GAM is mainly metabolized in the liver, with declad (loss of a cladinose) and M2 (N-
dealkylated-declad) as the major residues. The biotransformation of GAM was studied in rats 
and dogs and was found to be similar in those species (EMA, 2008b). GAM and its 
metabolites were found to be primarily eliminated in the faeces and secondarily in urine, 
around 50% and 15%, respectively (EMA, 2008b). 
 
4.2.6. Pharmacodynamic properties 
Since macrolides are classified as time-dependent antimicrobial agents with significant post-
antibiotic effect, the efficacy of these antibiotics is generally accepted to correlate with both 
T>MIC and AUClast/MIC (Van Bambeke and Tulkens, 2001; Andes et al., 2004; Hesje et al., 
2007; Barbour et al., 2010; Giguère and Tessman, 2011). The MIC90 values for M. 
haemolytica, P. multocida and H. somni are 0.5 µg/mL, 1 µg/mL and 1 µg/mL, respectively 
(EMA, 2008b). These in vitro results have been confirmed in in vivo studies in cattle suffering 
from BRD (Baggott et al., 2011; Torres et al., 2013). Berghaus et al. (2011) evaluated the 
efficacy of GAM against pneumonia in foals, and established its high activity (MIC90 0.125 
µg/mL and 1.0 µg/mL for S. zooepidemicus and R. equi, respectively). Also in vivo, GAM 
demonstrated good efficacy in the treatment of foals with bronchopneumonia (Hildebrand 
et al., 2015). In sheep, GAM has been evaluated to control footrot, infected with D. nodosus, 
resulting in good clinical cure rates (Forbes et al., 2014; Strobel et al., 2014). Furthermore, in 
pigs GAM has a low MIC for M. hyopneumoniae (0.25 µg/mL), whereas the MIC for A. 
pleuropneumoniae is higher (2 µg/mL) (Wyns et al., 2014). To the author’s knowledge, no 
data from in vivo infection studies in pigs are available yet. At present, also PD studies of 
GAM in poultry are lacking. 
Besides the antimicrobial activities, several reports suggest that macrolides have 
immunomodulatory properties as well (Kanoh and Rubin, 2010). This immunopharmacology 
can be described as the influence on the immune system by modifying the endogenous 
immune responses to the benefit of the host in the treatment of diseases (Hadden and 
Kishimoto, 1993). Kovaleva et al. (2012) showed that macrolides can temper the 
inflammatory response at different levels (cytokines, inflammatory cells and structural cells). 
They considered several in vitro and in vivo studies with different macrolide antibiotics and 
pathogens. Notwithstanding, no inhibiting effect of GAM on prostaglandin E2 (PGE2), tumor 
necrosis factor α (TNF-α) and interleukin 6 (IL-6) could be noticed in pigs and calves in a 
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lipopolysaccharide (LPS) inflammation model (Wyns et al., 2015b; Plessers et al., 2015a). 
Also induction of neutrophil apoptosis could be induced by macrolides (Chin et al., 1998; Lee 
et al., 2004; Fisher et al., 2011). The pro-apoptotic effects of tulathromycin are caspase-3 
dependent and would alter in function of concentration of the antimicrobial and time of 
exposure (Fischer et al., 2011). To the authors’ knowledge, no studies about the 
immunomodulatory properties of macrolides in poultry have been reported. 
Another PD property of macrolides is the ability to stimulate the gastro-duodenal activity 
(Giguère, 2013). This pro-kinetic action is based on the activation of the motilin receptor and 
this at a dose which is lower than the antimicrobial dose (Peeters et al., 1989). No research 
has been performed yet to confirm the pro-kinetic assets of GAM. 
 
  
  
 
Table 6. Pharmacokinetic properties of gamithromycin in plasma, lung tissue and pulmonary epithelial lining fluid (PELF) in different animal species. 
 ROA Dose 
mg/kg BW 
AUCinf 
µg.h/mL 
t1/2el 
h 
tmax 
h 
Cmax 
µg/mL 
Vd 
L/kg 
Cl 
mL/kg/h 
F 
% 
References 
PLASMA           
Cattle 
IV 
SC 
3  
6 
4.28 
9.42 
44.90 
50.80 
- 
1.00 
- 
0.75 
24.90 
ND 
0.71 
ND 
- 
110 
Huang et al., 
2010 
Chicken 
IV 
SC 
6 
6 
4.00 
4.09 
14.12 
11.63 
- 
0.13 
- 
0.89 
20.89 
ND 
1.77 
ND 
- 
102 
Watteyn et al., 
2013a 
Foal IM 6 3.96 39.10 1.00 0.33 ND ND ND 
Berghaus et al., 
2011 
Pig 
IV 
SC 
6 
6 
3.67 
4.31 
16.03 
18.76 
- 
0.63 
- 
0.41 
31.03 
ND 
1.69 
ND 
- 
118 
Wyns et al., 2014 
LUNG           
Cattle SC 6 2235.00 93.00 12.00 27.80 - - - 
Giguère et al., 
2011 
PELF           
Cattle SC 6 348.00 50.60 24.00 4.61 - - - 
Giguère et al., 
2011 
Foal IM 6 117.00 63.60 24.00 2.15 - - - 
Berghaus et al., 
2011 
ROA, route of administration; AUCinf, area under the plasma concentration-time curve from time 0 to infinity; t1/2el , half-life of elimination; tmax, time to maximum plasma 
concentration; Cmax,  maximum plasma concentration; Vd, volume of distribution; Cl, total body clearance; F, absolute bioavailability. 
IV, intravenous; IM, intramuscular; SC, subcutaneous; ND, not determined; -, not possible to determine due to the ROA or the matrix (lung or PELF) 
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Ornithobacterium rhinotracheale is a common avian respiratory pathogen and often affects 
turkeys during the production round, resulting in significant economic losses. Antimicrobial 
therapy can be applied in the course of outbreaks, but a careful evaluation has to be made 
on the choice of antimicrobial agent with respect to antimicrobial resistance and clinically 
efficacy.  
Florfenicol (FF) has been registered to administer in drinking water for many animal species 
to treat respiratory infections. Besides, gamithromycin (GAM), a newer macrolide, is also 
used for treatment of respiratory infections and has remarkable pharmacokinetic and 
pharmacodynamic (PK/PD) properties, such as a high distribution to tissue and a prolonged 
action after a single bolus administration. Both antimicrobials are registered for veterinary 
species, but not for turkeys. Since a proper therapeutic effect relies on the understanding of 
the PK as well as the PD, it is important to obtain these data in the species of interest. 
Moreover, it is known that FF and GAM have a high distribution to the respiratory tract in 
several species. But to what extent the concentrations in the lungs and the pulmonary 
epithelial lining fluid (PELF) differ from those in plasma is still unknown in turkeys. 
Although parenteral administration is sometimes used, oral drinking water medication is the 
most commonly used route of drug administration in intensively reared poultry. Drug intake 
between animals can vary due to both animal factors and environmental factors. Hence, 
gaining an insight into the importance of these factors is mandatory for the establishment of 
an efficient treatment protocol.   
Therefore, the GENERAL AIM of this doctoral thesis was to evaluate the efficacy of FF and GAM, 
which are currently not used in poultry, against an O. rhinotracheale infection in turkeys, 
based on a PK/PD approach.  
 
To establish the general aim, following SPECIFIC AIMS were formulated: 
1. To study the pharmacokinetic properties of FF in plasma and respiratory tissue in 
turkeys, and to relate these with pharmacodynamic characteristics, with respect to 
different photoperiods and feeding schemes.  
2. To investigate the pharmacokinetic properties of the macrolide GAM in plasma and 
respiratory tissue in turkeys, and to relate these with pharmacodynamic 
characteristics.  
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3. To determine the efficacy of FF to treat turkeys infected with O. rhinotracheale by 
means of drinking water medication. Furthermore, to determine the influence of 
housing conditions, especially photoperiod, on the water intake, and hence to the 
efficacy of the drug. 
4. To evaluate the efficacy of a single bolus administration, either subcutaneous or 
oral, of GAM as a treatment of O. rhinotracheale infection.  
 
Experimental Studies 
55 
 
 
 
 
 
EXPERIMENTAL STUDIES 
  
  
 
  
Experimental Studies – Chapter 1 
57 
 
 
 
 
 
 
 
Chapter 1 
Pharmacokinetics and pharmacodynamics of selected 
antimicrobials in turkeys 
  
  
Experimental Studies – Chapter 1.1 
59 
 
 
 
 
 
 
 
 
 
Chapter 1.1 
Pharmacokinetics and pharmacodynamics of florfenicol in plasma, 
lung tissue and pulmonary epithelial lining fluid in turkeys  
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from:  
Watteyn A.*, Russo E.*, Garmyn A., De Baere S., Pasmans F., Martel A., Haesebrouck F., Montesissa C., De 
Backer P. and Croubels S. (2013). Clinical efficacy of florfenicol administered in the drinking water against 
Ornithobacterium rhinotracheale in turkeys housed at different environmental conditions: a PK/PD 
approach. Avian Pathology, 42(5), 474-481. *Shared first authorship 
 
Watteyn A., Devreese M., De Baere S., De Backer P. and Croubels S. Pharmacokinetics of florfenicol in 
turkey plasma, lung tissue and pulmonary epithelial lining fluid after continuous or single bolus 
administration. In preparation. 
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Abstract 
Florfenicol (FF) is registered as a treatment for bovine and swine respiratory diseases. Also 
turkeys often suffer from respiratory tract infections, although there is no registered 
formulation based on FF for poultry on the market in Europe. The aim of this study was to 
evaluate whether FF might be suited for treatment of Ornithobacterium rhinotracheale 
infections in turkeys. First, the minimum inhibitory concentration (MIC) of FF against 38 
isolates of the respiratory pathogen O. rhinotracheale was determined. Both the MIC50 and 
MIC90 were set at 1 µg/mL. 
As FF has to be effective at the respiratory tract, data about the antimicrobial concentrations 
at the target site are needed. Therefore, the concentration and pharmacokinetic 
characteristics of FF in plasma, lung and pulmonary epithelial lung fluid (PELF) in turkeys 
were determined, either during and after continuous drinking water medication (30 mg/kg 
body weight/day for 5 days) or after a single oral bolus (30 mg/kg body weight). Plasma, lung 
tissue and PELF samples were collected at different time points after administration and FF 
was quantified by liquid chromatography followed by tandem mass spectometry. After 
single bolus administration, FF was rapidly absorbed in plasma (mean tmax = 1.02 h) and 
distributed to the respiratory tract (mean tmax = 1.0 h). The mean t1/2el in plasma and lung 
tissue was similar, around 6 h, whereas it was slightly higher in PELF, namely 8.7 h. After oral 
bolus dosing, the mean Cmax in plasma was twice as high as in the lung tissue, 4.26 µg/mL 
and 2.64 µg/g respectively, while in PELF it was much lower, 0.39 µg/mL. Consequently, the 
time above the MIC90 was 67.4% and 50.0% of a 24 h interval in plasma and lung tissue, 
respectively, but PELF concentrations never exceeded the MIC90. During drinking water 
medication, lung concentrations were slightly higher than plasma concentrations, although 
these concentrations were never above the MIC90. FF was not detected in PELF during 
drinking water medication. 
In poultry rearing, drinking water is a commonly used route to administer medication, but 
drug uptake can be affected by many factors. Therefore, the influence of two important 
environmental parameters, namely photoperiod and feeding schemes, on FF uptake in 
turkeys was also evaluated. This experiment was conducted during a 5-day treatment of 30 
mg/kg body weight FF administered via drinking water and considering different 
photoperiods and feeding schemes (group 20/4L: photoperiod of 20 h, fed ad libitum; group 
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16/8L: photoperiod of 16 h, fed ad libitum; group 16/8R: photoperiod of 16 h, fed ad libitum 
but feed was withdrawn during the dark period and replaced 1 h after lighting). At day 1 of 
the treatment, plasma concentrations of all groups were above the MIC90 during 37.7%, 
63.5% and 53.1% of a 24 h interval for respectively 20/4L, 16/8L and 16/8R. Only in the 
16/8L and 16/8R groups, the MIC90 was also exceeded on day 5 (47.9% and 21.5% of a 24 h 
interval, respectively). The results demonstrated an important influence of the photoperiod 
on the pharmacokinetics of FF. It can be advised that the photoperiod should be less than 20 
h to have sufficient drug intake. On the other hand, there was no effect of feed restriction on 
the pharmacokinetics during continuous administration. 
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Introduction 
Florfenicol (FF) has a broad antibacterial action against several pathogens responsible for 
respiratory tract infections, urinary tract infections and infections of the gastrointestinal 
system. An excellent clinical response of FF in bovine and swine respiratory diseases can be 
attributed to the remarkable pharmacokinetic (PK) characteristics and the low resistance of 
cattle and swine pathogens like Mannheimia haemolitica, Pasteurella multocida, 
Actinobacillus pleuropneumoniae, which all show a minimum inhibitory concentration 
(MIC90) below 1 µg/mL (Shin et al., 2005). In turkeys, FF has been proven to be effective 
against Ornithobacterium rhinotracheale infection, using drinking water medication during 
five days at a dose of 30 mg/kg body weight (BW) per day (Marien et al., 2007). However, 
pharmacodynamic data, such as the minimum inhibitory concentration (MIC), of FF against 
O. rhinotracheale are still lacking. Also, only few data about the PK behaviour of FF in 
respiratory tissues are available, namely in broiler chickens and pigs (Afifi and Abo el-Sooud, 
1997; Li et al. 2002). Due to species dependent differences in anatomy and physiology, PK 
studies have to be performed in the species of interest. To the authors’ knowledge, only one 
PK study of FF has been performed in turkeys after single bolus administration of 30 mg/kg 
BW either per oral (PO) or intravenously (IV) (Switala et al., 2007), but no concentrations in 
lung tissue nor pulmonary epithelial lining fluid (PELF), the sites of action, have been 
reported yet.  
Furthermore, medicated drinking water is the most applied route of drug administration to 
poultry. Besides many advantages, this way of administration has also disadvantages. Drug 
intake between animals can vary dramatically due to both animal factors (hierarchy, flock 
size, sex, age, body weight, species, breed, health status, etc.) and environmental factors 
(temperature, humidity, feed and water availability, photoperiod, etc.) (Vermeulen et al., 
2002). Moreover, the solubility and stability of the drug is of utmost importance and may be 
influenced by many factors of the water quality (such as pH, hardness, contamination). 
Especially for FF, information about its stability in drinking water is scarce (Hayes et al., 
2003). Besides drug intake variability, there can be differences in PK properties of FF after 
oral administration in fasted and fed broiler chickens (Shen et al., 2003; Baert and De Backer, 
2006). These authors reported differences in bioavailability, maximum plasma concentration 
and time to maximum plasma concentration. Moreover, another study showed the influence 
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of the applied photoperiod on the PK of doxycycline during drinking water administration in 
turkeys (Santos et al., 1997). The eating and drinking patterns may alter depending the light 
scheme (Classen et al., 1994), which could have a huge influence on the uptake of drinking 
water medication. As FF is a time-dependent antibiotic (Hesje et al., 2007), it is important to 
have a frequent drug intake. Accordingly, a study with different housing conditions based on 
photoperiod and feeding schemes is mandatory for the establishment of an efficient 
treatment protocol.  
The first aim of this research was to determine the MIC of FF for O. rhinotracheale. 
Subsequently, the concentrations and PK characteristics in plasma, lung tissue and PELF after 
single oral bolus administration (30 mg FF/kg BW) were determined. In order to represent 
field conditions, plasma, lung tissue and PELF concentrations and PK characteristics of FF 
were also studied during and after continuous drinking water medication during 5 days at 
the same dose of 30 mg/kg BW/day. The last objective was to evaluate the plasma 
concentration-time curves, obtained during and after the continuous administration via the 
drinking water (30 mg/kg body weight, BW) during a 5-day period, taking into account 
different photoperiods and feeding schemes. 
 
Materials and methods 
Veterinary drug, chemicals, solutions and materials  
Florfenicol, 2,2-dichloro-N-[1S,2R)-1-(fluoromethyl)-2-hydroxy-2-[4-(methylsulfonyl)-
phenyl]ethyl]-acetamide, used for the animal experiments was obtained from Zhejiang 
Hisoar Pharmaceutical Co., LTD (Zhejiang, China). Because of the low water solubility (1 
mg/mL), the FF bolus for the single oral bolus PK study, was given as a suspension of FF in 
tap water at a concentration of 6 mg/mL. For the continuous drinking water PK study, the 
medicated drinking water was prepared daily by stirring an appropriate solution (mean ± SD 
concentration was 74.3 ± 3.4 mg FF/L tap water) for 30 minutes, followed by sonication for 
20 minutes to dissolve the FF. 
 
FF standard (99.0% purity) used for the analytical experiments was obtained from Dr. 
Ehrenstorfer GmbH (Augsburg, Germany) and the internal standard (IS) thiamphenicol (TAP, 
>97.5% purity) was purchased from Sigma-Aldrich (Bornem, Belgium).  
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All products (sodium hydroxide and acetic acid) and reagents (high-performance liquid 
chromatography (HPLC) grade methanol and water, analytical grade ethyl acetate) were 
purchased from VWR (Leuven, Belgium). Ultra-high performance liquid chromatography 
(UHPLC) water and acetonitrile (ACN) were obtained from Biosolve (Valkenswaard, The 
Netherlands).  
Millex-GV PVDF filter units (0.22 µm) were obtained from Millipore (Brussels, Belgium). 
Stock solutions (1 mg/mL) of each analyte were prepared in methanol. By diluting the stock 
solutions with methanol, working solutions of 0.1, 0.2, 0.5, 1, 2, 5, 10, 20, 50, 100, 200 and 
400 μg/mL of FF and of 50 µg/mL of TAP were obtained. The FF stock and working solutions 
were stable for 9 months at 2-8 °C and TAP solutions were stable for 111 days at 2-8 °C.  
 
Minimum Inhibitory Concentration 
The MIC of FF was determined using the agar dilution method. General procedures, 
weighing and inoculation were according to the Clinical and Laboratory Standard Institute 
(CLSI) standards. Since no standard conditions for susceptibility testing of O. rhinotracheale 
are described (CLSI, 2013), Mueller Hinton broth supplemented with 5% horse blood was 
used, as described by Devriese et al. (2001). The plates were incubated for 48 h at 35 °C in a 
5% CO2 atmosphere. Thirty-eight isolates (37 field isolates, originating from poultry, and the 
O. rhinotracheale type strain LMG 9086T, originally isolated from a turkey) were used. The 
concentrations of FF tested ranged between 0.016 and 32 µg/mL. Escherichia coli ATCC 
25922 and Staphylococcus aureus ATCC 29213 were used as control strains, as indicated by 
the CLSI  guidelines (CLSI, 2013). 
The determination of the MIC was performed in duplo, with an interval of 1 week. 
 
PK-experiment – single oral bolus administration 
This study was performed using fifty-four 6-week-old female turkey poults (Hybrid 
Converter, local commercial turkey farm) with a mean (± SD) BW of 2.063 (± 0.195) kg 
(Hybrid Converter, local commercial turkey farm) and were housed according to the 
requirements of the European Union (Anonymous, 2010). The light scheme was set at 16 h 
light and 8 h dark. After a fasting period of 12 h, the birds received a FF bolus of 30 mg/kg 
BW by gavage in the crop, followed by rinsing with tap water. Four hours after the bolus 
administration, the birds received feed. 
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Blood (1 mL) was collected from six turkeys by venipuncture from the medial metatarsal vein 
into heparinised tubes (Vacutest Kima, Novolab, Geraardsbergen, Belgium) at different time 
points, before (time 0) and post administration (p.a.; 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10 and 24 
h) for PK analysis. Plasma was separated by centrifugation and stored at ≤ -15 °C, pending 
analysis. 
Furthermore, animals (n=6) were sacrificed at different time points to collect plasma, lung 
tissue and PELF. Euthanasia was performed at 1, 2, 4, 6, 8, 12, 24, 36 and 48 h after the oral 
bolus administration. Birds were anesthetized by an intramuscular injection of a 
combination of xylazine (Xyl-M 2%, VMD, Arendonk, Belgium), zolazepam and tiletamine 
(Zoletil 100, Virbac, Wavre, Belgium), followed by exsanguination. The whole right lung was 
removed for FF analysis. The complete left lung was used to collect PELF as described by 
Bottje et al. (1999). In brief, after weighing the lung, it was lavaged with heparin-saline (200 
units heparin per mL of 0.9% saline) at a volume of 2 mL/g lung through a cannula in the first 
bronchus. The PELF/saline solution was collected in a petri dish and the amount of fluid was 
measured to determine the recovery, which ranged from 80.0 to 100%. The fluid was 
centrifuged (5250 x g for 3 min) to remove red blood cells. Both the lung tissue and PELF 
were stored at ≤ -15 °C until analysis. 
The animal experiment was approved by the Ethical Committee of the Faculty of Veterinary 
Medicine and Bioscience Engineering, Ghent University (EC 2014/68). 
 
PK-experiment – continuous drinking water administration 
During an acclimatisation period of five days, water consumption (non-medicated tap water) 
of twenty 3-week-old female turkey poults (Hybrid Converter, local commercial turkey farm) 
with a mean (± SD) BW of 0.812 (± 0.074) kg was measured to calculate a correct dose of the 
medicated drinking water. Thereafter, the turkeys received FF via the drinking water during 
a 5-day period (target dose: 30 mg/kg BW/day). During the whole experiment, the light 
scheme was set at 16 h light and 8 h dark. 
Blood (1 mL) of six turkeys was collected and stored at the same way as the oral bolus study, 
except for sampling points. Blood was taken immediately before (time 0), and at 10, 24, 34, 
48, 58, 72, 82, 96, 106 and 120 h after the start of the medicated water administration. Also 
the collection of lung tissue and PELF was similar as the oral bolus experiment, although the 
euthanasia of four birds at each time point took place at day 2 (24 h), 4 (72 h), 6 (120 h), 8 
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(168 h) and 10 (216 h), after the start of the continuous drinking water medication. The 
recovery of the PELF/saline solution ranged between 71.4 to 96.0%. 
The animal experiment was approved by the Ethical Committee of the Faculty of Veterinary 
Medicine and Bioscience Engineering, Ghent University (EC 2013/108). 
 
PK-experiment – different housing and feeding conditions 
Eighteen 3-week-old female turkeys, with a mean (± SD) BW of 0.573 ± 0.052 kg were 
randomly divided in three groups (6 animals/group) with different environmental conditions. 
The light schedule of the first group was 20 h light (between 8 h a.m. and 4 h a.m.)/4 h dark 
and they were fed ad libitum (20/4L). The light schedule of the second group was 16 h light 
(between 8 h a.m. and 12 h p.m.)/8 h dark and were fed fed ad libitum (16/8L) and the third 
group was provided the same light cycle and was fed ad libitum except during the dark 
period in which feed was withdrawn (16/8R). These animals received feed again at 1 h after 
the light was put on.  
FF was administered continuously to the three groups via the drinking water during a 5-day 
period (target dose: 30 mg/kg BW). In order to determine the inclusion rate of the drug in 
the drinking water and to evaluate the real amount of drug ingested, all animals were 
weighed before the treatment and the water uptake was measured daily from 3 days before 
until the end of the treatment.  
Blood (1 mL) was collected as described above at different time points: immediately before 
(time 0), at 1, 2.5, 5, 7.5, 10, 15 and 24 h on day 1 and day 5, and on day 6 also at 2, 4 and 8 
h. Plasma was separated by centrifugation and stored at ≤-15 °C, pending analysis. 
Water samples of the medicated drinking water were collected daily immediately after its 
preparation and after 24 h, in order to evaluate the homogeneity and stability, respectively. 
Medicated drinking water was replaced every 24 h by a freshly prepared solution. The 
medicated drinking water samples were stored at -20 °C pending analysis. 
The trial was approved by the Ethical Committee of the Faculty of Veterinary Medicine and 
Bioscience Engineering, Ghent University (EC 2011/027 and EC 2011/096). 
 
Florfenicol analyses in plasma, lung tissue, PELF and drinking water 
Quantification of FF in the plasma samples was performed using an in-house developed and 
validated LC-MS/MS method. The plasma samples (250 µL) were spiked with 12.5 µL of the 
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IS TAP (50 µg/mL), followed by vortexing (15 s) and an equilibration period (5 min). 
Subsequent to the addition of 100 µL of sodium hydroxide 1 M, the samples were vortexed 
(15 s), mixed with 4 mL of ethyl acetate, and again vortexed (15 s). The samples were 
extracted by horizontal rolling for 20 min, followed by centrifugation (3725 g, 10 min). The 
supernatant was transferred to a glass tube and evaporated to dryness using a nitrogen 
stream (40 °C). The residue was redissolved into 250 µL of 0.1% acetic acid in water and ACN 
(80:20, v/v), filtered through a 0.22 µm Millex-GV PVDF filter and transferred to an 
autosampler vial.  
Each lung sample was homogenized with an equal weight of water, using an Ultra Turrax 
mixer (Ika, Staufen, Germany). A 0.5 g aliquot of this lung tissue homogenate (corresponding 
with 0.25 g of lung tissue) was used for the FF analysis. Further sample preparation of lung 
tissue and PELF samples was similar to the plasma samples.  
The water samples were diluted 500 times with HPLC water. An aliquot of 250 µL was spiked 
with 12.5 µL of the IS TAP working solution (50 µg/mL), followed by vortex mixing (15 s) and 
transfer to an autosampler vial. 
 
The LC system consisted of a quaternary, low-pressure mixing pump with vacuum degassing, 
type Surveyor MSpump Plus and an autosampler with temperature controlled tray and 
column oven, type Surveyor Autosampler Plus, from Thermo Scientific (Breda, the 
Netherlands).  
The chromatographic separation was achieved on a Hypersil Gold column (50 x 2.1 mm 
internal diameter (i.d.); particle size (d.p.): 1.9 µm) with a guard column of the same type 
(Hypersil Gold, 10 x 2.1 mm i.d., d.p.: 3 µm), both from Thermo Scientific.  
The column temperature was maintained at 45 °C. The injection volume was 10 µL and the 
analysis was carried out with gradient elution using (A) 0.1% acetic acid in UHPLC water and 
(B) UHPLC ACN as the mobile phases at a flow rate of 0.30 mL/min. The gradient conditions 
were as follows: 0 – 2.2 min: 85% A, 15% B; 2.2 - 2.5 min: linear gradient to 20% A; 2.5 – 3.8 
min: 20% A, 80% B; 3.8 – 4.0 min: linear gradient to 85% A; 4.0 – 6.0 min: 85% A, 15% B.  
The LC column effluent was interfaced to a TSQ Quantum Ultra triple quadrupole mass 
spectrometer, equipped with a heated electrospray ionisation (h-ESI) probe (all from Thermo 
Scientific). The analysis of FF and TAP was performed in negative ionization mode.  
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Instrument parameters were optimised for the analytes. For each compound, the two most 
intense precursor ion > product ions transitions were selected and monitored in the selected 
reaction monitoring (SRM) mode. The most intense product ion was used for quantification 
(i.e. FF: m/z 356.1 > 336.0, TAP: m/z 354.1 > 185.0). 
Prior to routine application, the method was validated in-house by a set of parameters 
(linearity, within-run and between-run accuracy and precision, limit of quantification (LOQ), 
limit of detection (LOD), selectivity) that were in compliance with the recommendations as 
defined by the European Community (Anonymous, 2002) and with reference guidelines 
defined in other EU documents (Knecht and Stork, 1974; Heitzman, 1994; VICH GL 49, 2015). 
Quadratic calibration curves were constructed using matrix-matched calibrator samples 
(concentration range: 10 – 5000 ng/mL) and the correlation coefficients (r = 0.9983, 0.9998, 
0.9981 for plasma, lung tissue and PELF, respectively) and goodness-of-fit coefficients (g = 
13.25%, 7.54%, 9.17% for plasma, lung tissue and PELF, respectively) fell within the accepted 
ranges, i.e. r ≥ 0.99 and g < 20%, respectively.  
Within-run precision (repeatability) and accuracy were determined by analyzing blank 
samples that were spiked on the same day. The samples were spiked at 25, 250 and 2500 
ng/mL; 25, 250 and 2500 ng/g; 25, 100 and 1000 ng/mL, for respectively plasma, lung tissue 
and PELF samples. The between-run precision and accuracy were determined by analyzing 
quality control samples together with each analytical batch of samples, run on different 
days. The concentration levels for plasma, lung tissue and PELF were 100, 250 and 2500 
ng/mL; 25, 250 and 2500 ng/g; 100 and 1000 ng/mL, respectively. The results of the 
validation are shown in Table 1. 
As can be seen, these results fell within the accepted ranges for accuracy (-20% to +10% of 
the theoretical concentration) and precision (within-run precision: relative standard 
deviation (RSD) ≤ RSDmax with RSDmax of 15% for concentration levels ≥ 10 and < 100 ng/mL 
or ng/g, and RSDmax  of 10% for concentration levels ≥ 100 ng/mL or ng/g; between-run 
precision: RSD ≤ RSDmax with RSDmax = 2
(1−0.5logConc), i.e. 27.9%, 22.6%, 19.7%, 16.0% and 
13.9% at 25, 100, 250, 1000 and 2500 ng/mL or ng/g, respectively). 
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Table 1. Within-run and between-run validation results for FF analyses in plasma, lung tissue and 
PELF. 
 
Plasma 
ng/mL 
 Lung tissue 
ng/g 
 PELF 
ng/mL 
Within-run 25  250  2500   25   250  2500   25  100  1000  
Accuracy (%) -11.4 5.8 5.3  5.5 -19.8 4.3  -13.7 -2.2 -10.9 
Precision (RSD) (%) 9.1 9.9 3.8  6.4 4.2 8.6  11.0 5.2 5.2 
Between-run 100  250  2500   25   250  2500   25  100  1000  
Accuracy (%) -8.0 -13.0 -3.8  0.8 3.2 -6.1  ND -1.7 -2.6 
Precision (RSD) (%) 7.3 3.0 10.6  15.2 14.0 12.0  ND 9.6 9.4 
ND, not determined 
 
The LOQ was 25 ng/mL for plasma, 25 ng/g for lung tissue and 20 ng/mL for PELF. Values 
below the LOQ were not included in the plasma concentration-time curves and the PK 
analysis.  
 
Pharmacokinetic, pharmacodynamic and statistical analyses 
Following plasma PK parameters were determined by one-compartmental analysis 
(WinNonlin 6.3, Pharsight, CA, USA): area under the plasma concentration-time curve from 
time 0 to infinity (AUCinf); absorption rate constant (kabs); elimination rate constant (kel); 
absorption half-life (t1/2abs); elimination half-life (t1/2el), expressed as the harmonic mean; 
volume of distribution, not corrected for absolute oral bioavailability (Vd/Fabs); total body 
clearance, scaled by absolute oral bioavailability (Cl/Fabs); maximum plasma concentration 
(Cmax) and time to Cmax (tmax). For lung tissue, AUCinf, kel, t1/2el, Cmax and tmax were calculated in 
a similar way.  
 
The PK data are expressed as mean ± SD for plasma. For lung and PELF a sparse sampling 
protocol was applied and values are expressed as mean. 
The PK/PD index calculated was the time the plasma concentrations remained above the 
MIC (T>MIC), defined as the cumulative percentage of time over a 24-hour period that the 
drug concentrations exceed the MIC and should be more than 40% (Hesje et al., 2007). 
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The areas under the curve (AUC) of the FF concentration-time curve studied under the 
different housing and feeding conditions were analysed by the Kruskal Wallis test. A p-value 
below 0.05 was considered statistically significant. The AUC was calculated by the linear 
trapezoidal rule. These statistical analyses were performed using SPSS Statistics 22 (IBM SPSS 
software, New York, USA). 
 
Results 
Stability of FF in drinking water 
The mean (± SD) FF concentration in the medicated drinking water just after preparation was 
100.2% (± 0.50%) of the theoretical concentration, indicating a good homogeneity. After 24 
h, the FF concentration was 100.4% (± 0.96%) of the initial concentration (t = 0 h), confirming 
the excellent stability of FF in the drinking water.  
 
MIC evaluation 
The in vitro activity of FF against 38 O. rhinotracheale isolates was tested. Following MIC 
values were obtained: 0.5, 1.0, 2.0 and 4.0 µg/mL in respectively 3 (7.9%), 32 (84.2%), 2 
(5.3%) and 1 (2.6%) of the 38 isolates tested. The MIC50 and MIC90 values were both 1 µg/mL 
(Fig. 1). 
 
 
 
Figure 1. Minimum inhibitory concentration (MIC) distribution of FF in 38 isolates of 
Ornithobacterium rhinotracheale. The MIC50 and MIC90 were both set at 1 µg/mL. 
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PK/PD – single  oral bolus vs. continuous drinking water administration 
In the experiment with continuous drinking water, a reduction of the water consumption 
during the treatment period was observed (5.35 ± 0.21 L/kg), in comparison with the 
acclimatization period (8.12 ± 0.37 L/kg). 
 
The plasma concentration-time profiles of both the oral bolus and continuous experiment 
are depicted in Figure 2. The concentrations during continuous administration were nearly 
constant during 5 days, followed by a fast elimination when drinking water medication 
stopped. The Cmax was much higher after bolus administration and was reached after one 
hour. During the elimination phase, at the time point of 8 h, a slight rise in plasma 
concentration can be observed. After 24 h, all plasma concentrations were below the LOQ. 
 
Table 2 presents the PK characteristics of FF in plasma, lung and PELF. FF was rapidly 
absorbed in plasma and distributed to the respiratory tract (mean kabs = 4.64 h
-1 in plasma; 
mean tmax is 1 h in plasma, lung tissue as well as in PELF). The mean t1/2el in plasma and lung 
tissue was similar, 6.27 h and 5.96 h respectively, whereas it was slightly higher in PELF, 8.70 
h. In plasma, the mean Cmax is twice as high as in the lung tissue, 4.26 µg/mL and 2.64 µg/g 
respectively. The mean concentration in PELF was much lower, i.e. at 0.39 µg/mL. 
After a single oral bolus, the FF concentration in plasma and lung tissue exceeded the MIC90 
for 16.2 and 12 h, respectively. 
 
The mean concentrations in plasma, lung tissue and PELF are shown in Figure 3. Figure 4 
shows the individual curves. During drinking water medication, the concentrations in plasma 
and lung tissue increased, with lung/plasma ratios above 1 (Table 3). After treatment, from 
day 6 onwards, no concentrations could be detected in plasma and only very low 
concentrations in lung tissue. The concentrations in PELF were at all time points below the 
LOQ. After oral bolus administration, the concentrations in plasma, lung tissue as well as 
PELF were higher compared to drinking water medication. Although, only at 6 and 24 h the 
lung concentration were higher than the plasma concentrations. 
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B 
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Figure 2. Panel A: Mean (+ SD) plasma concentration (log scale) versus time curve of florfenicol (FF) 
in turkeys, after either 5-day continuous oral administration of FF via medicated water at a target 
dose of 30 mg/kg BW/day (n=6, continuous experiment,) or a single oral bolus administration of FF 
at a dose of 30 mg/kg BW (n=6, oral bolus experiment, ). Panel B: Individual plots of 6 turkeys after 
bolus administration. Panel C: Individual plots of 6 turkeys during drinking water medication. 
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Figure 3. Mean (+SD) plasma, lung tissue and PELF concentrations of florfenicol (FF) in turkeys, after 
either a 5-day continuous oral administration of FF via medicated water at a target dose of 30 mg/kg 
BW/day (panel A) or a single oral bolus administration of FF at a dose of 30 mg/kg BW (panel B). At 
each time point, four (continuous drinking water) or six (oral bolus) turkeys were taken into account. 
Values below the LOQ are indicated by ◊. At 36 and 48 h after oral bolus, all concentrations were 
below the LOQ and are not presented.  
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Figure 4. Individual plasma, lung tissue and PELF concentrations of florfenicol (FF) in turkeys, after 
either a 5-day continuous oral administration of FF via medicated water at a target dose of 30 mg/kg 
BW/day (panel A) or a single oral bolus administration of FF at a dose of 30 mg/kg BW (panel B). At 
each time point, six (oral bolus) or four (continuous drinking water) turkeys were sampled.  
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Table 2. Pharmacokinetic properties of florfenicol in turkey poults after oral (PO) bolus 
administration of 30 mg/kg body weight, in plasma (n=6), lung tissue and PELF (both n=6 at each time 
point). Results are presented as mean ± SD (plasma) or mean (lung and PELF). 
Parameter Units Plasma Lung PELF 
AUCinf h.µg/mL or h.µg/g
 48.56 ± 18.76 32.63 2.97 
kabs h
-1 4.64 ± 3.24 - - 
kel    h
-1 0.011 ± 0.05 0.12 0.08 
t1/2 abs    h 0.15 
A - - 
t1/2 el    h 6.27 
A 5.96 8.70 
Vd/Fabs L/kg
 6.75 ± 1.56 - - 
Cl/Fabs L/kg/h
 0.74 ± 0.42 - - 
tmax h 1.02 ± 0.39
 1.00 1.00 
Cmax µg/mL or µg/g
 4.26 ± 1.30 2.64 0.39 
AUCinf, the area under the plasma concentration-time curve from time 0 to infinity; kabs, absorption rate 
constant; kel, elimination rate constant; t1/2abs, half-life of absorption; t1/2el, half-life of elimination; Vd/Fabs, 
volume of distribution (not corrected for the absolute oral bioavailability); Cl/Fabs, clearance (scaled by absolute 
oral bioavailability); tmax, time to maximum plasma concentration; Cmax,  maximum plasma concentration. 
A: harmonic mean 
 
 
Table 3. The mean concentration ratios of lung/plasma and pulmonary epithelial lining fluid 
(PELF)/plasma after oral bolus or drinking water medication during 5 days of florfenicol at a dose of 
30 mg/kg BW. 
Oral bolus Continuous drinking water 
Time Lung/Plasma PELF/Plasma Time Lung/Plasma PELF/Plasma 
1 h 0.64 ± 0.47 0.12 ± 0.10 24 h (day 2) 2.01 ± 1.01 ND 
2 h 0.27 ± 0.21 0.24 ± 0.33 72 h (day 4) 1.27 ± 0.42 ND 
4 h 0.79 ± 0.53 0.55 ± 1.03 120 h (day 6) ND ND 
6 h 1.16 ± 0.24 0.15 ± 0.05 168 h (day 8) ND ND 
8 h 0.91 ± 0.35 0.12 ± 0.04 216 h (day 10) ND ND 
12 h 0.98 ± 0.45 0.08 ± 0.03    
24 h 1.09 ± 0.31 ND    
    ND, not determined 
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PK/PD – different housing and feeding conditions 
The inclusion rate of FF in the medicated drinking water was determined on the basis of 
mean BW and water uptake per group, and it was between 67.5 and 144.3 mg/L. The daily 
water intake remained mainly constant before, during and after the treatment in the three 
groups (mean ± SD: 1.69 ± 0.13 L), with the exception of group 16/8R that drank less on day 
5. The mean effective drug intake ranged from 28.2 to 33.1 mg/kg BW/day for all groups. 
However, on day 5 group 16/8R received only 24.4 mg/kg BW. 
The mean plasma concentration-time profiles of FF and the MIC-value are depicted in Figure 
5A and 5B for day 1 and day 5, respectively. Remarkable is that on day 1, almost all animals 
of the 20/4L group had a drop in FF plasma concentration (<400 ng/mL) between 5 and 10 h 
after the start of medication (5/6 turkeys), while none of the other groups displayed these 
low FF concentrations. However, this decline resulted not in a significant difference of the 
AUC between the groups. On day 5, a significant difference was observed between 16/8L 
and 16/8R. This was probably due to the reduced water intake.  
On day 1, plasma concentrations above the MIC could be seen for 37.7%, 63.5% and 53.1% 
of a 24 h interval for respectively 20/4L, 16/8L and 16/8R groups. However, on day 5 group 
20/4L never reached the MIC and groups 16/8L and 16/8R exceeded the MIC for 47.9% and 
21.5% of a 24 h interval, respectively. 
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Figure 5. Mean (+ SD) plasma concentration–time profiles of florfenicol in group 20/4L (20h light and 
4 h dark, fed ad libitum, ), group 16/8L (16 h light and 8 h dark, fed ad libitum, ), group 16/8R (16 
h light and 8 h dark, fed ad libitum from 1h after lighting, ) on day 1 (A) and day 5 (B) of a 5-day 
continuous oral administration of florfenicol via medicated water (target dose: 30 mg/kg BW/day). 
The red line indicates the MIC90 value of 1 µg/mL. 
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Discussion 
Notwithstanding FF may be used to treat turkeys from respiratory infections and PK studies 
in the species of interest are essential, no data on PK characteristics of FF in respiratory 
tissue of turkeys have been published before. A single oral bolus experiment was performed 
to determine the concentrations in plasma, lung and PELF and to calculate the 
corresponding PK characteristics. On the other hand, also a continuous drinking water 
medication experiment was carried out to represent the treatment in field conditions, 
determining the concentrations and PK characteristics in these body fluids and tissue. An 
important drawback of FF, as active pharmaceutical ingredient to use in medicated drinking 
water, is the low aqueous solubility. Only after stirring and sonication, the drug was 
dissolved in the drinking water. As already reported, drug intake can be affected by many 
factors using this way of oral medication. In this study, the influence of two important 
parameters, namely photoperiod and prandial status on FF uptake using drinking water 
administration, has been tested. The results demonstrated an important influence of the 
photoperiod on the PK of FF. On the other hand, there was no effect of the feeding schemes 
on the disposition of the antibiotic. 
 
MIC evaluation 
This is the first study to evaluate the in vitro susceptibility of several O. rhinotracheale strains 
to FF. Also no susceptibility breakpoints have been defined yet. The very strict range of O. 
rhinotracheale MIC values reported for the 38 isolates suggested that 1 µg/mL might be the 
MIC value of the wild type of this bacterium. The unimodal distribution of the MIC values 
suggests there is no indication for acquired antimicrobial resistance. As the evaluated 
bacterial population is maybe not large enough, further studies are necessary to confirm 
these data. 
 
Plasma pharmacokinetics 
After a single oral bolus of 30 mg/kg BW, FF showed a fast absorption. This is in accordance 
with other studies in avian species after an oral FF bolus of the same dose, mean plasma tmax 
varied from 0.30 to 2.00 h (Afifi and Abo El-Sooud, 1997; Shen et al., 2003; Switala et al., 
2007; Chang et al., 2010; Abu-Basha et al., 2012). Also in pigs, the tmax was similar, namely 
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1.50 h, after a single oral bolus (Jiang et al., 2006). The mean Cmax in plasma determined in 
this study was lower compared to Switala et al. (2007), 4.26 and 12.25 µg/mL, respectively. 
The same was observed for the mean AUC, 48.56 and 77.62 µg.h/mL respectively. The 
results of both parameters suggest a lower oral bioavailability of the used active substance. 
In Leghorn and Taiwan native chickens (Chang et al., 2010), the plasma concentrations were 
similar to turkeys as reported by Switala et al. (2007), while our results were comparable 
with those in broiler chickens (Afifi and Abo El-Sooud, 1997; Shen et al., 2003).  
With a Vd above 1 L/kg BW, FF is moderate distributed extravascular. The Vd of FF is at 
variance between different bird species, with a Vd ranging from 1.06 L/kg BW in turkeys, 
over around 5 L/kg BW in quails, pigeons, ducks and broiler chickens, up to 8.70 L/kg BW in 
Japanese quails (Afifi and Abo El-Sooud, 1997; El-Banna, 1998; Switala et al., 2007; Ismail and 
El-Kattan, 2009; Koc et al., 2009b). Although plasma protein binding was not determined in 
this study, many others reported a low binding for FF in different animal species, < 25% 
(Adams et al., 1987; Afifi and Abo El-Sooud, 1997; Abd El-Aty et al., 2004). This low extent is 
consistent with the high Vd. 
The elimination process is expressed by the total body Cl and consequently also partly by 
t1/2el. Since no IV bolus was administered, Cl was not corrected for the absolute 
bioavailability (Fabs). Therefore, the mean Cl found in our study (0.74 L/kg/h) could be lower. 
There is a wide range in Cl value among avian species, depending on their BW, from 0.3-0.6 
L/kg/h in larger birds (turkey and Muscovy ducks) towards 1.6 L/kg/h in broiler chickens, 3.9 
L/kg/h in pigeons and 5.3 L/kg/h in quails (Afifi and Abo El-Sooud, 1997; El-Banna, 1998; 
Switala et al., 2007; Ismail and El-Kattan, 2009). A mean plasma t1/2el of 6.27 h in turkeys was 
comparable with that of Muscovy ducks (El-Banna, 1998), whereas it was twice as high as 
reported in chickens (Afifi and Abo El-Sooud, 1997; Shen et al., 2003; Ismail and El-Kattan, 
2009). Also Switala et al. (2007) found a lower t1/2el value, 3.76 h in turkeys. After 24 h post 
administration, almost all FF was eliminated from the body. 
Regarding the plasma concentration-time profile of the continuous drinking water 
medication, the plasma concentrations balanced around 1 µg/mL. After stopping the 
medicated drinking water, FF was rapidly eliminated from the plasma and target tissues. 
Despite the significant difference between 16/8L and 16/8R on day 5, we considered that 
the two different feeding schemes have no influence on the plasma concentration as no 
differences were observed at day 1. The differences on day 5 could be assigned to the lower 
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water intake of group 16/8R. Therefore, no differences in plasma concentrations between 
16/8L and 16/8R have been pointed out in this study, although several studies confirmed the 
influence of feeding status on the oral bioavailability (Varma et al., 1986; Baert and De 
Backer, 2006; Shen et al., 2003; Chang et al., 2010). There could be several reasons for these 
findings. First of all, the experiments were performed in different species (chicken vs. 
turkey). Also the way of administration is very important. In contrast to previous studies 
whereby the chickens received a bolus of FF, we administered the drug via continuous 
drinking water medication. At last, the restricted and the ad libitum group received both 16 
h of light, which was demonstrated as a good photoperiod. Consequently, all turkeys 
showed a rest period before the light was switched on (24 h), suggesting that they did not 
eat during the dark period. 
As can be seen in Figures 2 and 4, it is expected that the groups which received FF via the 
drinking water, have high interanimal variability. The variable intake of medicated water can 
be the result of the pecking order, stage of sickness or accessibility to water. Only a few 
studies reported information about drinking behaviour in poultry (Ross and Hurnik, 1983; 
Puma et al., 2001). However, also after a single oral bolus, high variability between the 
individual turkeys occur. Consequently, the observed interindividual differences are probably 
the result of a variation in absorption, distribution, and elimination of the drug. 
 
Lung and PELF pharmacokinetics 
Despite that the concentrations of FF in tissues have been reported in avian (Anadón et al., 
2008; Chang et al., 2010) as well as mammalian species (Lane et al., 2008), only one study 
described the PK characteristics of FF in lung tissues. After intramuscular administration of 
20 mg FF/kg BW to pigs (Liu et al., 2003), the mean Cmax and tmax of FF in turkey lung tissue 
was comparable with pigs, 2.64 µg/g – 1 h and 2.46 µg/g – 2 h for turkey and pig, 
respectively. This confirms the rapid distribution from plasma to lung tissue. However, a 
great discrepancy can be observed between turkey and pig concerning the elimination from 
lung tissue. In pigs the t1/2el was 38.5 h whereas in turkeys, the mean t1/2el for lung tissue was 
5.96 h. A possible explanation could be the infection status of the animals. In the study of Liu 
et al. (2003), the pigs were experimentally infected with Actinobacillus pleuropneumoniae 
and this could enhance the affinity of the lung tissue for FF. 
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To compare the concentrations in either lung tissue and PELF to the plasma concentrations, 
lung/plasma and PELF/plasma ratios were calculated. For the continuous drinking water 
experiment, the lung/plasma concentration was above 1 during the treatment, affirming the 
high affinity for the respiratory tract. Throughout the medication period, the FF lung 
concentrations increased. After stopping the treatment, only low FF lung concentrations and 
no plasma concentrations could be detected. In all PELF samples, the FF concentration was 
below the LOQ.  
After the oral bolus administration, the lung/plasma ratio was above 1 only at 6 h and 24 h. 
This would imply a more rapid elimination from plasma compared to lung tissue, although 
the t1/2el of plasma and lung are comparable. After 8 h, the plasma concentrations increased 
and this also reflected a higher lung concentration at 12 h. This phenomenon could be 
explained by enterohepatic circulation of FF (Pasmans et al., 2008). The high concentration 
of FF in bile from chickens confirms this suggestion (Afifi and Abo El-Sooud, 1997). After 
multiple oral doses of 30 mg/kg BW/day for 5 successive days, Afifi and Abo El-Sooud (1997) 
found detectable lung concentrations (20 µg/g) until 48 h after the last dose. The Cmax 
reported in that study was similar to the mean Cmax in the present study, 2.80 and 2.64 µg/g 
respectively. In contrast to continuous drinking water medication, FF was detectable in PELF 
after single bolus administration. However, the PELF/plasma ratios were very low. 
This low FF concentrations in PELF could be due to the collection method of PELF and/or to 
the anatomy and physiology of the respiratory tract of birds (Watteyn et al., 2015). 
 
Plasma and tissue PK/PD  – oral bolus vs. continuous drinking water administration 
After a single oral bolus, the time above the MIC90 was 67.4% and 50% of a 24 h interval in 
plasma and lung tissue, respectively, but PELF concentrations never exceeded the MIC90. On 
the contrary, during drinking water treatment the lung and PELF concentrations were never 
above the MIC90. Also the plasma concentrations were just below the MIC90. This could be 
due to a reduction of the water consumption during the treatment period compared to the 
acclimatization period. The reason for this reduction is unknown. Consequently, the 
postulated dosage of FF of 30 mg/kg BW/day was not reached, only 26.3 ± 3.12 mg/kg  
BW/day. 
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Plasma PK/PD – different housing and feeding conditions 
During the continuous drinking water medication, the plasma concentrations were around 
the MIC.  
In the continuous drinking water medication experiment with respect to the photoperiod, 
the two groups with 16 h of light fulfilled to the criterion of a T>MIC of minimum 40% on day 
1 (63.1% and 53.1% for 16/8L and 16/8R, respectively). No significant difference between 
the two feeding schemes were observed. The group 20/4L displayed a very irregular plasma 
concentration versus time curve on day 1, with a limited time period above MIC (37.7%) and 
a drop in plasma concentration at 8 and 10 h after the start of the administration of the 
medicated drinking water. On day 5, the group 16/8R did not achieve 40% (only 21.5%), but 
this can be related due to a reduced water uptake with unknown reason. From these plasma 
concentration-time curves, it is obvious that the photoperiod 20/4L is unfavourable to reach 
sufficient plasma levels. Furthermore, it has to be mentioned that this light scheme is no 
longer allowed in poultry-rearing, a minimum of 6 h of darkness is required (Anonymous, 
2007). Classen et al. (1994) demonstrated that turkeys given a gradually increased light 
pattern ate and drank more frequently compared to turkeys provided constant light. Also 
other studies in chickens and turkeys have already related extreme photoperiods with a 
change in feeding cycles (Newberry, 1992; Brown et al., 2008; Lewis et al., 2009). Diurnal 
species, like turkeys, eat less in dark than in light conditions, resulting in longer between-
feeding intervals (Howie et al., 2010). As feeding uptake in birds is strongly connected with 
water uptake, changes in photoperiod can easily affect the drinking water uptake. Santos et 
al. (1997) have reported the same effect during the administration of doxycycline, and 
underlined the importance of photoperiod during continuous water administration of drugs, 
especially if the applied drug has a short half-life of elimination. The unusual plasma 
concentration-time curve in the 20/4L group could be related to an atypical water uptake, as 
a result of a too short dark period. 
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Conclusion 
FF was very rapidly absorbed and distributed to the lung tissue after a single oral bolus in 
turkeys. The presented PK and PD characteristics motivate the use of FF as a treatment for 
respiratory diseases in turkeys, such as O. rhinotracheale infections. Ideally, the in vivo 
efficacy of FF against O. rhinotracheale should be determined in an experimental infection 
model. 
This study confirms also the negative influence of a light scheme with 20 h of light in drug 
administration as reported by Santos et al. (1997). The continuous administration of 30 mg 
of FF/kg BW via the drinking water for 5 days at a photoperiod of 16 h resulted in better 
PK/PD indices compared to a photoperiod of 20 h. Replacing the drinking water once daily 
would be sufficient as FF is stable over a 24 h period.  
However, FF as such is not applicable for drinking water medication as the water solubility is 
very low (only 1 mg/mL), which implies an elaborate preparation of the medicated water. 
Therefore, an appropriate water soluble formulation would be preferable.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Acknowledgements 
The authors wish to thank Jelle Lambrecht, Matteo Stecca and Anja Van den Bussche for their 
excellent laboratory assistance.  For the aid in the animal experiment, we thank Gunther Antonissen, 
Nathan Broekaert, Thomas De Mil, Sophie Fraeyman, Elke Gasthuys, Joline Goossens, Elke Plessers, 
Charlotte Watteyn and Heidi Wyns. 
Experimental Studies – Chapter 1.2 
85 
 
 
 
 
 
 
 
 
 
Chapter 1.2 
Pharmacokinetics and pharmacodynamics of gamithromycin in 
plasma, lung tissue and pulmonary epithelial lining fluid in turkeys, 
after a single bolus 
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Abstract 
The macrolide gamithromycin (GAM) has the ability to accumulate in tissues of the 
respiratory tract. Consequently, GAM might be a suitable antibiotic to treat bacterial 
respiratory infections in poultry, such as Ornithobacterium rhinotracheale. As O. 
rhinotracheale infections are common in turkey flocks, the aim of this study was to 
determine the pharmacokinetic (PK) parameters of GAM in plasma, lung tissue and 
pulmonary epithelial lining fluid (PELF) of turkeys and to correlate them with 
pharmacodynamic (PD) characteristics (PK/PD). The animal experiment was performed with 
64 turkeys, which received either a subcutaneous (SC, n=32) or an oral (PO, n=32) bolus of 6 
mg GAM/kg body weight (BW). GAM concentrations in plasma, lung tissue and PELF were 
measured at different time-points post administration (p.a.), and PK characteristics were 
determined using non-compartmental modelling. The mean maximum plasma concentration 
after PO administration was a ten-fold lower than after SC injection (0.087 and 0.89 µg/mL, 
respectively), whereas there were no differences in lung concentrations between both 
routes of administration. However, lung concentrations at day 1 p.a. were significantly 
higher than plasma levels for both routes of administration (2.22 and 3.66 µg/g for PO and 
SC, respectively). Consequently, lung/plasma ratios were high, up to 50 and 80 after PO and 
SC administration, respectively. GAM could not be detected in PELF, although this might be 
attributed to the collection method of PELF in birds. The GAM minimum inhibitory 
concentration (MIC) was determined for 38 O. rhinotracheale strains with MIC50 and MIC90 of 
2 and >32 µg/mL, respectively. PK/PD correlation for lung tissue demonstrated that the time 
above the MIC90 of the susceptible population (2 µg/mL) was 1 day after PO bolus and 3.5 
days after SC administration. The area under the curve (AUClast)/MIC ratio for lung tissue was 
233 and 90 after SC and PO administration, respectively. To conclude, GAM is highly 
distributed to lung tissue in turkey poults, suggesting that it has the potential to be used to 
treat respiratory infections such as O. rhinotracheale. 
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Introduction 
Gamithromycin (GAM) is a new generation macrolide antibiotic, belonging to the azalide 
subgroup. Macrolides are widely used antibiotics in veterinary medicine. A unique feature of 
these compounds is their ability to accumulate in the respiratory tract (Giguère, 2013). GAM 
is indicated for the treatment of bovine respiratory disease (BRD) (Baggott et al., 2011), but 
is currently not registered for use in other species. Nevertheless, the manufacturer has 
intentions to register the product for treatment of swine respiratory disease (SRD) since just 
recently, maximum residue levels (MRLs) have been established for porcine species too 
(EMA, 2015). 
In poultry, bacterial infections of the respiratory tract frequently result in economic losses 
due to an increased mortality and feed conversion rate, a reduced growth and high medical 
costs (Van Empel and Hafez, 1999). Ornithobacterium rhinotracheale is a Gram-negative 
bacterium causing respiratory symptoms in several bird species. Infections with O. 
rhinotracheale have been treated with several classes of antimicrobials, including β-lactam 
antibiotics, tetracyclines, fluoroquinolones, florfenicol and macrolides, but with variable 
outcomes (Marien et al., 2006, 2007; Garmyn et al., 2009a,b, Warner et al., 2009; Agunos et 
al., 2013; Watteyn et al., 2013b). Several studies demonstrated that the sensitivity of O. 
rhinotracheale to antimicrobials is strain-dependent (Devriese et al., 1995, 2001).  
The pharmacokinetic (PK) behaviour of GAM has been studied in cattle (Huang et al., 2010; 
Giguère et al., 2011), foals (Berghaus et al., 2011), broiler chickens (Watteyn et al., 2013a) 
and swine (Wyns et al., 2014). However, no data are available for turkey poults, neither for 
plasma nor for tissues. 
GAM has a high volume of distribution (Vd > 20 L) in all investigated species, due to its 
accumulation in tissues and high affinity for the respiratory tract. Huang et al. (2010) 
analyzed whole lung homogenate of cattle and reported concentrations that were 250 to 
400 times higher than the corresponding plasma concentrations. Also in pulmonary 
epithelial lining fluid (PELF), the concentrations of GAM were much higher compared to 
plasma, with a maximum plasma concentration (Cmax) of 0.43 and 0.33 µg/mL in plasma and 
4.16 µg/mL and 2.15 µg/mL in PELF for cattle and foals, respectively (Giguère et al., 2011; 
Berghaus et al., 2011). This emphasizes the need to quantify the antibiotic in the target 
pulmonary tissues as well, and not only in plasma. 
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Since GAM has a spectrum against O. rhinotracheale, and combined with the ability to 
accumulate in pulmonary tissues, it might be used to treat O. rhinotracheale infections. 
Therefore, the aim of the present study was to determine the PK behaviour of GAM in 
plasma as well as in lung tissue and PELF of turkey poults, and to relate these results to the 
minimum inhibitory concentration (MIC) values of recent O. rhinotracheale isolates. 
 
Materials and Methods 
Experimental protocol 
Sixty-four 3-week-old female turkey poults with a mean body weight (BW) (± SD) of 0.556 (± 
0.057) kg (Hybrid Converter, local commercial turkey farm) were housed according to the 
requirements of the European Union (Anonymous, 2010). The animals were acclimatized for 
4 days and received water and feed ad libitum. Feed was withdrawn from 12 h before until 6 
h after GAM administration. The turkeys were randomly divided in two groups. Thirty-two 
animals received a subcutaneous (SC) bolus injection of 6 mg/kg BW GAM in the neck region. 
The other 32 birds were administered the same dose, but orally (PO) by gavage in the crop. 
Blood (1 mL) was collected from 5 animals per group by venipuncture of the leg vein into 
heparinized tubes (Vacutest Kima, Novolab, Geraardsbergen, Belgium) at different time 
points before (time 0 h) and post administration (p.a.; 0.08, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10 
and 12 h, and furthermore once daily in the morning from day 2 (24 h) until day 10 p.a. and 
once on days 12 and 14). Blood samples were centrifuged at 1500 x g at 4 °C for 10 min. 
Plasma was collected and stored at  ≤ -15 °C until analysis.  
From each group, four animals were sacrificed at different time points (day 1, 5, 10, 15, 20, 
30, 40 and 50 p.a.) to collect plasma, lung tissue and PELF. For that, the birds were 
anesthetized using a combination of xylazine (Xyl-M 2%, VMD, Arendonk, Belgium), 
zolazepam and tiletamine (Zoletil 100, Virbac, Wavre, Belgium), followed by exsanguination. 
The whole right lung was removed for GAM analysis. The complete left lung was used to 
collect PELF as described by Bottje et al. (1999). In brief, after weighing the lung, it was 
lavaged with heparin-saline (200 units heparin per mL of 0.9% saline) at a volume of 2 mL/g 
lung through a cannula in the first bronchus. The PELF/saline solution was collected in a petri 
dish and the amount of fluid was measured to determine the recovery, which ranged from 
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71.2 to 92.9%. The fluid was centrifuged (5250 x g for 3 min) to remove red blood cells. Both 
the lung tissue and PELF were stored at ≤ -15 °C until analysis. 
The animal experiment was approved by the Ethical Committee of the Faculty of Veterinary 
Medicine and Bioscience Engineering, Ghent University (EC 2013/107). 
 
Veterinary drug, analytical standards, chemicals and solutions 
Zactran, containing 150 mg GAM/mL (Merial Ltd, North Brunswick, NJ, USA) was used for the 
animal experiment. Just before drug administration, it was diluted with aqua ad injectabilia 
up to a concentration of 15 mg GAM/mL. 
The analytical standard of GAM and the internal standard (IS), deuterated-GAM (d5-GAM), 
were kindly donated by Merial Ltd and stored at 2 – 8 °C. Stock solutions of 1 mg/mL of GAM 
and d5-GAM were prepared in methanol (MeOH) and stored at ≤ -15 °C. Working solutions 
of 0.025, 0.050, 0.10, 0.25, 0.50, 1.0, 2.5, 5.0, 10.0, 25.0, 50.0 and 100 µg/mL of GAM were 
prepared by appropriate dilution in HPLC water. Working solutions of 1.0 and 10.0 µg/mL of 
the IS were prepared in HPLC water by appropriate dilution of the stock solution. The 
working solutions of GAM and IS were stored at 2 – 8 °C.  
The solvents used for HPLC analysis (water and acetonitrile, ACN) were of LC-MS grade and 
obtained from Biosolve (Valkenswaard, The Netherlands). All other solvents and reagents 
were of HPLC grade (water, ACN, MeOH and diethylether) or analytical grade (formic acid, 
ammonium acetate, sodium hydroxide (NaOH) and ammonium hydroxide) and purchased 
from VWR (Leuven, Belgium). Millex-GN Nylon (0.20 µm) syringe filters were obtained from 
Merck Millipore (Overijse, Belgium). Ostro protein precipitation and phospholipid removal 
96-well plates (25 mg) were obtained from Waters (Zellik, Belgium). HybridSPE-Phospholipid 
cartridges (30 mg/mL) were purchased from Sigma-Aldrich (Bornem, Belgium). 
 
Gamithromycin analysis 
Sample preparation for the analysis of GAM in turkey plasma, using the Ostro 96-well plates 
and a validated high performance liquid chromatography method with tandem mass 
spectrometric detection (LC-MS/MS), was performed as described by Watteyn et al. (2013a) 
for chicken plasma. Lung and PELF samples were analyzed using a validated LC-MS/MS 
method by De Baere et al. (2015). 
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The limit of quantification (LOQ) was 5 ng/mL, 50 ng/g and 20 ng/mL for plasma, lung tissue 
and PELF, respectively (De Baere et al., 2015). 
 
Minimum Inhibitory Concentration 
The MIC of GAM was determined using the agar dilution method, as described in Chapter 
1.1. The concentrations of GAM tested ranged between 0.03 and 32 µg/mL.  
The determination of the MIC was performed in duplo, with an interval of 3 weeks. 
 
Pharmacokinetic and statistical analysis 
Following plasma PK parameters were determined by non-compartmental analysis 
(WinNonlin 6.3, Pharsight, CA, USA): area under the plasma concentration-time curve from 
time 0 to the last time point with a quantifiable concentration (AUClast); the AUC from time 0 
to infinity (AUCinf); elimination rate constant (kel); elimination half-life (t1/2el); volume of 
distribution (Vd); total body clearance (Cl); Cmax and time to Cmax (tmax). The relative oral 
bioavailability (Frel) was calculated according to the following equation:            
Frel (%) 
A Clast PO
A Clast SC
 × 100. For lung tissue, AUClast, AUCinf, kel, t1/2el, Cmax and tmax were calculated 
in a similar way. Results below the LOQ were not taken into account. 
The plasma PK data are expressed as mean ± SD and were statistically analyzed by the 
nonparametric Mann-Whitney U test, using SPSS Statistics 22 (IBM, New York, USA). A value 
of P < 0.05 was considered significant. No SD could be calculated for the lung samples, as a 
sparse sampling protocol was used. Hence, no statistical analysis was performed.  
 
Results 
The semi-logarithmic plots of the mean and individual plasma concentration-time curves of 
GAM after SC and PO administration are depicted in Figure 1, while Figure 2 shows the 
comparison between the concentration-time curves in plasma and lung tissue.  
 
 
 
 
 
Experimental Studies – Chapter 1.2 
92 
A 
 
B 
 
C 
 
 
Figure 1. Panel A: Mean (± SD) plasma concentration versus time curve of gamithromycin (GAM) in 
turkeys, after subcutaneous (SC, n=5) or oral (PO, n=5) administration of 6 mg/kg BW GAM. Panel B: 
Individual plots of 5 turkeys after SC bolus administration. Panel C: Individual plots of 5 turkeys after 
PO bolus administration. p.a., post administration. 
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Figure 2. Panel A: Mean (+SD) plasma and lung tissue concentrations of gamithromycin (GAM) in 
turkeys, after subcutaneaous (SC) or oral (PO) administration of 6 mg/kg BW GAM. At each time 
point, four turkeys were taken into account. Values below the LOQ are indicated by ◊. The 
lung/plasma concentration ratios are displayed above the corresponding route of administration. 
p.a., post administration. Panel B: Individual plasma, lung tissue and PELF concentrations of GAM in 
turkeys after either a SC or PO single bolus administration. 
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
4 
4.5 
1 5 10 15 20 
C
o
n
ce
n
tr
at
io
n
 G
A
M
 (
µ
g/
m
L 
o
r 
µ
g/
g)
 
 
Time p.a. (days) 
Plasma SC 
Lung SC 
Plasma PO 
Lung PO 
54.4 ± 31.0 
87.9 ± 5.3 
51.9 ± 44.1 
79.6 ± 23.1 
◊ ◊ ◊ ◊ ◊ ◊ ◊ 
0.0 
1.0 
2.0 
3.0 
4.0 
5.0 
0 5 10 15 20 
C
o
n
ce
n
tr
at
io
n
 G
A
M
 (
µ
g/
m
L 
o
r 
µ
g/
g)
 
Time p.a. (days) 
Plasma SC 
Lung SC 
Plasma PO 
Lung PO 
54.7 ± 16.2 
Experimental Studies – Chapter 1.2 
94 
Table 1 shows the main PK properties of GAM for plasma and lung tissue. As can be 
observed, the AUClast as well as the AUCinf after PO administration for both plasma and lung 
tissue were much lower than after SC administration, with significant difference in plasma (P 
< 0.01 and P < 0.05 for AUClast and AUCinf, respectively.). After PO administration, Cmax in 
plasma was a ten-fold lower than after SC administration (0.087 and 0.89 µg/mL, 
respectively). Nevertheless, this discrepancy between SC and PO was not seen in the lung 
tissue (Cmax of 2.22 and 3.66 µg/g after PO and SC administration, respectively). The Vd and Cl 
were corrected for the relative oral bioavailability (Frel = 25.0%), and were not significantly 
different between routes of administration. Consequently, the t1/2 el in plasma for both 
routes of administration were not significantly different (Table 1 and Figure 1). 
As can be seen in Figure 2, the lung/plasma concentration ratios of GAM were up to 87.9. No 
plasma concentrations were detected from 10 and 15 days onwards after PO and SC 
administration, respectively.  
The concentration of GAM in all PELF samples was below the LOQ of 20 ng/mL. 
 
The MIC values of the 38 O. rhinotracheale isolates ranged from 0.25 to >32 µg/mL, namely 
0.25, 0.5, 1.0, 2.0, 4.0 and >32 µg/mL in respectively 1 (2.6%), 4 (10.5%), 9 (23.7%), 7 
(18.4%), 3 (7.9%) and 14 (36.8%) of the evaluated strains (Figure 3). For the type strain LMG 
9086, the MIC was 0.5 µg/mL. The MIC50 and MIC90 were 2 and >32 µg/mL, respectively. The 
control strains E. coli ATCC 25922 and S. aureus ATCC 29213 showed a MIC of >32 and 4 
µg/mL, respectively. 
 
 
Figure 3. Minimum inhibitory concentration (MIC) distribution of gamithromycin in 38 strains of 
Ornithobacterium rhinotracheale. The MIC50 and MIC90 were 2 and >32 µg/mL, respectively. 
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Table 1. The mean pharmacokinetic properties of gamithromycin in turkey poults after subcutaneous (SC) and oral (PO) bolus administration of 6 mg/kg BW, 
in plasma (n=5) and lung tissue (n=4 at each time point). Results are presented as mean ± SD. 
Parameter Units 
Plasma Lung 
SC PO SC PO 
AUClast h.µg/mL or h.µg/g
 5.14 ± 1.62 1.28 ± 0.72* 452.02 165.63 
AUCinf h.µg/mL or h.µg/g
 6.85 ± 2.83 2.17 ± 1.30* 466.85 180.75 
kel    h
-1 0.020 ± 0.0069 0.023 ± 0.20 0.0075 0.012 
t1/2 el    h 34.9 
A 29.7 A 92.6 59.8 
Vd/Fabs L/kg
 53.69 ± 19.66 203.52 ± 126.87 - - 
Cl/Fabs L/kg/h
 1.02 ± 0.47 3.80 ± 2.37 - - 
tmax h 0.08 ± 0.00
 0.85 ± 0.22* 24.0 24.0 
Cmax µg/mL or µg/g
 0.89 ± 0.41 0.087 ± 0.099* 3.66 2.22 
Frel % - 25.0 - - 
AUClast, area under the plasma concentration-time curve from time 0 to the last time point with a quantifiable concentration; AUC inf, the AUC from time 0 to infinity; kel, 
elimination rate constant; t1/2el, half-life of elimination; Vd/ Fabs, volume of distribution (not corrected for Fabs); Cl/Fabs, clearance (scaled by absolute oral bioavailability); tmax, 
time to maximum plasma concentration; Cmax,  maximum plasma concentration; Fabs, absolute bioavailability; Frel, relative oral bioavailability 
A: harmonic mean 
*
: significant difference (P < 0.05) in plasma between routes of administration 
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For macrolides in general, both the time the plasma concentration exceeds the MIC (T>MIC) 
and the area under the inhibitory curve (AUC/MIC) are taken into account as PK/PD indices. 
Considering the clear bimodal MIC distribution (Figure 3), the isolates were divided in a 
susceptible population (MIC between 0.25 and 4 µg/mL) and a resistant population (MIC >32 
µg/mL). In this study, the plasma concentrations never exceeded the MIC90 of the 
susceptible population, which was 2 µg/mL. The T>MIC90 in lung tissue was approximately 
3.5 days and 1 day after SC and PO administration, respectively. The AUCinf/MIC in plasma 
was 3.43 and 1.09 after SC and PO administration, respectively. For lung tissue, the 
AUClast/MIC was 233 and 90 after SC and PO administration, respectively. 
 
Discussion 
As macrolides, including GAM, are commonly used in cattle to treat BRD, a possible positive 
effect of GAM to cure an O. rhinotracheale infection in turkeys can be put forward. To 
identify the disposition of GAM in turkeys, a PK study of GAM in plasma, lung tissue as well 
as PELF was performed. These results were correlated to the MIC of several O. 
rhinotracheale strains in order to establish a pharmacokinetic/pharmacodynamic (PK/PD) 
correlation.  
The commercial formulation of GAM is only indicated for SC use, but as mass medication 
through drinking water and feed is the most important route of drug administration in 
poultry, GAM was also given orally as a single bolus in the crop.  
 
Plasma 
To the author’s knowledge, no plasma PK studies of macrolides in turkeys have been 
performed. After SC administration, GAM was absorbed very rapidly, with a tmax of 0.08 h, 
whereas tmax after oral administration was delayed (0.85 h). This rapid SC absorption was 
also seen in broiler chickens (Watteyn et al., 2013a). The t1/2 el of GAM was not significantly 
different between SC and PO administration (34.9 h and 29.7 h, respectively), and is similar 
to foals after intramuscular administration of 6 mg/kg BW GAM (39.1 h; Berghaus et al., 
2011). Cattle show a longer t1/2 el, around 50 h after SC administration (Huang at al., 2010; 
Giguère et al., 2011), while pigs eliminate the drug more rapidly after SC injection (t1/2 el = 
18.8 h; Wyns et al., 2014). In contrast with turkeys, chickens have a shorter t1/2 el after SC 
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administration (11.6 and 34.9 h for chicken and turkey, respectively), which can be partially 
attributed to a higher clearance in comparison with turkeys (1.77 and 1.02 L/kg/h for chicken 
and turkey, respectively; Watteyn et al., 2013a). Notwithstanding the Vd is similar for GAM in 
cattle, chickens and pigs (around 20 L/kg), in turkeys it was found to be higher (53.69 L/kg) 
and might thus also be responsible for the longer t1/2 el seen in turkeys. An explanation for 
this discrepancy is possible differences in protein binding across species (Rivière et al., 1997). 
Cl and Vd are not corrected for the absolute SC bioavailability (Fabs), as there are no PK 
parameters available after intravenous (IV) administration in turkeys. Taking into account 
that GAM is completely absorbed after SC injection in other species, including cattle, 
chickens and pigs, it can be suggested that it is also the case for turkeys (Huang et al., 2010; 
Watteyn et al., 2013a; Wyns et al., 2014). Comparing the AUC of GAM after PO and SC 
administration, this results in a relative bioavailability (Frel) of 25% after PO. When the Cl and 
Vd are adjusted for this Frel, these parameters have equal values after PO and SC 
administration. 
The maximum plasma concentration after a SC administration of 6 mg/kg BW GAM in 
turkeys (0.89 µg/mL) is equivalent to the Cmax reported for cattle and chickens (0.75 and 0.89 
µg/mL respectively; Huang et al., 2010; Watteyn et al., 2013a). This value is higher compared 
to foals (IM administration) and pigs, namely 0.33 and 0.41 µg/mL after administration of 
the same dose, respectively (Berghaus et al., 2011; Wyns et al., 2014). After an oral bolus, 
the Cmax in plasma is remarkably lower (0.087 µg/mL). A possible hypothesis for this 
difference could be the presence of the microbiota in the crop which could inactivate 
macrolides (Dutta and Devriese, 1981; Devriese and Dutta, 1984). 
 
Lung 
Although plasma concentrations of macrolides are often below the MIC of the pathogen, 
these drugs are effective in the treatment of respiratory diseases due to high levels of the 
active substance in target tissues, represented by their high Vd. Therefore, to evaluate the 
PK/PD correlation of macrolides, it is of great importance to measure drug concentrations in 
the target tissues. In the present study, high lung concentrations were detected, with 
lung/plasma concentration ratios between 54.7 to 87.9 after SC injection. This is in 
accordance with previous reports (Huang et al., 2010; Giguère et al., 2011) where 
lung/plasma ratios up to 200 were observed after SC administration of GAM in cattle. 
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Although lower compared to SC administration, high lung/plasma ratios were also observed 
after oral administration (51.9 – 54.4). Notwithstanding the Cmax in plasma after PO was a 
ten-fold lower than after SC administration, this discrepancy was not observed in the lung 
(3.66 and 2.22 µg/g after SC and PO administration on day 1 p.a.). As macrolides can be 
considered as time-dependent antibiotics, the AUC is even more important than Cmax. If the 
AUC would be a parameter to compare the amount of drug in plasma and lung tissue, this 
ratio (AUClung/AUCplasma) remains constant, after SC as well as PO administration (respectively 
53.6 and 51.9 on day 1 p.a.; 55.5 and 45.3 on day 5 p.a.). After SC injection, the t1/2 el of GAM 
in lung tissue was similar for cattle and turkeys, namely around 90 h (Huang et al., 2010; 
Giguère et al., 2011), while it was shorter after oral administration (59.8 h).  
 
PELF 
Currently, the pathogenesis of O. rhinotracheale and the factors determining colonization of 
the host tissue are still unclear. O. rhinotracheale adheres to avian erythrocytes and tracheal 
cells, behaving as an extracellular pathogen (De Haro-Cruz et al., 2013). In contrast, Zahra et 
al. (2013) isolated small-colony variants of O. rhinotracheale, which persist intracellularly in 
murine RAW 264.7 macrophages. This new insight is of great importance for a successful 
treatment with antimicrobials, although it is not clear if O. rhinotracheale is also able to 
persist in avian macrophages. It is most likely that the distribution of GAM varies among the 
different compartments of the respiratory tract, such as intracellularly in host defense cells 
(e.g. macrophages), extracellularly and in bronchial fluid (Huang et al., 2010; Giguère, 2013). 
As in this study whole lung tissue homogenates were analyzed, the mean concentration in all 
these compartments was measured. Determination of GAM in PELF might give a more 
accurate prediction as these concentrations are of importance for extracellular pathogens. 
Therefore, Giguère and Tessman (2011) concluded that measurement of the concentrations 
of macrolides in PELF would be a better predictor of their efficacy than either lung or plasma 
concentrations. As macrolides reach high intracellular concentrations, tissue homogenates 
could overestimate extracellular concentrations in relation to the PELF.  
 
To date, no PK data of macrolides in PELF from poultry are available. Giguère et al. (2011) 
detected PELF concentrations of GAM in cattle that were much higher than in plasma, but 
lower than in lung tissue (ratios between 4.7 and 127 for PELF/plasma and between 16 and 
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650 for lung/plasma). Also in foals, GAM reached high levels in PELF, with PELF/plasma ratios 
between 4.7 - 70 (Berghaus et al., 2011). Remarkably, in this study no concentrations of 
GAM above the LOQ could be detected in PELF of turkeys. A possible explanation could be 
the typical anatomical arrangement of the respiratory system in avian species. The 
intrapulmonary primary bronchus ramifies in several secondary bronchi and ends in the 
abdominal air sac. The ventro- and laterobronchi end also in air sacs via ostia, while the 
dorsobronchi give rise to parabronchi. In contrast to mammals, birds have flow-through 
lungs with a nearly constant volume, in which the gas exchange takes place in the 
parabronchi. As air sacs act as bellows, they are the sites of volume expansion and move air 
through the parabronchi (Brown et al., 1997; Fedde et al., 1998; Powell, 2000). These 
anatomical differences have an influence on the collection method for PELF. In mammals, 
PELF is collected by intrabronchial administration of saline in live animals, followed by 
aspiration of the saline solution and a recovery correction based on an endogenous 
component, such as ureum. In poultry, on the other hand, the bronchi are connected with 
the air sacs via ostia. As a consequence, it is impossible to apply the same technique as in 
mammals. The used technique in this study was based on a heparin-saline solution to flush 
the ex vivo lungs, which distributed in the lung and was immediately flushed out of the lungs 
through these ostia as was reported by Bottje et al. (1999). In contrast, Bernhard et al. 
(2001) used an in situ method in ducks and chickens. The air sacs were ligated and lungs 
were flushed with saline, followed by aspiration of the fluid. In vivo collection in chickens has 
also been described. After placing the bird on its back, a tubing was threaded down the 
exteriorized trachea to the bronchi and air was evacuated from the lung. Warm buffer was 
administered and the fluid sample was aspirated (Holt et al., 2005). The results obtained 
might therefore be dependent on the collection method. 
 
Another factor related to the discrepancy seen in GAM concentrations in PELF between 
mammals and turkeys is the different immunology between the two classes, as GAM also 
distributes in macrophages. The epithelial surface of the mammalian lung is covered by a 
thin layer of PELF and resident immune cells, such as macrophages (Reynolds, 1987). On the 
contrary, birds have less or even no phagocytic cells in healthy lavage samples. A small 
number of macrophages can be found on the epithelial lining of the parabronchi, whereas 
leucocytes are often present on the surface of the air sacs (Härtle and Kaspers, 2014). To 
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conclude, the avian intracellular distribution of GAM in PELF is difficult to measure, as 
macrophages are not a constitutively present cell population. 
However, concentrations of FF in PELF could be measured after a single oral bolus of FF 
(Chapter 1.1). 
 
MIC and PK/PD correlation 
The sensitivity of O. rhinotracheale to antibiotics is very inconsistent and highly strain-
dependent (Devriese, 1995; Devriese et al., 2001). In this study, a MIC50 of GAM against O. 
rhinotracheale of 2 µg/mL was obtained, while the MIC90 would be considered to be more 
than 32 µg/mL. This remarkable difference suggests an indication for acquired antimicrobial 
resistance of the pathogen against GAM. Also the MIC distribution of the 38 evaluated 
strains typically points towards acquired resistance as it has a bimodal distribution with 14 of 
the 38 isolates not belonging to the wild-type population (Fig. 3). Since GAM has never been 
used to treat an O. rhinotracheale infection, the acquired resistance might be a cross-
resistance from other macrolides, such as erythromycin and tylosin. Devriese et al. (2001) 
evaluated the sensitivity and resistance to several macrolides in Belgian O. rhinotracheale 
strains. Tylosin also had a wide range of MIC values (1 to ≥ 64 µg/mL), although normal 
susceptibility levels for the type strain LMG 9086T (MIC of ≤ 0.12 µg/mL) were observed. In 
the Netherlands, none of the tested O. rhinotracheale strains were inhibited by 
erythromycin or tilmicosin at a concentration of 64 µg/mL, whereas the MIC50 and MIC90 for 
tylosin were 4 and 8 µg/mL, respectively (van Veen et al., 2001). Also tylvalosin showed 
rather low MIC values against O. rhinotracheale strains originating from Germany and the 
Netherlands, with a MIC50 of 2 µg/mL and MIC90 of 8 µg/mL (Schwarz et al., 2012). 
Since macrolides are classified as time-dependent antimicrobials with significant post-
antibiotic effects, the efficacy of these antibiotics is generally accepted to correlate with 
both T>MIC and AUClast/MIC (Van Bambeke and Tulkens, 2001; Andes et al., 2004; Hesje et 
al., 2007; Barbour et al., 2010; Giguère and Tessman, 2011). The established plasma cut-off 
values for Gram-negative bacteria are 40-50% for T>MIC, expressed for the dosage interval, 
and 125 for AUC/MIC, based on a 24 h period in plasma steady state conditions (Lees et al., 
2008). As GAM has never been used to treat an infection with O. rhinotracheale resistant 
strains at the current dosage scheme, the authors decided to take only the susceptible 
population into account, in which the MIC90 was 2 µg/mL. Whether the T>MIC values 
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calculated in this study are high enough for a good efficacy of GAM against O. rhinotracheale 
is difficult to evaluate, as there are no cut-off values available for slowly eliminating 
antimicrobials, such as GAM. Recently, it was suggested that the time period to determine 
the T>MIC of these antibiotics may extend 24 h (Martinez et al., 2013). 
 
Since GAM was given as a single bolus, no steady state situation was achieved, instead the 
AUCinf was taken into account for plasma PK/PD correlations (Martinez et al., 2013). 
Furthermore, adapted cut-off values could be considered as lung tissue concentrations of 
macrolides tend to be higher than plasma concentrations. This was supported since a good 
efficacy for tulathromycin and azithromycin was correlated with low plasma AUC/MIC ratios, 
only 3.38 and 5, respectively (Lodise et al., 2005; Martinez et al., 2013). Similar values were 
found for GAM. Considering the AUClast/MIC for lung tissue, the cut-off value of 125 can be 
accepted. Results far above and around this value were found for GAM. Both plasma 
AUCinf/MIC and lung AUClast/MIC results could therefore assume a good activity of GAM 
against O. rhinotracheale.  
 
Conclusion 
It can be concluded that the absorption of GAM after SC as well as PO administration is rapid 
and a high tissue distribution is reflected in the high Vd. Although the plasma concentrations 
after oral absorption are much lower than after SC injection, the lung concentrations after 
both routes of administration are nearly equivalent after 24 h. These high concentrations in 
the target lung tissue are of major importance for the treatment of respiratory infections, 
such as O. rhinotracheale. Nevertheless, an improved or appropriated formulation for oral 
therapy or an adjusted dose of GAM could improve the plasma and lung concentrations after 
PO administration. 
The low GAM concentrations in PELF found in this study could be a result of the different 
anatomy of the respiratory system in birds compared to mammals, which would require a 
different collection method for PELF. Also a difference in immune cells present in the 
respiratory tract of birds compared to mammals might be responsible. To date, the 
collection of PELF in poultry is poorly investigated and requires more research. For 
macrolides, there is no single PK/PD index that correlates with efficacy for all members in 
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this class of antibiotics. The authors endeavor to correlate the plasma and lung PK 
parameters to the MIC values, but whether these values result in a therapeutic efficacy 
should be further determined in experimental and field infection studies (Marien et al., 
2005, 2006, 2007; Garmyn et al., 2009a,b).  
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in turkeys 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from:  
Watteyn A.*, Russo E.*, Garmyn A., De Baere S., Pasmans F., Martel A., Haesebrouck F., Montesissa C., De 
Backer P. and Croubels S. (2013). Clinical efficacy of florfenicol administered in the drinking water against 
Ornithobacterium rhinotracheale in turkeys housed at different environmental conditions: a PK/PD 
approach.  Avian Pathology, 42(5), 474-481. *Shared first authorship 
  
 
  
Experimental Studies – Chapter 2.1 
107 
Abstract 
In poultry rearing, medicated drinking water is a commonly used administration route, but 
drug uptake can be affected by many factors. In this study, the influence of two important 
parameters, photoperiod and feeding schemes, on florfenicol efficacy against 
Ornithobacterium rhinotracheale was evaluated. This Gram-negative bacterium is a 
respiratory pathogen that often affects turkeys.  
All birds were oculonasally infected with O. rhinotracheale at a dose of 8.5 log10 cfu, 
preceded by infection with avian metapneumovirus (APV, at a dose of 4.4 log10 CD50). The 
positive control group received no treatment. Florfenicol was given to the treated groups as 
a 5-day treatment of 30 mg/kg body weight florfenicol administered via drinking water and 
considering different photoperiods and feeding schemes (group 20/4L: photoperiod of 20 h, 
fed ad libitum; group 16/8L: photoperiod of 16 h, fed ad libitum; group 16/8R: photoperiod 
of 16 h, fed ad libitum but feed was withdrawn during the dark period and replaced 1 h after 
lighting).  Starting from the APV infection till the end of the experiment, the animals were 
clinically examined and scored daily. Additionally, tracheal swabs were collected at several 
days post-bacterial infection (p.b.i.). Necropsy was performed at 6 and 14 days p.b.i. to 
evaluate the presence of gross lesions, and to collect trachea and lung tissue samples and 
airsac swabs for O. rhinotracheale quantification.  
In all groups, a clinical improvement could be noticed, resulting in reduction of the clinical 
score. However, only the 16/8L and 16/8R groups showed significant differences from the 
control group. The results demonstrated an important influence of the photoperiod on the 
clinical outcome in an infection model. It can be advised that the photoperiod should be < 20 
h to have sufficient drug intake. Nevertheless, there was no effect between fed and fasted 
turkeys for the clinical outcome. 
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Introduction 
Viral and bacterial respiratory diseases often affect turkeys during the production round, 
resulting in economic losses due to an increased mortality and feed conversion rate, a 
reduction in growth rate and high medical costs (van Empel and Hafez, 1999).  
Ornithobacterium rhinotracheale is a Gram-negative bacterium that affects the respiratory 
tract causing severe respiratory symptoms, depression, reduction in feed uptake and growth 
rate. To exert its pathogenic action, this bacterium needs the association with a predisposing 
factor that primarily affects the respiratory tract, like viral infections (avian 
metapneumovirus (APV), influenza virus, turkey rhinotracheitis virus, Newcastle disease 
virus) or environmental factors, such as poor management, inadequate ventilation, poor 
hygiene, high stocking density, high ammonia level, simultaneous infections, incorrect 
temperature and relative humidity, which can affect bird immunity (van Empel and Hafez, 
1999).  
To control O. rhinotrachelae infections in poultry-rearing, a strict biosecurity level and 
optimal environmental conditions are required. An effective vaccine is available but not 
commonly used in the field due to the seroselectivity (van Empel and Hafez, 1999; Murthy et 
al., 2007). Antimicrobial therapy can be applied during outbreaks but a careful evaluation 
has to be made on the antimicrobial agent choice as a high resistance level against a wide 
range of antimicrobial classes employed in aviculture has been reported (van Veen et al., 
2001; Soriano et al., 2003; Zaini et al., 2008). This choice is hampered by the absence of a 
commercial screening method for the evaluation of antimicrobial sensitivity. A study 
evaluated the efficacy of three antimicrobial drugs in an in vivo infection model against O. 
rhinotrachelae in turkey, i.e. enrofloxacin (10 mg/kg), amoxicillin and florfenicol (FF, both 20 
mg/kg), and enrofloxacin was found the most successful drug, followed by FF (Marien et al., 
2006). However, in this research, plasma concentrations of FF were not measured and no 
correlation was made with the clinical outcome. Also no stability examinations of FF in the 
medicated drinking water were considered. A recent study proved the stability of FF during a 
ten day period at concentrations of 10 and 100 µg/mL (Muijsers et al., 2012). 
Florfenicol is a broad spectrum synthetic antibiotic developed for veterinary use. It is a 
structure analogue of thiamphenicol (TAP), with a fluorine atom at the 3’ carbon position. 
This antibiotic acts as an inhibitor of the protein synthesis at the 50S ribosomal subunit by 
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blocking peptidyltransferase, and has a bacteriostatic action (Liu et al., 2003, Papich and 
Rivière, 2009). Efficacy of FF has been demonstrated against many animal diseases (Marien 
et al., 2007; Roiha et al., 2011; Thiry et al., 2011; Del Pozo Sacristan et al., 2012) and FF has 
been approved in Europe for treatment of fish, cattle, pigs and chickens (EMA, 2002). In pig 
and poultry farming it is current practice to administer antimicrobials via medicated feed or 
drinking water (Vermeulen et al., 2002). Drinking water medication is the most commonly 
used route of drug administration in intensively reared poultry, treating contemporaneously 
sick animals, but it can also give rise to some disadvantages. Drug intake between animals 
can vary dramatically due to both animal factors (hierarchy, flock size, sex, age, weight, 
species, breed, health status, etc.) and environmental factors (temperature, humidity, feed 
and water availability, photoperiod, etc.) (Vermeulen et al., 2002). This can lead to sub-
bacteriostatic or –cidal concentrations, resulting in therapy failure. 
The eating and drinking patterns alter depending the light scheme (Classen et al., 1994), 
which could have a huge influence on the uptake of drinking water medication. As FF is a 
time-dependent antibiotic (Hesje et al., 2007), it is important to have a frequent drug intake. 
Previously, the influence of the photoperiod was demonstrated on the pharmacokinetics 
and pharmacodynamics (PK/PD) (Watteyn et al., 2013). During a light period of 20 h the 
concentrations of FF showed a drop, while it was more constant during 16 h of light. Also 
different feeding schemes were investigated. However, no influence of feed restriction was 
observed. Accordingly, a study with the same different housing conditions based on 
photoperiod and feeding schemes is mandatory for the establishment of an efficient 
treatment protocol.  
The aim of this research was to evaluate the efficacy of continuous water medication with 30 
mg/kg body weight (BW) of FF during 5 days in turkeys against O. rhinotrachelae infection in 
an in vivo infection model.  
 
Materials and methods 
Micro-organisms 
The O. rhinotrachelae strain LMG 9086T was originally isolated from a turkey with a 
respiratory tract infection. The strain was serotyped as type A in an agar gel precipitation 
test, kindly performed by Prof. Hafez (Institute of Poultry Diseases, Free University of Berlin, 
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Germany; Hafez and Sting, 1999). The strain was cultured for 48 h at 37 °C on Columbia agar 
(Oxoid Ltd, Basingstoke, Hampshire, UK) with 5% sheep blood in a 5% CO2 atmosphere, 
followed by growing into brain heart infusion broth (Oxoid) for 24 h at 37 °C with agitation. 
The cultured bacteria were washed twice in phosphate-buffered saline (PBS) followed each 
time by 5 min of centrifugation at 1509 x g at 4 °C. The bacterial challenge inoculum was 
prepared by resuspending the pellet in PBS to obtain a final concentration of 108 colony-
forming units (cfu)/mL. To confirm the titre, 10-fold dilutions in PBS were inoculated on 
sheep blood agar and the number of colonies was counted. 
The APV strain A/T6/96 (subtype A) was kindly donated by Prof. Nauwynck (Laboratory of 
Virology, Faculty of Veterinary Medicine, Ghent University, Belgium). The strain was isolated 
during a respiratory outbreak on a Belgian turkey farm (Van de Zande et al., 1998) 
 
Veterinary drug 
Florfenicol, 2,2-dichloro-N-[1S,2R)-1-(fluoromethyl)-2-hydroxy-2-[4-(methylsulfonyl)-
phenyl]ethyl]-acetamide, was obtained from Zhejiang Hisoar Pharmaceutical Co., LTD 
(Zhejiang, China). 
The medicated drinking water was prepared daily by stirring an appropriate solution for 30 
minutes, followed by sonication for 20 minutes to dissolve the FF. 
 
Clinical experiment 
Fifty-six 1-day-old female turkeys (Moorgut Kartzfehn, Bösel, Germany) were housed 
according to the requirements of the European Union (Anonymous, 2010). They were kept 
together in an isolation room with HEPA-filtered air on wood shavings, had free access to 
feed and water, and received 15 h of light/day. At 3 weeks of age the animals were randomly 
divided in 4 groups (14 animals each) with different environmental conditions. The first 
group received 20 h light (between 8 h a.m. and 4 h a.m.)/4 h dark and was fed ad libitum 
(20/4L). The second group received 16 h light (between 8 h a.m. and 12 h p.m.)/8 h dark and 
was fed ad libitum (16/8L) and the third group had the same light cycle and was fed ad 
libitum except during the dark period in which feed was taken away (16/8R). These animals 
received feed again 1 h after the light was put on. The last group was a positive control 
group (C), with the same conditions as 16/8L. 
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All animals were negative for maternally derived antibodies to APV and O. rhinotrachelae at 
2 weeks, by analysing the blood using commercially available enzyme-linked immunosorbent 
assay (ELISA) kits (Biochek, Gouda, the Netherlands). Tracheal swabs from all birds were 
collected and analysed to verify the absence of O. rhinotrachelae. 
Table 1 displays the time schedule of the experiment. 
At 23 days of age all animals were oculonasally infected with APV at a dose of 4.4 log10 
ciliostatic dose (CD50), using a virus stock titre of 5.5 log10 50% CD50/mL after the third 
passage in tracheal organ cultures. 
Three days post-viral infection (p.v.i.) all animals were infected with O. rhinotrachelae at a 
dose of 8.5 log10 cfu by dividing a total of 250 µL of inoculum equally over the nostrils and 
eyes. 
The control group (C) was not treated with FF, while the 3 other groups (20/4L, 16/8L and 
16/8R) received FF continuously via the drinking water during a 5-day period (target dose: 30 
mg/kg BW/day) starting one day post-bacterial inoculation (p.b.i.). Animals were all weighed 
the day of APV inoculation, and again the day of O. rhinotrachelae inoculation. The water 
uptake was measured daily from 3 days before until the end of the treatment. These data 
were used to determine the inclusion of FF in the medicated drinking water and to evaluate 
the exact amount of drug daily received (based on BW and drinking water intake). 
A clinical examination of all turkeys was made daily until 14 days p.b.i., and the clinical signs 
of animals were scored as follows: 0, no clinical signs; 1, clear nasal exudates; 2, turbid nasal 
exudates; 3, nasal exudates with mild swollen infra-orbital sinuses; 4, nasal exudates with 
extreme swollen infra-orbital sinuses; 5, nasal exudates with extreme swollen infra-orbital 
sinuses and frothy eyes; 6, death.  
Tracheal swabs were collected from all groups for quantification of O. rhinotrachelae using 
cotton-tipped aluminium shafted swabs (Copan Diagnostics Inc., Corona, USA) at 1, 2, 4, 6, 8, 
10 and 14 days p.b.i. Swabs were processed immediately after collection and the 
quantification (cfu/mg of mucus) was performed as described by Marien et al. (2005).  
Six birds of each group were sacrificed at 6 days p.b.i. and the remaining birds were 
sacrificed at 14 days p.b.i. Euthanasia was performed by intravenous injection of 0.3 mL/kg 
BW of T61 (Intervet, Belgium). Necropsy of all birds was performed to evaluate the presence 
of gross lesions. At 6 days p.b.i., samples of the trachea and lungs were collected for O. 
rhinotrachelae quantification. A 10% tissue suspension in PBS was prepared from these 
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samples. The air sacs were sampled with cotton swabs for bacterial isolation. At day 14 p.b.i. 
the trachea, lungs and air sacs were sampled with cotton swabs for O. rhinotrachelae 
isolation. All samples were processed immediately after collection following the procedure 
described by Garmyn et al. (2009a,b). 
The clinical trial was approved by the Ethical Committee of the Faculty of Veterinary 
Medicine and Bioscience Engineering of Ghent University (EC2011/001). 
 
Table 1. Time schedule of the infection experiment. 
Day  -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Infection  APV 
  
ORT 
              
Therapy  
    
X X X X X 
         
Clinical 
score  
X X X X X X X X X X X X X X X X X X 
Tracheal 
swabs      
X X 
 
X 
 
X 
 
X 
 
X 
   
X 
Necropsy  
         
n=6 
       
n=8 
APV, avian metapneumovirus; ORT, O. rhinotracheale 
 
Statistical analyses 
The parameters were statistically analysed by means of single-factor analysis of variance 
(ANOVA) with Bonferroni correction. The area under the curve (AUCday 1-6pbi) of the bacterial 
titre and the isolation of O. rhinotrachelae in trachea and lung were analysed by the Kruskal 
Wallis test. A P-value < 0.05 was considered statistically significant. 
For the analysis of clinical score and tracheal swabs, both the mean score and the AUC of the 
clinical score-time curve and the titre-time curve, respectively, were considered. The AUC 
was calculated by the linear trapezoidal rule. These statistical analyses were performed using 
SPSS Statistics 20 (IBM SPSS software, New York, USA). 
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Results 
During the experiments, mortalities did not take place in any of the experimental groups. 
Tracheal swabs before infection were all negative for O. rhinotrachelae.  
Mean BW (± SD) for each group of turkeys at the day before the bacterial infection, 6 and 14 
days p.b.i. are reported in Table 2. At all occasions, there was no significant difference in BW 
between groups. 
As can be seen in Figure 1, respiratory signs were observed in the four experimental groups, 
starting from day 1 p.b.i., followed by a decrease of the clinical score around day 4 p.b.i. 
There were statistically significant differences between 16/8L vs. C (17.33 ± 5.04 and 34.00 ± 
8.53, respectively, with p<0.01) and 16/8R vs. C (19.86 ± 6.34 and 34.00 ± 8.53, respectively, 
with p<0.01) for AUCday 1-14 pbi (mean ± SD) of the clinical score.  
 
 
 
 
Figure 1. Mean clinical scores of turkeys inoculated with avian metapneumovirus and O. 
rhinotracheale, and which were not treated (group C, ×) or treated with 30 mg/kg of florfenicol via 
medicated water for 5 days: group 20/4L (20h light and 4 h dark, fed ad libitum, ), group 16/8L (16 
h light and 8 h dark, fed ad libitum, ), group 16/8R (16 h light and 8 h dark, fed ad libitum from 1h 
after the lighting, ). 
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Figure 2. Mean O. rhinotracheale titres in tracheal swabs collected from turkeys inoculated with 
avian metapneumovirus and O. rhinotracheale, and which were not treated (group C, ×) or treated 
with 30 mg/kg of florfenicol via medicated water for 5 days: group 20/4L (20h light and 4 h dark, fed 
ad libitum, ), group 16/8L (16 h light and 8 h dark, fed ad libitum, ), group 16/8R (16 h light and 8 
h dark, fed ad libitum from 1h after the lighting, ). 
 
 
Figure 2 shows O. rhinotrachelae titres in tracheal swabs over a period of 14 days. Up to 6 
days p.b.i. no increase in titres could be observed in the groups treated with FF. This resulted 
in significant differences for the AUCday 1-14 pbi (mean ± SD) between C (30.06 ± 5.28) and all 
treated groups (17.06 ± 9.62, 14.13 ± 5.59, 11.30 ± 8.06, with p<0.05, p<0.01 and p<0.01 for 
20/4L, 16/8L and 16/8R respectively).  
 
Results of necropsy are depicted in Table 2. Bacterial titres of trachea and lung samples 
collected 6 days p.b.i. showed a significant difference between the non-treated group (group 
C) and all other groups. Samples collected 14 days p.b.i. showed no statistical difference 
between groups. Almost all tissues were negative for O. rhinotrachelae. 
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Table 2. Clinical score, tracheal O. rhinotrachele titres, isolation of O. rhinotrachele from several organs and mean body weight of turkeys inoculated with avian 
metapneumovirus and O. rhinotrachele with an interval of 3 days and treated with 30 mg/kg FF via drinking water for 5 days, with different photoperiods. 
Group Clinical score 
O. rhinotracheale 
titres in tracheal 
swabs 
Isolation of O. rhinotracheale Body weight (g) 
 
AUC 
day 1-6 pbi 
AUC 
day 1-14 pbi 
AUC 
day 1-6 pbi 
AUC 
day 1-14 pbi 
6 days pbi  
(log10cfu/mL) 
14 days pbi  
(n positive/n tested) 
Before 
infection 
6 days pbi 14 days pbi 
Trachea Lung Airsac 
 
Trachea Lung Airsac  
  
C 
14.7 ± 
5.5 A 
34.0 ± 
8.5 A 
13.3 ± 
2.2 A 
30.1 ± 
5.3 A 
6/6 
6.01 ±  
0.20 A 
6/6 
3.63 ± 
0.69 A 
2/6 
 
0/8 0/8 0/8 
442.1 ±  
69.5 A 
702.1 ± 
102.8 A 
1146.0 ± 
171.1 A 
20/4L 
12.6 ± 
4.2 AB 
27.9 ± 
6.6 AB 
0.98 ± 
2.7 B 
17.1 ± 
9.6 B 
2/6 
0.88 ±  
1.36 B 
1/6 
0.65 ± 
1.59 B 
0/6 
 
1/8 0/8 0/8 
429.3 ±  
60.0 A 
775.6 ± 
104.9 A 
1240.0 ± 
147.5 A 
16/8L 
9.0 ± 
2.6   B 
17.3 ± 
5.0 C 
0.84 ± 
1.7 B 
14.1 ± 
5.6 B 
0/6 
   0.00 B 
0/6 
   0.00 B 
0/6 
 
3/8 0/8 0/8 
433.2 ±  
60.3 A 
763.4 ± 
101.6 A 
1095.5 ± 
142.0 A 
16/8R 
10.0 ± 
2.5 B 
19.9 ± 
6.3 BC 
0.11 ± 
0.4 B 
11.3 ± 
8.1 B 
0/6 
   0.00 B 
0/6 
   0.00 B 
0/6 
 
1/8 0/8 0/8 
450.7 ±  
50.4 A 
779.9 ± 
112.9 A 
1205.7 ± 
149.8 A 
All results are presented as mean ± SD. 
Group 20/4L, 20h light and 4 h dark, fed ad libitum; group 16/8L, 16 h light and 8 h dark, fed ad libitum; group 16/8R, 16 h light and 8 h dark, fed ad libitum from 1 h after the lighting, all 
treated with FF (30 mg/kg BW); or no treatment (group C). Data are presented as the mean value ± standard deviation. 
A, B, C, D 
Treatments sharing a letter do not differ from one another at the 5% global significance level. 
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Discussion 
Medicated drinking water is a commonly used administration route to treat intensively 
reared poultry. As already reported, drug intake however can be affected by many factors 
using this way of oral medication. In this study, the influence of two important parameters, 
namely photoperiod and feeding schemes on FF uptake using drinking water administration, 
has been tested. The results demonstrated an important influence of the photoperiod on the 
clinical outcome in an ORT infection model. Nevertheless, there was no effect of the feeding 
schemes. 
 
The clinical scores highlight a difference between the two photoperiods, the 20/4L group has 
a scoring that is intermediate between the other two treated groups and the untreated 
control group. The replication degree of O. rhinotrachelae in the trachea at the end of the 
therapy confirms this difference. This is in accordance with our PK/PD findings previously 
discussed (Watteyn et al., 2013). The decreased efficacy of the therapy in the group 20/4L is 
most probably related to the irregular and too low plasma concentration of the drug as 
mentioned in the PK/PD study. Indeed, the PK/PD index T>MIC was below 40% in the group 
20/4L, suggesting an insufficient concentration of FF to be efficacious to eradicate the 
bacterium (Watteyn et al., 2013).  
No differences were seen between the groups 16/8L and 16/8R. Therefore, we can conclude 
that there was no effect of feed restriction on the therapeutic outcome. 
Marien et al. (2006) tested a commercially available drinking water formulation of FF (20 
mg/kg BW) in a similar in vivo infection mode and reported no significant reduction in clinical 
symptoms. FF did reduce the bacterial titre, but only to 3 log10 cfu/g mucus. However, during 
our clinical trial, the administration of a higher dose of 30 mg FF/kg BW via the drinking 
water for a 5-day period was able to reduce the bacterial titre in tracheal swabs at 6 days 
p.b.i. to less than 1 log10 cfu/mL in all treated groups. This discrepancy between the two 
studies could be related to the different dose of the drug. 
For every treated group, the bacterial titre remained below 0.5 log10 cfu/mL during the 
administration of the drug. A few days after the end of the treatment, there was an increase 
of the bacterial growth to 3 and 4 log10 cfu/mL for the groups with 16 and 20 h of light, 
respectively. This is in accordance with the PK/PD findings reported by Watteyn et al. 
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(2013b). Florfenicol was eliminated out of the body after 24 h. However, the mean clinical 
score in the first 3 days of antibiotic administration was high, in which the control group had 
the highest score, followed by respectively the groups with 20 h and 16 h of light. The 
presence of the clinical symptoms in the treated groups seems to be rather associated with 
APV infection alone as already reported by other investigators (Van de Zande et al., 2001). 
From day 4 of treatment onward, these clinical scores were strongly reduced. Accordingly, it 
can be stated that the administration of FF at the onset of the viral respiratory infection can 
significantly reduce clinical symptoms caused by secondary bacterial infections, such as O. 
rhinotrachelae. 
 
In conclusion, this study confirms the need for a dark period of more than 4 h in medicated 
drinking water administration. The continuous administration of 30 mg of FF/kg BW via the 
drinking water for 5 days at a photoperiod of 16 h seems to be effective to cure of an O. 
rhinotracheale infection in turkeys.  
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Abstract 
Ornithobacterium rhinotracheale is a common avian respiratory pathogen that often affects 
turkeys during the production round, resulting in important economic losses. The objective 
of this study was to evaluate the clinical efficacy of gamithromycin (GAM) against O. 
rhinotracheale in turkeys. The birds were oculonasally inoculated with 8.5 log10 colony 
forming units of O. rhinotracheale, preceded by infection with avian metapneumovirus (APV, 
at 4.4 log10 50% ciliostatic dose). Besides a negative (CONTR-, not infected, not treated) and 
a positive control group (CONTR+, infected, not treated), there were two treated groups 
administered GAM (6 mg/kg body weight) either subcutaneously (GAM SC) or orally (GAM 
PO) as a single bolus at one day post-bacterial infection (p.b.i.). Starting from the APV 
infection till the end of the experiment, the animals were clinically examined and scored 
daily. Additionally, tracheal swabs were collected at several days p.b.i. Necropsy was 
performed at 4, 8 and 12 days p.b.i. to evaluate the presence of gross lesions, and to collect 
trachea and lung tissue samples and airsac swabs for O. rhinotracheale quantification.  
The clinical score of the GAM SC group showed slightly lower values and birds recovered 
earlier compared to GAM PO and CONTR+. O. rhinotracheale titres were significantly 
reduced in tracheal swabs of the SC group between 2 and 4 days p.b.i. At necropsy, CONTR+ 
showed higher O. rhinotracheale titres and lung tissues compared to the treated groups. 
Moreover, at 8 days p.b.i. only the lung samples of CONTR+ were positive. 
In conclusion, the efficacy of GAM against O. rhinotracheale was demonstrated in the lung 
tissue. However, the PO bolus administration of the commercially available product was not 
as efficacious as the SC bolus. 
 
  
Experimental Studies – Chapter 2.2 
122 
Introduction 
Ornithobacterium rhinotracheale is a Gram-negative bacterium, which causes respiratory 
disease in poultry, characterized by pneumonia, tracheitis and airsacculitis (Hinz et al., 1994). 
An infection with this agent often results in severe economic losses due to increased 
mortality and feed conversion rate, reduction in growth rate and egg production as well as 
increased medical costs (Van Empel and Hafez, 1999). In Canada, O. rhinotracheale is even 
the third most frequently diagnosed pathogen in turkeys (Agunos et al., 2013). A bacterin 
vaccine against this bacterium is available, but not commonly used in the field, as it does not 
provide strong and cross-protection against the various serotypes of O. rhinotracheale (Van 
Empel and Hafez, 1999; Schuijffel et al., 2006; Murthy et al., 2007). Hence, antimicrobial 
drug therapy is most frequently applied, but the sensitivity of O. rhinotracheale to antibiotics 
is strain-dependent (Devriese, 1995; Devriese et al., 2001; Schwarz et al., 2012; Watteyn et 
al., 2015). The efficacy of drinking water therapy has already been tested for different 
antimicrobial drugs using an O. rhinotracheale infection model in turkeys, and enrofloxacine 
as well as florfenicol were found to be effective to cure the infection (Marien et al., 2006; 
Watteyn et al., 2013b), whereas amoxicillin was not (Marien et al., 2006). Moreover, the 
photoperiod has an important influence on the water consumption and consequently on the 
uptake of drugs. Accordingly, this may have an effect on the pharmacokinetics (PK) of drugs 
when applied in drinking water, as well as on the clinical outcome (Watteyn et al., 2013b). 
The latter study in turkeys demonstrated that the photoperiod should preferably be less 
than 20 h to have sufficient florfenciol (FF) intake.  
Macrolides are frequently used antibiotics in veterinary medicine. Their mode of action is 
based on inhibition of bacterial protein biosynthesis at the 23S ribosomal RNA in the 50S 
subunit of the ribosome, where they bind to different bases of the peptidyl transferase 
centre and prevent the translocation process (Cobos-Trigueros et al., 2009). Gamithromycin 
(GAM) is a new macrolide and member of the azalide class. At present, it is only registered 
for use in cattle to treat Bovine Respiratory Disease (BRD). GAM is a long-acting antibiotic 
with accumulation in lung tissue as supported by its extended elimination half-life and large 
volume of distribution in several animal species, including turkeys (Huang et al., 2010; 
Giguère et al., 2011; Watteyn et al., 2013a; Wyns et al., 2014; Watteyn et al., 2015). 
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To date, no studies have been reported demonstrating the efficacy of any macrolides in an in 
vivo O. rhinotracheale infection model in turkeys. The remarkable PK and pharmacodynamic 
(PD) properties of GAM are interesting to treat turkeys of an O. rhinotracheale infection. 
Therefore, the aim of this study was to examine the efficacy of GAM in a dual infection 
model with APV/O. rhinotracheale in turkeys. This was examined on basis of clinical signs, 
titration of the bacterium and body weight (BW) gain. Necropsy was performed at different 
time points to evaluate the long-acting properties of GAM. Apart from a single subcutaneous 
(SC) administration, also a single oral (PO) administration was assessed, both at a dose of 6 
mg/kg BW.  
 
Materials and methods 
Micro-organisms 
The O. rhinotracheale strain LMG 9086T was originally isolated from a turkey with a 
respiratory tract infection. The minimum inhibitory concentration (MIC) of GAM against this 
strain is 0.5 µg/mL (Watteyn et al., 2015). LMG 9086T was serotyped as type A in an agar gel 
precipitation test, kindly performed by Prof. Hafez (Institute of Poultry Diseases, Free 
University of Berlin, Germany; Hafez and Sting, 1999). The strain was cultured for 48 h at 37 
°C on Columbia agar (Oxoid Ltd, Basingstoke, Hampshire, UK) with 5% sheep blood in a 5% 
CO2 atmosphere, followed by growing into brain heart infusion broth (Oxoid) for 24 h at 37 
°C with agitation. The cultured bacteria were washed twice in phosphate-buffered saline 
(PBS) followed each time by 5 min of centrifugation at 1509 x g at 4 °C. The bacterial 
challenge inoculum was prepared by resuspending the pellet in PBS to obtain a final 
concentration of 108 colony forming units (cfu)/mL. To confirm the titre, 10-fold dilutions in 
PBS were inoculated on sheep blood agar and the number of colonies was counted. 
The used APV strain A/T6/96 (subtype A) was isolated during a respiratory outbreak on a 
Belgian turkey farm (Van de Zande et al., 1998). The virus stock had a titre of 5.3 log10 50% 
ciliostatic dose (CD50)/mL after the third passage in tracheal organ cultures. 
 
Veterinary drug  
The veterinary drug Zactran (Merial Ltd, North Brunswick, NJ, USA) contains 150 mg/mL 
(15.0% w/v) GAM as active substance in a buffered solution with monothioglycerol, succinic 
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acid and glycerol formal. This commercially available formulation was diluted with aqua ad 
injectabilia up to a concentration of 15 mg GAM/mL (1.5% weight/volume). This solution was 
used for both SC injection and PO dosing. 
 
Animal experiment 
The animal experiment was based on an avian metapneumovirus (APV) – O. rhinotracheale 
challenge infection model described by Marien et al. (2005). Sixty-four one-day-old non-
vaccinated female turkeys (Moorgut Kartzfehn, Bösel, Germany) were housed according to 
European (Anonymous 2010). They were housed in group in an isolation room with HEPA-
filtered air on wood shavings, had free access to feed and water, and the light schedule was 
16 h of light/day. At 18 days of age, they were randomly divided in four groups (16 animals 
each), a negative control group (CONTR-; not infected, not treated), a positive control group 
(CONTR+; infected, not treated) and two treated groups (GAM SC and GAM PO, both 
infected and treated), and each group was housed separately. 
All animals were negative for maternally derived antibodies to APV and O. rhinotracheale at 
2 weeks of age, as tested with enzyme-linked immunosorbent assays (ELISA). Additionally, 
tracheal swabs (Copan Diagnostics Inc., Corona, USA) from all birds were collected one day 
before O. rhinotracheale inoculation and analysed to verify the absence of O. rhinotracheale. 
Table 1 displays the time schedule of the experiment. 
At 22 days of age all animals, except the CONTR- group, were inoculated with 4.4 log10 CD50 
APV, by dividing a total volume of 250 µL of inoculum equally over the nostrils and eyes.  
Three days post-viral infection (p.v.i.), all animals were oculonasally inoculated with 8.5 log10 
cfu O. rhinotracheale as described above. The turkeys in the CONTR- group received an equal 
volume of PBS in the nostrils and eyes. 
The turkeys in the treated groups received at one day post-bacterial inoculation (p.b.i.) a 
single bolus of GAM (6 mg/kg BW) either SC in the neck region (GAM SC) or PO in the crop 
(GAM PO). 
All animals were weighed at the day of O. rhinotracheale inoculation and at the day of 
necropsy. 
A clinical examination of all turkeys was performed daily until 12 days p.b.i., and the clinical 
signs were scored as follows: 0, no clinical signs; 1, clear nasal exudates; 2, turbid nasal 
exudates; 3, nasal exudates with mild swollen infra-orbital sinuses; 4, nasal exudates with 
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extreme swollen infra-orbital sinuses; 5, nasal exudates with extreme swollen infra-orbital 
sinuses and frothy eyes; 6, death.  
Tracheal swabs were collected from all birds for quantification of O. rhinotracheale using 
cotton-tipped aluminium shafted swabs (Copan Diagnostics Inc., Corona, USA) at 1, 2, 4, 6, 8, 
10 and 12 days p.b.i. Swabs were processed immediately after collection and the number of 
cfu/mL was determined as described by Marien et al. (2005).  
Six birds of each group were sacrificed at 4 and 8 days p.b.i., and the remaining four birds 
were sacrificed at 12 days p.b.i. The animals were intramuscularly sedated with a 
combination of xylazine (XylM 2%, VMD, Arendonk, Belgium), zolazepam and tiletamine 
(Zoletil 100, Virbac, Wavre, Belgium), followed by exsanguination.  
Necropsy of all birds was performed to evaluate the presence of gross lesions. Tracheal 
tissue, sampled from larynx to syrinx, and the entire lung were collected for O. 
rhinotracheale quantification. A 10% (w/v) tissue suspension in PBS was prepared from these 
samples. The thoracal air sacs were sampled for bacterial isolation using cotton swabs. All 
samples were processed immediately after collection following the procedure described by 
Garmyn et al. (2009a,b). 
The animal experiment was approved by the Ethical Committee of the Faculty of Veterinary 
Medicine and Bioscience Engineering of Ghent University (EC2013/182). 
 
Table 1. Time schedule of the infection experiment. 
Day  -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 
Infection  APV 
  
ORT 
            
Therapy  
    
X 
           
Clinical score  X X X X X X X X X X X X X X X X 
Tracheal swabs  
  
X 
 
X X 
 
X 
 
X 
 
X 
 
X 
  
Necropsy  
       
n=6 
   
n=6 
   
n=4 
   APV, avian metapneumovirus; ORT, O. rhinotracheale 
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Statistical analyses  
The following parameters were statistically analysed by means of single-factor analysis of 
variance (ANOVA) with Bonferroni correction: body weight, the area under the curve of the 
clinical score from day 2 till day 12 p.b.i. (AUCday 2 to 12 p.b.i.) and O. rhinotracheale titres in 
tracheal swabs. The AUCday 2 to 4 p.b.i., AUCday 2 to 8 p.b.i., both for the clinical score and O. 
rhinotracheale titres in the tracheal swabs, and the titres of O. rhinotracheale in trachea and 
lung tissue on day 4, 8 and 12 were analysed by the Kruskal Wallis test, as these parameters 
were not homogenous. A P value < 0.05 was considered statistically significant. All statistical 
analyses were performed using SPSS 22 (IBM, New York, USA). 
 
Results 
Body Weight 
The mean BW (± SD) for the different groups at several time points are listed in Table 2. Only 
at 8 days p.b.i., the CONTR- had a significant higher BW compared to the infected groups.  
 
Clinical signs 
Mortalities did not occur in any of the experimental groups. The negative control group 
showed no clinical signs and was at all time points negative for O. rhinotracheale. All the 
infected groups had similar mean clinical scores, but GAM SC fully recovered three days 
earlier than the other two groups (Figure 1). As indicated in Table 2, the AUC of the clinical 
scoring from day 0 to the day of necropsy (day 4, 8 or 12) showed no significant difference 
between the infected groups (Table 2). By the last day of the experiment, the remaining 
turkeys of all groups clinically recovered from the APV/O. rhinotracheale infection. 
 
Macroscopic findings 
 At necropsy, no gross lesions were found in any of the birds.  
 
Bacterial titration of tracheal swabs 
The tracheal swabs, collected one day before O. rhinotracheale inoculation were all negative 
for O. rhinotracheale. The bacterial titration of the tracheal swabs were compared between 
groups by means of the AUC from day 0 to day of necropsy (Table 2). The AUCday 2 to 4 p.b.i. of 
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GAM SC was significantly lower than CONTR+.  The other results showed no significant 
differences. As can be seen in Figure 2, the tracheal swabs were positive for O. 
rhinotracheale till day 6 p.b.i. for the CONTR+ group, whereas for GAM SC and GAM PO they 
were positive till day 8 and 10 p.b.i., respectively.  
 
 
Figure 1. Mean clinical score of turkeys inoculated with APV and O. rhinotracheale, and which were 
not treated (CONTR+), or treated with a single dose of 6 mg/kg body weight gamithromycin, either 
subcutaneously (GAM SC) or orally (GAM PO). Turkeys from the CONTR- group were not infected and 
not treated. 
 
 
 
Figure 2. Mean O. rhinotracheale titres in tracheal swabs collected from turkeys inoculated with APV 
and O. rhinotracheale, and which were not treated (CONTR+), or treated with a single dose of 6 
mg/kg body weight gamithromycin, either subcutaneously (GAM SC) or orally (GAM PO). Turkeys 
from the CONTR- group were not infected and not treated.  
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Table 2. Mean ± SD body weight, clinical score and tracheal O. rhinotracheale titres of turkeys inoculated with APV and O. rhinotracheale with an interval of 
3 days, treated once with 6 mg/kg body weight gamithromycin (GAM) subcutaneously (SC) or orally (PO) at 1 day p.b.i. 
Group CONTR- GAM SC GAM PO CONTR+ 
Body weight (kg)     
Before infection 0.81 ± 0.08A 0.80 ± 0.08 A 0.77 ± 0.09 A 0.74 ± 0.08 A 
4 days p.b.i. 0.97 ± 0.11 A 0.96 ± 0.10 A 0.99 ± 0.08 A 0.94 ± 0.15 A 
8 days p.b.i. 1.40 ± 0.09 A 1.18 ± 0.11 B 1.17 ± 0.14 B 1.18 ± 0.12 B 
12 days p.b.i. 1.40 ± 0.37 A 1.66 ± 0.20 A 1.46 ± 0.15 A 1.50 ± 0.05 A 
Clinical score     
AUCday 2 to 4 p.b.i. 0.0 ± 0.0
 A 5.14 ± 1.04 B 5.25 ± 1.21 B 5.36 ± 1.51 B 
AUCday 2 to 8 p.b.i. 0.0 ± 0.0
 A 14.45 ± 2.14 B 15.60 ± 3.00 B 16.33 ± 5.99 B 
AUCday 2 to 12 p.b.i. 0.0 ± 0.0
 A 17.25 ± 1.90 B 18.81 ± 5.38 B 17.50 ± 7.34 B 
O. rhinotracheale titres in tracheal swabs 
AUCday 2 to 4 p.b.i. 0.0 ± 0.0
 A 2.87 ± 2.82 B 4.53 ± 2.47 BC 5.20 ± 2.88 C 
AUCday 2 to 8 p.b.i. 0.0 ± 0.0
 A 13.93 ± 9.31 B 16.75 ± 5.88 B 14.11 ± 8.27 B 
AUCday 2 to 12 p.b.i. 0.0 ± 0.0
 A 21.31 ± 7.83 B 23.73 ± 9.07 B 13.19 ± 7.36 AB 
CONTR-, not infected and not treated; GAM SC: infected and treated with GAM subcutaneously; GAMI PO, infected and 
treated with GAM orally; CONTR+, infected and not treated 
Data presented as mean ± SD. Groups sharing an uppercase superscript letter within one row do not differ from one 
another at the 5% global significance level. 
p.b.i., post bacterial infection  
  
 
Table 3. Isolation of O. rhinotracheale from trachea, lung and airsac samples, expressed as mean ± SD log10 CFU/mL and number of positive samples/number 
tested samples, in turkeys inoculated with APV and O. rhinotracheale with an interval of 3 days, treated once with 6 mg/kg body weight gamithromycin 
(GAM) subcutaneously (SC) or orally (PO) at 1 day p.b.i. 
Group 4 days p.b.i.  8 days p.b.i.  12 days p.b.i. 
Trachea Lung Airsac  Trachea Lung Airsac  Trachea Lung Airsac 
CONTR- 0.0 ± 0.0 A 
0/6 
0.0 ± 0.0 A 
0/6 
0/6  0.0 ± 0.0 A 
0/6 
0.0 ± 0.0 A 
0/6 
0/6  0.0 ± 0.0 A 
0/4 
0.0 ± 0.0 A 
0/4 
0/4 
GAM SC 2.08 ± 1.69 AB 
4/6 
1.04 ± 1.71 AB 
2/6 
 
2/6 
 1.28 ± 3.14 A 
1/6 
0.0 ± 0.0 A 
0/6 
 
0/6 
 0.0 ± 0.0 A 
0/4 
0.0 ± 0.0 A 
0/4 
 
0/4 
GAM PO 2.37 ± 1.19 AB 
5/6 
2.21 ± 1.17 BC 
5/6 
 
2/6 
 0.0 ± 0.0 A 
0/6 
0.0 ± 0.0 A 
0/6 
 
0/6 
 0.0 ± 0.0 A 
0/4 
0.0 ± 0.0 A 
0/4 
 
0/4 
CONTR+ 4.23 ± 2.20 B 
5/6 
3.27 ± 1.64 C 
5/6 
 
2/6 
 0.42 ± 1.02 A 
1/6 
1.20 ± 1.32 B 
3/6 
 
0/6 
 0.0 ± 0.0 A 
0/4 
0.0 ± 0.0 A 
0/4 
 
0/4 
CONTR-, not infected and not treated; GAM SC: infected and treated with GAM subcutaneously; GAMI PO, infected and treated with GAM orally; CONTR+, infected and not 
treated; 
Data presented as mean ± SD. Groups sharing an uppercase superscript letter within one column do not differ from one another at the 5% global significance level. 
p.b.i., post bacterial infection 
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Bacterial titration in tissue samples  
The results of the isolation of O. rhinotracheale from the necropsy samples are shown in 
Table 3. At 4 days p.b.i., 4/6, 5/6 and 5/6 of the trachea samples were positive for O. 
rhinotracheale in the GAM SC, GAM PO and CONTR+ groups, respectively. The mean 
bacterial titres of these samples were 2.08 and 2.37 log10 cfu/mL for GAM SC and GAM PO 
groups, respectively, whereas the titre of the CONTR+ group was about 2 log10 higher (4.23 
log10 cfu/mL). The O. rhinotracheale titres of the lung samples at 4 days p.b.i. were 
significantly lower for the GAM SC group compared to CONTR+. For all infected groups, two 
out of six airsac samples were positive. At 8 days p.b.i., only the lung samples of the CONTR+ 
group were positive for O. rhinotracheale, resulting in a significant difference with the GAM 
SC and GAM PO groups. All samples were negative at 12 days p.b.i. 
 
Discussion 
This is the first study investigating the in vivo efficacy of a macrolide antibiotic against O. 
rhinotracheale infections in turkeys.  
The commercial formulation of GAM is registered for SC use in cattle only. Accordingly, GAM 
was also administered SC in this study. On the other hand, as mass medication through 
drinking water is the most important route of drug administration in poultry, the same 
diluted formulation of GAM was also given orally as a single bolus in the crop at the same 
dose. An earlier study demonstrated different plasma PK properties of GAM between both 
routes of administration in turkeys, mainly with respect to the bioavailability. There is a 
lower absorption of the antimicrobial after PO administration compared to SC, with a 
relative bioavailability of GAM after PO administration of only 25% (Watteyn et al., 2015). In 
the current study, a slightly improved clinical recovery was observed after SC administration 
of GAM, compared to the PO administration. This can be explained by the PK parameters in 
lung tissue, since a difference in mean maximum concentration obtained after single SC and 
PO administration of the same dose was seen in lung tissue, i.e. 3.66 and 2.22 µg/g after SC 
and PO administration, respectively (Watteyn et al., 2015). Moreover, the mean elimination 
half-life of GAM in lung tissue was 92.6 and 59.9 h after SC and PO administration, 
respectively, which implies a longer availability of the drug in lung tissue after SC dosing.  
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In contrast with florfenicol therapy by continuous drinking water medication during 5 days 
(Marien et al., 2006; Watteyn et al., 2013b), no re-emergence of the bacterium could be 
determined in the period after drug administration. These findings can be supported by the 
PK/PD profile of GAM in turkeys (Watteyn et al., 2015). The results of this earlier study 
indicated that lung concentrations were above the MIC of GAM against O. rhinotracheale 
strain LMG 9086T during a rather long period (5 and 10 days after PO and SC administration, 
respectively). Also after this period, GAM can still be efficacious as it is known that 
macrolides exert an important post antibiotic effect (Andes et al., 2004). However, O. 
rhinotracheale was detected for a longer period in the tracheal swabs in the treated groups, 
compared to the CONTR+ group. This might be due to a higher distribution of GAM to lung 
tissue compared with trachea. However, no PK study of GAM in trachea tissue has been 
performed. 
 
Recent MIC determinations for GAM revealed that 14 of the 38 O. rhinotracheale isolates 
tested, did not belong to the wild type population, with MIC50 and MIC90 values of 2 and >32 
µg/mL. Consequently, if GAM is used in the field for treatment of O. rhinotracheale 
infections, preferably antimicrobial susceptibility testing should be performed on isolates 
associated with the disease outbreak. As until now, GAM has not been used in poultry, 
acquired resistance against this antimicrobial is most probably due to cross-resistance with 
other antimicrobials. Indeed, depending on the resistance mechanism, cross-resistance may 
occur with other macrolides, lincosamides and streptogramin B antibiotics (Leclercq and 
Courvalin, 1991; Zhanel et al., 2001). High MIC50 values against O. rhinotracheale isolates 
have been published for the 16-membered macrolides tylosin (32 µg/mL) and tilmicosin 
(>128 µg/mL), which have been registered for use in poultry in several countries (Devriese et 
al., 2001; Schwarz et al., 2012). 
 
Conclusion 
Although no significant difference of clinical improvement could be noticed, GAM was able 
to reduce the titres in tracheal swabs in the early stage and in lung tissue compared to the 
CONTR+ group, suggesting a moderate efficacy of GAM against O. rhinotracheale infections 
in turkeys. This study indicated that a PO bolus administration of the commercially available 
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product was not as efficacious as a SC bolus. This difference between both routes of 
administration is likely due to different PK properties of GAM, especially with respect to lung 
tissue. Therefore, in order to use GAM for oral flock treatment in the poultry industry, dose 
titration and confirmation experiments and an adapted commercial PO formulation are 
needed.  
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To be or not to be, that is the question 
Hamlet – W. Shakespeare 
 
Respiratory diseases are a major problem in intensively reared poultry. It is known that these 
diseases can have multifactorial causes, such as viral and bacterial infections and 
environmental factors. To control bacterial infections, antimicrobial drugs are often applied 
in poultry industry. Also for Ornithobacterium rhinotracheale infections in turkeys, which can 
occur from the age of 2 weeks till slaughter, antimicrobials are often used. The frequently 
used antimicrobial drugs against this pathogen are β-lactams (ampicillin, amoxicillin), 
macrolides (tylosin, tilmicosin, tylvalosin), tetracyclines (oxytetracyclin, doxycycline) and 
fluoroquinolones (enrofloxacin). Resistance against the former antimicrobials has been 
described to some extent. However, florfenicol (FF) and gamithromycin (GAM) are two 
antimicrobials that have the potential to be effective against O. rhinotracheale and which 
are only registered for use in veterinary medicine, although for the moment only for use in 
mammals. 
The general aim of this doctoral thesis was to evaluate the pharmacokinetics (PK) of FF and 
GAM, their pharmacodynamics (PD) and their clinical efficacy in an O. rhinotracheale 
infection model. Figure 1 gives an overview of the study designs used, and the main results 
achieved in this doctoral thesis are summarized in Figure 2. 
 
In this General Discussion, reflections concerning appropriate antimicrobial use and their 
efficacy are mentioned. In particular, the necessity to use antimicrobials, the route of 
administration of a drug to poultry and the usefulness of PK/PD models in turkeys are 
discussed. Afterwards, a general conclusion is made and future perspectives are provided. 
 
  
 
 
Figure 1. Overview of the study designs used in the present doctoral thesis. 
  
 
Figure 2. Overview of the main results achieved in this doctoral thesis.
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To treat or not to treat 
At the end of the latest century, a new concept about comparative medicine was introduced, 
“One Health”. This can be defined as an approach to improve health and well-being through 
the prevention of risks and the mitigation of effects of crises that originate at the interface 
between humans, animals and their various environments (EFSA, 2015). Antimicrobial 
resistance is one of the topics within the field of One Health, as it is a worldwide concern for 
both human and animal health (WHO, 2014).  
To minimize the resistance selection against antimicrobial drugs, the key question in 
veterinary medicine is whether it is always necessary to treat with an antimicrobial or 
whether can the problems be prevented by alternatives such as an improved management. 
Moreover, if a treatment is necessary, which antimicrobial is the best choice and when does 
the treatment have to be started? 
 
The impact of management practices on poultry health is particularly high, because of the 
high stocking density during a production round. Optimal housing temperature and humidity 
as well as low dust and ammonia concentrations are crucial as preventive measures to avoid 
stress and sickness within the flock (Koknaroglu and Akunal, 2013). In addition, the 
photoperiod, or day/night rhythm, is of great importance for the health status. Longer 
periods of darkness give a low metabolic rate during this period, resulting in reduced 
metabolic diseases and consequently lower mortality (Classen et al., 2004). Chickens show a 
better humoral and cellular immune response in a day and night pattern compared to 
constant light regimes (Kirby and Froman, 1991; Moore and Siopes, 2000). Also Schwean-
Lardner et al. (2013) concluded that lighting programs have an effect on infectious diseases, 
with a higher morbidity and mortality with increased photoperiod. Hence, an optimal light 
scheme can result in a reduction of the application of antimicrobials.  
 
To reduce the use of antimicrobials, probiotics can be applied to maintain a good health. 
According to the World Health Organisation (WHO), probiotics are live microorganisms that, 
when administered in adequate amounts, confer a health benefit on the host (WHO, 2002). 
In broiler nutrition, they have a beneficial effect on the digestive tract such as modulation of 
the intestinal microbiota, pathogen inhibition and intestinal histological changes (Kabir, 
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2009). They might also exert immunomodulatory properties, with an effect on the humoral 
and cellular immune response (Koenen et al., 2004). In this respect, there is an indication of 
potential efficacy on infections beyond the gastrointestinal tract.  Oral intake of probiotics 
can indeed affect the severity of respiratory tract infections in humans, such as a common 
cold, with a reduction of the duration of symptoms, total symptoms scores and days with 
fever (de Vrese et al., 2005; Winkler et al., 2005). It can be interesting to study the effect of 
probiotics on respiratory infections in poultry too. In contrast, prebiotics are selectively 
fermented dietary ingredients, such as non-starch oligosaccharides, that result in specific 
changes in the composition and/or activity of the gastrointestinal microbiota (Ducatelle et 
al., 2015). Due to the microbial shift, also the bacterial metabolites can be modified. These 
metabolites can be absorbed into the blood and enter the systemic circulation, where they 
can interact with physiological processes of organs and peripheral tissues (Lenoir-Wijnkoop 
et al., 2007). Whether these prebiotics also have a positive effect on respiratory diseases is 
still unknown. 
 
In spite of preventive measures such as improved management and the use of pro- and 
prebiotics, an antimicrobial treatment is often required. Therefore, it is of great importance 
to make a well-considered selection of the antimicrobial class. The World Organisation for 
Animal Health (OIE) divided all antimicrobials used in food-producing animals in three 
classes, namely critically important, highly important and important (OIE, 2007). This 
classification is based on two criteria. The first is a response on a questionnaire whether the 
antimicrobial class is important. The second criterion is met when compounds within a class 
are identified as essential against specific infections and there is a lack of sufficient 
therapeutic alternatives. As the two antimicrobial drugs used in this research, FF and GAM, 
fulfil criteria 1 as well as 2, they are both classified as critically important antimicrobials.  
The phenicols are more used in animals compared to humans (1.05 and 0.087 mg/kg of 
estimated biomass, respectively) (EFSA, 2015). This is a result of the restricted use of 
chloramphenicol (CAP) in humans due to severe adverse effects such as irreversible aplastic 
anemia and bone marrow suppression (Schwarz et al., 2004) and FF is not registered for 
human use. As CAP is prohibited for use in food-producing animals, FF is the most used 
subclass in veterinary medicine. The resistance in poultry against FF is rather limited. 
According to a Belgian report, Escherichia coli has a high susceptibility for FF (DGZ, 2015). 
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Other gastrointestinal bacterial isolates from poultry, such as bacterial pathogens obtained 
from Campylobacter spp. and Clostridium perfringens, seemed to be highly susceptible to FF 
as well (Gholamiandehkordi et al., 2009; Agunos et al., 2013; Kashoma et al., 2014). FF has 
also a good activity against respiratory pathogens, such as Pasteurella multocida and 
Mycoplasma gallisepticum (Aye et al., 2001; Sellyei et al., 2009; Gharaibeh and Al-Rashdan, 
2011). The current research showed MIC values of 1 µg/mL against O. rhinotracheale. 
Moreover, the clinical study confirmed the efficacy of FF. Accordingly, these interesting MIC 
values as well as the successful in vivo efficacy study proved that FF would be a good therapy 
to treat turkeys suffering from an O. rhinotracheale infection. 
Although macrolides are the second highest selling antimicrobial class in human medicine, 
the total consumption is even higher in animals (11.51 and 8.72 mg/kg of estimated 
biomass, for animals and humans respectively) (EFSA, 2015). In contrast to phenicols, the 
macrolides have several members divided in subclasses, registered for both human and 
veterinary medicine. This wide application makes the macrolides more vulnerable for 
resistance selection because of the existence of cross-resistance between macrolides, 
lincosamides and streptogramin B. The zoonotic pathogen Campylobacter can be resistant to 
veterinary macrolides, such as tylosin, tilmicosin and tulathromycin, but also to the 
macrolides mainly used in human medicine, such as erythromycin, azithromycin and 
clarithromycin (Belanger and Shryock, 2007). This high resistance again several macrolides 
can explain the bimodal MIC distribution of O. rhinotrachele for GAM in the current study. 
Although GAM has never been used in poultry, more than 35% of the tested isolates showed 
acquired resistance (MIC >32 µg/mL). Also against other macrolides, such as erythromycin, 
tylosin and tilmicosin, high MIC values in O. rhinotracheale has been reported (Devriese et 
al., 2001; van Veen et al., 2001). An important issue to mention, is that the susceptibility is 
geographically dependent. Consequently, susceptibility testing of the O. rhinotracheale 
isolate is recommended before starting a treatment. Although the MIC of the used strain in 
our in vivo infection study was low (0.5 µg/mL), the results were not as promising as in the 
FF experiment. The area under the curve of the clinical scores did not differ significantly 
from the control group. Also the bacterial titre in trachea did not reduce significantly 
compared to the control group. 
To choose the most appropriate antimicrobial drug, the mechanism of action is another 
important determinant. The activity of antimicrobials can be either bacteriostatic or 
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bactericidal, but some compounds can exhibit both kinds of effects. GAM administered at 
normal doses acts bacteriostatic, whereas in higher doses the activity becomes bactericidal. 
When to administer a bacteriostatic versus a bactericidal antimicrobial depends on the 
immune response of the host, the bioburden in the host and the pathology of the disease 
process (Martinez et al., 2013). A bacteriostatic antimicrobial will only be effective in the 
presence of an adequate host defence. In case of immunosuppression, a bactericidal drug or 
bacteriostatic drug at bactericidal (higher) dose is recommended (Nemeth et al., 2015). In 
chickens and turkeys, the immunity can be impaired by environmental factors, such as high 
ammonia levels or mycotoxins, and infectious diseases, such as infectious bursal disease and 
Marek’s disease (Hoerr, 2010). Therefore, it is of great importance to know the health status 
of the flock in order to establish a correct treatment. When the bioburden is extremely high 
and when the bacteria synthesize toxins, the administration of a bactericidal antimicrobial 
can give rise to even more damage when the high concentrations of toxins are released from 
the bacterium (Martinez et al., 2013).  
 
An important issue in the treatment strategy is an optimal dose for the desired clinical 
effect. For antimicrobials it is of great importance to increase the efficacy and to reduce the 
selection pressure for resistance (McKellar et al., 2004). Therefore, dosage strategies have 
been developed to determine the best dosing regimen (involving dose rate, inter-dosing 
interval, duration of treatment and modalities of administration) (McKellar et al., 2004). 
These studies have to be perfomed in the target species as the dosage regimen for a drug in 
a given species may depend on its anatomy, biochemistry, physiology, and behaviour, as well 
as on the nature and causes of the condition requiring treatment (Toutain et al., 2010). An 
efficacious dose (ED) is calculated by PK and PD components, namely the clearance (Cl) and 
the bioavailability (F) of the drug (both PK parameters) and the efficacious plasma 
concentration (EC, PD parameter), ED 
     
 
 (Toutain et al., 2010). To determine the best 
plasma concentration, Monte Carlo simulations could be used with several PK and PD 
observations. 
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Beside their anti-infective effects, some antimicrobial agents have also anti-inflammatory 
and immunomodulatory effects. These properties could act synergistically with the 
antimicrobial activity. It has been shown that several macrolides have these properties 
(Kanoh and Rubin, 2010). Macrolides have been described as potent inhibitors of 
inflammation induced by lipopolysaccharide (LPS, a structure of the cellwall of Gram-
negative bacteria). This action relies on the inhibition of the acute phase response by 
decreasing the release of cytokines and acute phase proteins (Kanoh and Rubin, 2010). Also 
pro-apoptotic activities of macrolides were reported (Chin et al., 1998; Lee et al., 2004; 
Fisher et al., 2011). However, it must be mentioned that this inhibitory effect is mainly 
studied in vitro, and especially in vivo studies in poultry are lacking. This has also been 
reviewed by Plessers et al. (2015b) and Wyns et al. (2015a). 
However, for GAM no anti-inflammatory nor immunomodulatory properties could be 
demonstrated in an intravenous LPS challenge model in pigs and calves (Plessers et al., 
2015a; Wyns et al., 2015b). In these studies the animals were clinically scored and also 
several pro-inflammatory mediators, such as cytokines (tumor necrosis factor α, interleukin 
1β and IL-6), acute phase proteins (C reactive protein, haptoglobin, serum amyloid A) and 
eicosanoides (prostaglandin E2), were determined. For FF, in contrast, Zhang et al. (2008) 
found that the drug significantly inhibited murine cytokine production both in vitro and in 
vivo after LPS challenge.  
It would be interesting to study pro-inflammatory cytokines and acute phase proteins to 
investigate the immunomodulatory properties of these antimicrobial drugs in bacterial 
infection models, and to find out if these properties are beneficial to cure poultry from a 
respiratory infection. However, this is not straightforward in poultry. For instance, 
commercially available ELISA kits for avian cytokines or acute phase proteins are scarce 
compared to mammalian ELISA kits. 
 
The start of treatment could also be of importance as it can influence the exposure to the 
antimicrobial agent and also the selection of resistance (Ferran et al., 2009). In poultry 
medicine, a methaphylactic treatment is currently used, which means that all animals in the 
flock that are exposed to the pathogen, even if some do not display symptoms, are treated. 
Because of the high stocking density in poultry rearing, metaphylactic treatment of the flock 
can prevent further spread of the pathogen and cure subclinically infected animals (Hofacre, 
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2002). This also implies that the bacterial load at that moment targeted by the antimicrobial 
is lower compared to a later curative treatment, in which all animals are sick. Consequently, 
lower antimicrobial dosages could be applied to eradicate the bacterial population 
(Morrissey and George, 1999; Udekwu et al., 2009; Ferran et al., 2011). Moreover, due to 
the lower prevalence of mutants in these low inoculums, this early start of treatment may 
lead to a less frequent selection of resistant bacteria (Ferran et al., 2009; 2011). 
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To drink or not to drink 
Drinking water medication is commonly used in the poultry industry to treat sick birds. 
Moreover, other routes of administration are rarely applied in poultry medicine. Some 
difficulties are emerging in the manufactering process starting from an active 
pharmaceutical ingredient towards an efficacious drug, especially for drinking water 
medication.  
 
Flock treatment, mostly conducted by drinking water medication, is easy to perform, it has a 
low economic cost and the welfare of the birds is better as they have less stress (Vermeulen 
et al., 2002). A huge advantage of drinking water medication is the sufficient water uptake 
when birds are sick, while the feed intake is decreased. However, an individual registration 
of the intake of water, and the related drug uptake, is not possible under practical 
conditions. However, Monte Carlo simulations could be used to include the variability in PK 
and PD of the population. Following, different dosage regimens can be evaluated, resulting 
in the prediction of an appropriate regimen which will result in the clinical cure of >90% of 
the animals (Toutain, 2015). 
As drinking and eating behaviour depend on the sleeping/waking rhythm, the intake of drugs 
varies along the day. Consequently, the duration of the photoperiod has an effect on PK 
properties of drugs administered through the drinking water and feed. Accordingly, also the 
efficacy of drugs is influenced by the lighting regime. For antimicrobial drugs which are time-
dependent, it is important to have plasma concentrations or concentrations at the biophase 
above the MIC for a sufficiently long period. Concentrations below the MIC can give rise to 
treatment failure or may induce resistance selection. Thus, in the case of continuous 
drinking water medication, the photoperiod is of great importance (Santos et al., 1997; Lilia 
et al., 2008). Indeed, in the research presented in Chapter 1.1, low FF plasma concentrations 
were observed during the dark period. However, a too short dark period (4 h) can give rise to 
even lower concentrations. Since 2007, the European Union has layed down rules for the 
rearing of meat producing poultry. Concerning the photoperiod, the lighting must follow a 
24-hour rhythm and should include periods of darkness lasting at least 6 h in total, with at 
least one uninterrupted period of darkness of at least 4 h, excluding dimming periods 
(Anonymous, 2007). This doctoral thesis demonstrates that the period of darkness of 8 h is 
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superior to 4 h of darkness. Considering these findings, it is important for every farmer to 
know the water intake of their flocks, as these can depend of the environmental conditions 
(not only of the photoperiod, but also of the temperature or the humidity). Further studies 
could be conducted to relate other evironnmental factors to  the efficacy of antimicrobials.  
 
In case of individual treatment, oral or parenteral, only the sick animals receive the drug and 
this in a correct dosage. However, this is very time consuming and gives more stress to the 
animals due to the manipulation (Vermeulen et al., 2002). Only in eggs and one-day-old 
chicks, individual administration is performed in practice (Hofacre, 2002). In addition, it is 
important for food-producing animals to avoid both tissue damage and the presence of local 
residues after a parenteral administration, especially for long-acting formulations, such as 
GAM (Toutain et al., 2010). 
 
In the development of an adequate drinking water medication, the formulation of the drug 
is the most critical part. Ideally, the optimal drug is highly water soluble, homogenous and 
stable after dissolution, has a high oral bioavailability, a neutral flavour and is palatable. To 
achieve this goal, the addition of excipientia and/or specific formulation techniques are 
needed. 
For drinking water medication a high water solubility of the active substance could be an 
advantage, but this physicochemical characteristic often results in low intestinal 
permeability and oral bioavailability due to the high polarity and poor lipophilicity of those 
drugs (Martinez and Amidon, 2002). On the other hand, highly lipophilic compounds will 
typically have a low aqueous solubility, whereas the permeability will be high. To achieve a 
high oral bioavailability, a balance between these two properties is essential. Several 
pharmaceutical technical methods can increase the aqueous solubility, such as the 
formulation of solid dispersions, particle size reduction, complexation, use of hydrophilic 
carriers or preparations of the amorphous form (Aucamp et al., 2015). In our experiments 
with FF, the medicated drinking water was prepared by stirring an aqueous solution of FF 
standard for 30 minutes, followed by sonication for 20 minutes to dissolve the FF. However, 
these procedures are not feasible in practice. Hence, the major challenge is to develop a 
water soluble formulation for the lipophilic molecule FF that can be used in poultry practice. 
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The oral bioavailability of a drug is affected by the rate and extent of its absorption into the 
enterocytes from the gut lumen, but also by the possible presystemic elimination by the 
intestine and liver before it reaches the systemic circulation (Kwon, 2001). A low oral 
bioavailability can be due to gastric instability, low solubility, limited permeability or high 
intestinal and hepatic first-pass metabolism (Padovan et al., 2012). Also the presence of feed 
additives, for instance mycotoxin binders, can reduce the oral bioavailability by forming 
complexes between the drug and the binder (Devreese et al., 2012; De Mil et al., 2015). 
However, the feeding status of the animal (fed or fasted) and the inclusion rate of the binder 
can influence the extent of interaction. Although macrolides have excellent PK properties, 
such as a rapid absorption, very high tissue distribution with high tissue to plasma ratios and 
a long elimination half-life, the oral bioavailability can be considered low in most animal 
species. In chickens, tylosin has an oral bioavailability lower than 30% (Kowalski et al., 2002; 
Ji et al., 2014). The current formulation of GAM, intended for SC use, has also a low oral 
bioavailability in turkeys. Compared to a SC administration, the relative oral bioavailability 
was only 25%. As the absolute bioavailability in chickens is 100% after SC use (Watteyn et al., 
2013a), we can suggest that this is also 25% after oral administration. If GAM would be 
considered to be used in poultry medicine to treat respiratory infections, a new and better 
water soluble formulation has to be developed. 
Guggenbichler et al. (1985) stated that the intestinal commensal microbiota is less exposed 
to the antimicrobial when antimicrobials are administered parentally compared to orally, 
leading to more limited resistance selection. This is however highly dependend on the PK 
characteristics of the compound, e.g. oral bioavailability, intestinal secretion and route of 
excretion (renal vs biliair). However, a study with enrofloxacin in broiler chickens 
demonstrated that the intestinal microbiota is exposed to high levels of the antimicrobial, 
after oral as well as parenteral therapy (Devreese et al., 2014) although enrofloxacin is 
mainly renally excreted. Further investigation about the impact of the intestinal levels on 
resistance selection in the intestinal microbiota is needed.  
 
Whether to treat with a bolus, single or multiple, or continuous administration of an 
antimicrobial depends on the activity of the drug.   
For a concentration-dependent antimicrobial, for example fluoroquinolones, a high Cmax and 
a low tmax is advised for a maximal antibacterial effect. To obtain such high plasma 
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concentrations, a concentrated bolus administration is recommended (Sumano et al., 2003). 
This could be obtained via the normal drinking water system, with the use of a dispenser. To 
ensure rapid consumption of the medicated drinking water, it is advised to restrict drinking 
water 1 h before onset. 
FF and GAM are both time-dependent antimicrobial agents, in which an extended residence 
time above the MIC is important to achieve a good efficacy. Hence, continuous drinking 
water medication is an excellent method to administer FF. In our study, the plasma 
concentrations in turkeys were below or just around the MIC of 1 µg/mL during continuous 
drinking water medication at a dose of 30 mg/kg BW/day. Remarkably, after the oral bolus 
administration of the same dose, the T>MIC was more than 12 h. This suggest that a bolus is 
a more efficacious method to administer FF, as the disadvantage of a variable uptake is 
minimized. In practice, a pulsed dosage of 30 mg/kg BW each day, during 5 successive days 
can be administered in the drinking water to turkeys. 
In contrast to FF, GAM is a long acting antimicrobial in which a single bolus could be 
sufficient to reach adequate concentrations. After single SC administration of 6 mg/kg BW, 
the plasma levels remained below the MIC of 2 µg/mL. However, the lung concentrations 
were for a long time (3.5 days) above the MIC. As GAM concentration was not determined in 
trachea tissue, it is unknown to what extent GAM distributes to trachea tissue. After SC as 
well as PO administration, GAM was able to reduce the titre of O. rhinotracheale in trachea 
and lung tissue. But only the SC injection could significantly decrease the bacterial titre in 
lung tissue.   
Whether a single oral bolus of GAM would be sufficient to cure from a respiratory infection 
is still unknown. An appropriate formulation of GAM for oral dosing should be developed 
and applicated to a higher dose. 
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To extrapolate or not to extrapolate 
PK and PK/PD studies in mammals are more frequently reported compared to poultry, but 
the extrapolation of the PK properties from mammals to poultry is not straightforward. 
Some antimicrobial agents are widely distributed to tissues, resulting in higher tissue 
concentrations compared to plasma. Currently, the PK/PD indices are only based on plasma 
concentrations, and tissue values are not available. Another variable is the matrix in which 
the MIC is determined. The value of this in vitro PD parameter can vary among 
determination in broth medium, plasma or even tissue. 
 
Allometric scaling is the study of size and all its consequences which has been used for 
several decades in the field of drug development (Mahmood, 2005). Laboratory animals, 
such as mice, rabbits and pigs, are used for selection and screening of pharmaceutical 
compounds for human medicine. In veterinary medicine, the off-label use of veterinary 
drugs and eventually human drugs is quite common. This inaccuracy of extrapolation can 
lead to ineffectiveness or even toxic reactions. Mammals and birds differ in many aspects, 
such as cardiovascular, hepatic and the gastrointestinal, urinary and respiratory tract. These 
differences have consequences for the ADME processes of drugs (Dorrestein, 1992; Baert 
and De Backer, 2003; De Backer, 2006; Neirinckx et al., 2010, 2011). Therefore, PK studies in 
the species of interest are essential to predict the efficacy of drugs. 
The anatomy and physiology of the gastrointestinal tract are key determinants for the oral 
absorption of drugs. In contrast with mammals, avian species have a crop, a glandular 
stomach and a gizzard. In chickens, the pH in these regions is around 4.5 (Jimenez-Moreno et 
al., 2009), whereas the pH in the stomach is much lower in mammal species. These 
differences have an impact on drug absorption based on the ionization of the compound, 
which depends on the pKa of the drug (Rivière, 2011). The presence of Lactobacillus spp. in 
the crop can inactivate macrolides, which can result in a lower bioavalability of the drug 
(Devriese and Dutta, 1984). 
The distribution of drugs is affected by plasma and tissue protein binding. Between 
mammalian and avian species, but also among avian species, there is variety in the 
occurrence of binding proteins as well as the extent of protein binding (Baert and De Backer, 
2003; Antonissen et al., 2015). 
General Discussion 
149 
Biotransformation can be performed through various metabolic pathways, which can be 
divided in phase I and phase II reactions. The cytochrome P450 enzyme complex (CYP450) 
superfamily holds the most important enzymes of phase I biotransformation. In humans, 
CYP3A is predominant and is responsible for the biotransformation of 50% of the therapeutic 
drugs (Zhang et al., 1999). The avian isoform, CYP3A37, is 60% homologous to the human 
CYP3A4 (Ourlin et al., 2000). As a large variability between these CYP enzymes among animal 
species exists, extrapolation is difficult (Nebbia et al., 2001). Glucuronidation, sulfatation, 
methylation, glutathione conjugation and amino acid conjugation are major phase II 
reactions in the biotransformation of drugs. The most important amino acids participating in 
conjugation reactions are glycine, glutamine, taurine and ornithine (Kasuya et al., 1999). 
However, ornithine conjugation occurs only in birds and reptilian species, but has not been 
reported in mammalian species (Igarashi et al., 1992). Even among bird species differences 
in phase II reactions exist (Baert and De Backer, 2003, Baert et al., 2004). In anseriformes 
and galliformes the ornithine conjugation is of more importance compared to the 
glucoronide pathway, whereas in columbiformes the ornithine conjugation is absent (De 
Backer, 2006). 
The total body clearance measures the total ability of the living organism to eliminate a 
drug. To compare the elimination of drugs between animal species, the relative organ size 
and relative blood flow of the eliminating organs must be taken into consideration. In 
general, they both decrease when animal size increases. Since the liver and kidneys are the 
most important organs for the elimination of drugs, the relative amount of hepatic enzymes 
and relative number of nephrons/g weight of kidney tissue, which can be defined as the 
intrinsic clearance, as well as the hepatic and renal blood flow are of great importance. They 
are all negatively correlated with the body size. Therefore, it is stated that smaller species 
will eliminate drugs more rapidly compared to large animals (Lin, 1995; Baert and De Backer, 
2003; Toutain and Bousquet-Mélou, 2004; Neirinckx et al., 2011; Singh et al., 2011; 
Antonissen et al., 2015).  
Remarkably, it has to be mentioned that the structure of avian nephrons is heterogeneous. 
At the surface of the kidney, small nephrons with simple glomeruli are located, the so-called 
reptilian type (RT) nephrons. Nephron size increases with depth from the kidney surface 
onwards and result in more complex nephrons, the mammalian-type (MT) (Goldstein and 
Skadhauge, 2000). The sum of the single nephron glomerular filtration rates (SNGFR) is the 
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whole kidney glomerular filtration rate (GFR). Since the SNGFR increases with the complexity 
of the nephron, it is higer in MT nephrons compared to RT nephrons. The GFR varies with 
the body weight (BW) of the animal and for birds following equation can be used for 
allometric scaling, GFR   1.24   B 0.69. Additionally, for the extent of Cl, one can make a 
distinction between the feeding behaviour of animals, with increasing clearances from 
carnivores towards omnivores and herbivores (Toutain et al., 2010). In turkeys, the Cl of 
both FF and GAM was higher compared to mammals. This was also seen in PK studies of 
other drugs in birds in comparison with mammals, which is consistent with higher metabolic 
rates in birds (Baert and De Backer, 2003; Toutain and Bousquet-Mélou, 2004; Neirinckx et 
al., 2011; Singh et al., 2011; Watteyn et al., 2013a). 
Beside the specific types of nephrons, avian species also has a specific anatomical 
characteristic in the kidneys, i.e. a renal portal system. The renal portal vein functions like an 
artery by carrying blood to the tubules and this is controlled by valves. If drugs are injected 
into the legs of birds (IM, SC or IV), they can be excreted directly by the renal tubules before 
entering the systemic circulation (Lumeij, 1994). 
 
The current PK/PD indices, T>MIC, AUC/MIC and Cmax/MIC, have some limitations.  
As macrolide concentrations in tissue are often substantially higher compared to plasma 
concentrations and the PK/PD indices are limited to plasma concentrations, the 
interpretation of PK/PD analyses is ambiguous. Therefore, PK/PD data at the site of action, 
are more clinically relevant (Andes et al., 2004; Barbour et al., 2010; Giguère and Tessman, 
2011). Still, the interpretation of these results is difficult, as no PK/PD cut-off values for 
tissues have been established. GAM showed very high AUC/MIC values in lung tissue (233 
after SC administration), whereas the plasma values were much lower (only 3.43 after SC 
administration). Also for other macrolides, low plasma AUC/MIC ratios were correlated with 
good efficacy (Craig, 2001; Lodise et al., 2005; Martinez et al., 2013). More research should 
be performed to figure out if the current cut-off values for plasma can be extrapolated to 
tissue. An antimicrobial could be efficacious in more than one tissue, but to which extent a 
drug distributes to a specific tissue is not known. Therefore, specific tissue PK/PD could be 
needed. In contrast, Toutain et al. (2015) argued that plasma or serum concentrations can 
explain the efficacy of a drug without postulating the tissue as a reservoir. They 
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demonstrated the applicability of the PK/PD cut-offs of tulathromycin in serum as these cut-
off were consistent with the current breakpoints issued by CLSI. 
 
It should be mentioned that the current PK/PD indices T>MIC and AUC/MIC, are obtained for 
a single 24 h observation time point in steady-state conditions. Some antimicrobial agents, 
like GAM, act longer than 24 h, implying that this approach is not suitable. Toutain et al. 
(2007) stated that by dividing the AUC/MIC by the time interval of interest, a more universal 
metric is obtained. By using this alternative definition, the same metric can be applied to 
nearly any dosing regimen that may be used in steady-state conditions or single bolus 
administration. When implementing this information on our data, the distinction in PK/PD 
index reduces between SC and PO administration, from 233 and 90 to 0.49 and 0.38 for 
AUC/MIC and AUC/MIC/time, respectively (with time = 480 h and 240 h for SC and PO 
administration, respectively). Therefore, the value of this index has to be further defined. 
Also the use of Monte Carlo simulations to determine PK/PD cut-offs should be more 
encouraged. This approach will give hypothetical population information and are crucial to 
come to an optimal dosage regimen. 
 
Nowadays, it is standard practice to determine the MIC in artificial broth, in which there is 
no influence of in vivo matrices, such as binding proteins and pH. However, only the 
unbound, free fraction of a drug is active. Consequently, when a drug is highly bound to 
plasma proteins (e.g. tetracyclines), the MIC in plasma could be higher compared to broth, 
with a lower killing and post antibiotic effect. On the contrary, the MIC of macrolides can be 
lower in medium supplemented with serum. Bruyck et al. (2012) found that the permeability 
of P. aeruginosa was decreased and the expression of efflux pumps was increased in artificial 
medium. This results in more resistance against antimicrobials. Also GAM has a better effect 
in serum, suggesting the existence of a potentiating factor in serum (Mitchell et al., 2013). 
The comparison between an artificial and a more physiological relevant matrix is therefore 
worth to be carried out to know the clinical relevance of MIC values, especially for the 
classes of antimicrobials of which differences between plasma and broth have already been 
reported (Mouton et al., 2007; Dorey et al., 2014). 
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Also breakpoints for veterinary antimicrobials have to be further determined. CLSI has 
already reported some breakpoints for veterinary pathogens (CLSI, 2013), but it is necessary 
to extend this list. Also the veterinary division of EUCAST (VetCAST) intends to list 
breakpoints for antimicrobials for veterinary use in Europe (Veldman, 2015).  
 
The difference between drug analysis in lung tissue versus PELF has been discussed in 
Chapter 1.2. For antimicrobials which reach high intracellular concentrations, such as 
macrolides, PELF samples would be better because tissue homogenates could overestimate 
extracellular concentrations in relation to PELF (Giguère and Tessman, 2011). Although high 
concentrations of GAM were detected in PELF of cattle as well as foals (Giguère et al., 2011; 
Berghaus et al., 2011), no GAM could be detected in PELF of turkeys. An explanation could 
be the different collection method for PELF and the difference in anatomy and physiology of 
the respiratory tract between mammals and birds. However, the same methodology was 
used for PELF sampling in the FF study, in which FF was detectable in PELF although at low 
concentration. Also differences in intracellular distribution of drugs between mammals and 
birds could explain the very low concentrations of GAM in PELF, as avian macrophages are 
not constitutively present in PELF (Härtle and Kaspers, 2014). Accordingly, as GAM is more 
concentrated intracellularly than FF, the GAM concentrations in PELF might be lower. 
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To conclude and to look forward 
According to the presented PK/PD characteristics and in-depth clinical study, it is clear that 
the use of FF in drinking water can lead to a clinical efficacy for O. rhinotracheale infections 
in turkeys.  
For GAM, the PK/PD characteristics seem to be beneficial for the treatment of an O. 
rhinotracheale infection in turkeys, especially for lung tissue, in case of SC administration.  
 
It is generally accepted that drinking water medication is the best option to treat intensively 
reared poultry. In the current experiments, it was demonstrated that the light scheme is a 
major issue in the administration of medicated drinking water and drug uptake, which can 
lead to substantial variability in drug concentrations and efficacy related to different 
photoperiods. 
 
As the water solubility of FF is low, it is clear that the active substance FF as such is not 
applicable for drinking water medication. Therefore, it is advisable to develop a water 
soluble and stable formulation.  
Additional research on GAM should also be considered to develop a suitable formulation for 
oral dosing and to determine an efficient oral dose for GAM in poultry. Moreover, efficacy 
against other important avian pathogens of the respiratory tract, such as Mycoplasma spp, 
has to be studied as well in vitro (MIC determination) and in vivo field studies. 
It has to be emphasized that PK and PD characteristics, and the related PK/PD indices, of 
pharmaceuticals have to be evaluated in the species of interest as extrapolation is complex 
and mostly impossible. Moreover, it is advisable that adjustments for the PK/PD indices for 
drugs with a high tissue affinity and a long action is required. Also the determination of 
clinical breakpoints for veterinary pathogens for FF and GAM are requisite for further PK and 
PD research, as well as the definition of turkey specific PK/PD breakpoint values. Also more 
elaborate clinical trials with inclusion of placebo controls can give information on clinical 
breakpoint to define the relationship between measured MIC and probability of cure. 
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Ornithobacterium rhinotracheale is a common avian respiratory pathogen that often affects 
turkeys during the production round, resulting in significant economic losses. In the course 
of outbreaks, antimicrobial therapy is applied, but careful attention should be paid to 
posology, clinical efficacy of antimicrobials and potential antimicrobial resistance.  
Florfenicol (FF) and gamithromycin (GAM) are antimicrobial agents which are commonly 
used in veterinary medicine to treat respiratory infections. Due to their remarkable 
pharmacokinetic and pharmacodynamic (PK/PD) properties in several mammal species, 
these drugs may have the potency to cure turkeys from an O. rhinotracheale infection.  
In poultry, medication is mainly administered through the drinking water. However, when 
administrating medicated drinking water, drug intake can substantially vary among animals 
due to animal specific as well as environmental factors, such as light and feeding schemes. 
Hence, gaining insight into the importance of these factors is mandatory for the 
establishment of an efficient treatment protocol.  
Therefore, the GENERAL AIM of this doctoral thesis was to evaluate the pharmacokinetics of FF 
and GAM, which are both not currently used in poultry, and to study their efficacy against an 
O. rhinotracheale infection in turkeys. 
The GENERAL INTRODUCTION gives an overview of the respiratory infections in poultry, with a 
focus on O. rhinotracheale infections in turkeys. Currently, the main strategies to control O. 
rhinotracheale infections are the adjustment of management practices and, in case of 
bacterial outbreak, antimicrobial treatment. Although a vaccine is available, it is not 
frequently used in the field, due to the seroselectivity of the vaccine. Next, more information 
about drug administration in poultry in general is given and more specific, the importance of 
medicated drinking water is emphasised. Subsequently, general principles of PK/PD of 
antimicrobials are outlined and the physicochemical properties, mechanism of action and 
resistance, and PK and PD characteristics of FF and GAM are presented. 
Since a proper therapeutic effect relies on the understanding of the PK as well as the PD 
characteristics, it is important to obtain these data in the species of interest. CHAPTER 1 
describes the PK and PD characteristics of FF (CHAPTER 1.1) and GAM (CHAPTER 1.2) in plasma, 
lung tissue and pulmonary epithelial lining fluid (PELF) in turkeys, with respect to O. 
rhinotracheale.  
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After a single oral bolus administration of 30 mg/kg body weight (BW), FF was rapidly 
absorbed in plasma and rapidly distributed into the respiratory tract (tmax = 1.0 h for plasma 
and lung tissue). The mean half-life of elimination (t1/2el) in plasma and lung tissue was 
similar, around 6 h, whereas it was slightly higher in PELF, namely 8.7 h. In plasma, the mean 
maximum concentration (Cmax) was twice as high as in lung tissue, 4.26 µg/mL and 2.64 µg/g, 
respectively, while in PELF it was much lower, namely 0.39 µg/mL. On the other hand, during 
drinking water medication (5 days at a dose of 30 mg/kg BW/day), FF concentrations were 
higher in lung compared to plasma, resulting in lung/plasma concentration ratios above 1. 
The minimum inhibitory concentration (MIC) of FF for O. rhinotracheale was determined at 1 
µg/mL for both the MIC50 and MIC90.  After an oral bolus, the time above the MIC90 (T>MIC) 
was 67.4% and 50.0% of a 24 h interval in plasma and lung tissue, respectively, but PELF 
concentrations never exceeded the MIC90. After drug administration through drinking water, 
lung and PELF concentrations were never above the MIC90. Furthermore, during medicated 
drinking water treatment, different light and feeding schemes were evaluated and an 
important influence was demonstrated of the photoperiod on the PK of FF. During 16 h of 
light, the T>MIC was more than 40%, whereas it was less than 40% during a lighting period of 
20 h. Therefore, it can be advised that a photoperiod of 16 h is preferred above 20 h to have 
sufficient FF intake via drinking water. No influence of feed restriction was observed. 
The second antimicrobial, GAM, was given as a single subcutaneous (SC) or oral (PO) bolus at 
a dose of 6 mg/kg BW. The mean plasma Cmax after PO administration was a ten-fold lower 
than after SC injection (0.087 and 0.89 µg/mL, respectively). Mean maximum lung 
concentrations were significantly higher compared to plasma levels for both routes of 
administration (2.22 and 3.66 µg/g for PO and SC, respectively). Consequently, lung/plasma 
ratios were up to 50 and 80 after PO and SC administration of GAM, respectively. Although, 
GAM could not be detected in PELF. The MIC50 and MIC90 for O. rhinotracheale against GAM 
was determined at 2 and >32 µg/mL, respectively. For PK/PD correlations the MIC90 of the 
susceptible population (2 µg/mL) was taken into account. For lung tissue the T>MIC was 1 
day after PO bolus and 3.5 days after SC administration. The area under the curve (AUC)/MIC 
ratio for lung tissue was 90 and 233 after PO and SC administration, respectively, whereas 
this was only 1.1 and 3.4 in plasma after PO and SC administration. 
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In CHAPTER 2 the efficacy of FF (CHAPTER 2.1) and GAM (CHAPTER 2.2) was determined in an in 
vivo O. rhinotrachelae infection model in turkeys. In both experiments, the birds were 
infected with avian metapneumovirus (APV) and O. rhinotracheale, followed by a treatment 
with either FF or GAM. 
FF was given as a 5-day treatment at a dose of 30 mg/kg BW/day, administered via drinking 
water.  Different photoperiods and feeding schemes were taken into account. During 
treatment, a clinical improvement could be noticed, resulting in a reduction of the clinical 
score. The results demonstrated an important influence of the photoperiod on the clinical 
outcome in an infection model, with significant lower clinical scores in the groups with 16 h 
of light as compared to the group with  20 h of light. No effect of feed restriction was noticed 
with respect to the clinical outcome. 
GAM was given as a single bolus, either SC or PO, at a dose of 6 mg/kg BW. After SC 
administration of GAM, a slightly better clinical outcome could be noticed and turkeys 
recovered earlier compared to those treated with PO GAM and the non-treated group. After 
SC as well as PO administration of GAM, the bacterial titre of O. rhinotracheale in trachea 
and lung tissue could be reduced. Although, only the SC injection could significantly decrease 
the bacterial titre in lung tissue.   
In CONCLUSION, the presented PK/PD characteristics and the results of the clinical studies 
using a standardised O. rhinotracheale infection model, show that FF and GAM can 
potentially be used in a treatment of O. rhinotrachelae infections in turkeys.  
Because of the poor water solubility, FF as such is not applicable for medicated drinking 
water treatment. Therefore, an appropriate pharmaceutical formulation with a higher water 
solubility and dissolution rate would be preferable. The present studies also confirm the 
importance of the light scheme in medicated drinking water treatment. With respect to the 
clinical trials, FF was able to inhibit O. rhinotracheale in the trachea and lung tissue, resulting 
in clinical improvement. 
For GAM, the PK/PD characteristics were appropriate to cure turkeys from an O. 
rhinotracheale infection, especially for lung tissue. Indeed, the outcome of the clinical study 
could confirm the efficacy of GAM against O. rhinotracheale, but only in lung tissue and after 
SC administration. 
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Ornithobacterium rhinotracheale is een frequent voorkomend respiratoir pathogeen bij 
pluimvee. Voornamelijk kalkoenen worden hiermee vaak besmet tijdens de opfokperiode, 
hetgeen resulteert in grote economische verliezen. Bij een uitbraak wordt er een 
antimicrobiële therapie aangewend, maar hierbij moet steeds aandacht worden besteed aan 
belangrijke aspecten zoals dosering, klinische werkzaamheid van het antibioticum en 
mogelijke resistentieselectie. 
Florfenicol (FF) en gamithromycine (GAM) zijn antimicrobiële geneesmiddelen die voor de 
behandeling van respiratoire infecties frequent gebruikt worden in de diergeneeskunde. 
Door de gunstige farmacokinetische (PK) en farmacodynamische (PD) eigenschappen van 
beide geneesmiddelen in diverse zoogdieren, zouden deze antibiotica ook gebruikt kunnen 
worden bij de behandeling van O. rhinotracheale infecties bij de kalkoen.  
In de pluimveesector dient men geneesmiddelen meestal toe via het drinkwater. Indien 
gemedicineerd drinkwater wordt aangewend, kan de opname van de actieve substantie 
echter zeer sterk variëren tussen de dieren onderling, afhankelijk van zowel fysiologische en 
pathologische omstandigheden bij het dier zelf, alsook omgevingsfactoren, zoals licht- en 
voederschema’s. Daardoor is het nuttig om de invloed van deze factoren te onderzoeken om 
zo een efficiënt behandelingsschema te kunnen bepalen. 
De ALGEMENE DOELSTELLING van dit doctoraat was de evaluatie van de farmacokinetische 
eigenschappen van FF en GAM, die beide momenteel nog geen toepassing kennen in de 
pluimveesector, alsook het nagaan van hun werkzaamheid bij een O. rhinotracheale infectie 
in kalkoenen. 
In de ALGEMENE INLEIDING wordt een overzicht gegeven van respiratoire infecties bij pluimvee, 
met onder meer het aspect van O. rhinotracheale infecties bij kalkoenen. Op dit ogenblik zijn 
de belangrijkste methoden om een O. rhinotracheale infectie onder controle te houden in de 
eerste plaats de aanpassingen van het bedrijfsmanagement en in geval van een bacteriële 
uitbraak, het gebruik van antimicrobiële middelen. Hoewel een vaccin beschikbaar is, wordt 
dit in de praktijk niet frequent gebruikt wegens de serospecificiteit van het vaccin. 
Vervolgens wordt er aandacht besteed aan geneesmiddelengebruik bij pluimvee in het 
algemeen, en in het bijzonder wordt de toediening via gemedicineerd drinkwater besproken. 
Nadien worden de algemene principes van PK/PD uitgelegd om tenslotte de fysicochemische 
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eigenschappen, het werkings- en resistentiemechanisme, en de specifieke PK en PD 
eigenschappen van FF en GAM te vermelden. 
Het is bekend dat de therapeutische efficiëntie van een geneesmiddel zowel afhankelijk is 
van de PK als van de PD eigenschappen. Daarbij is het evenwel noodzakelijk dat deze data 
worden verkregen in iedere diersoort waarvoor het geneesmiddel is bestemd. HOOFDSTUK 1 
beschrijft de PK en PD eigenschappen van FF (HOOFDSTUK 1.1) en GAM (HOOFDSTUK 1.2) in 
plasma, longweefsel en pulmonale epitheliale vloeistof (PELF) in kalkoenen, met betrekking 
tot O. rhinotracheale.    
Na toediening van een eenmalige orale bolus van 30 mg/kg lichaamsgewicht (LG) werd FF 
snel geabsorbeerd in het plasma en vervolgens snel verdeeld naar de longen (tmax = 1.0 u 
voor zowel plasma als longweefsel). De gemiddelde eliminatie halfwaardetijd (t1/2el) in 
plasma en longweefsel was nagenoeg identiek, ongeveer 6 u, maar was iets hoger in PELF, 
namelijk 8.7 u. De gemiddelde maximale plasmaconcentratie (Cmax) was dubbel zo hoog als 
de Cmax in longweefsel, 4.26 µg/ml en 2.64 µg/g respectievelijk, terwijl in PELF een veel 
lagere concentratie werd opgetekend (0.39 µg/ml). In tegenstelling tot de rechtstreekse 
orale bolus, werden tijdens de drinkwatermedicatie (5 dagen, dosis van 30 mg/kg LG/dag) 
hogere FF longconcentraties waargenomen dan in het plasma, en was de long/plasma ratio 
dus hoger dan 1. De minimum inhiberende concentratie (MIC) van FF tegenover O. 
rhinotracheale werd vastgelegd op 1 µg/ml, en dit zowel voor MIC50 als MIC90. Na toediening 
van een orale bolus bedroeg de tijd dat de FF concentratie hoger was dan de MIC (T>MIC) 
67.4% voor plasma en 50.0% voor longweefsel tijdens een 24 u interval, maar de PELF 
concentraties bedroegen nooit meer dan de MIC90. Na toediening van het antibioticum via 
drinkwater werden zowel in longweefsel als in PELF geen concentraties bekomen boven de 
MIC90. Tijdens de experimenten met gemedicineerd drinkwater werden ook diverse licht- en 
voederschema’s bestudeerd. De studies toonden aan dat het lichtschema een belangrijke 
invloed had op de PK van FF. De T>MIC bedroeg meer dan 40% wanneer 16 u licht werd 
voorzien, terwijl bij 20 u licht dit lager bleek dan 40%. Daaruit kan worden geconcludeerd 
dat een periode van 16 u licht te verkiezen is boven een 20 u lichtcyclus om tot een optimale 
opname van FF via drinkwatermedicatie te komen. Invloed van voederschema’s op de PK 
van FF werd niet waargenomen. 
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Het tweede antibioticum, GAM, werd toegediend via een eenmalige subcutane (SC) of orale 
(PO) bolus aan een dosis van 6 mg/kg LG. Na toediening van de orale bolus was de 
gemiddelde Cmax in plasma tien maal lager dan na SC injectie (0.087 en 0.89 µg/ml, 
respectievelijk). De gemiddelde maximale longconcentraties waren significant hoger in 
vergelijking met de plasmaconcentraties voor beide toedieningswijzen (2.22 en 3.66 µg/g na 
PO en SC, respectievelijk). Zo waren long/plasma ratio’s tot 50 en 80 na respectievelijk PO en 
SC toediening van het antibioticum. GAM kon echter niet gedetecteerd worden in PELF. De 
MIC50 en MIC90 van O. rhinotracheale voor GAM werden vastgelegd op 2 en >32 µg/ml, 
respectievelijk. Voor de PK/PD correlatie werd de MIC90 van de gevoelige populatie (2 µg/ml) 
in beschouwing genomen. Zo bleek de T>MIC in longweefsel 1 dag na PO en 3.5 dagen na SC 
toediening te bedragen. De oppervlakte onder de curve (AUC)/MIC ratio voor longweefsel 
was 90 en 233 na respectievelijk PO en SC toediening, terwijl voor plasma slechts waarden 
van 1.1 en 3.4 werden opgetekend na respectievelijk PO en SC toediening. 
In HOOFDSTUK 2 werd de werkzaamheid van FF (HOOFDSTUK 2.1) en GAM (HOOFDSTUK 2.2) 
nagegaan in een in vivo O. rhinotracheale infectiemodel in kalkoenen. In beide experimenten 
werden de dieren geïnfecteerd met aviair metapneumovirus en O. rhinotracheale, en 
werden ze vervolgens behandeld met ofwel FF of GAM. 
FF werd continu toegediend gedurende 5 dagen aan kalkoenen via drinkwatermedicatie aan 
een dosis van 30 mg/kg LG/dag. Verschillende licht- en voederschema’s werden toegepast. 
Gedurende de behandeling werd een duidelijk klinische verbetering waargenomen. De 
resultaten toonden ook een belangrijke invloed van het lichtschema aan op de klinische 
score, met significant betere klinische resultaten in de groepen met 16 u licht ten opzichte 
van de groep met 20 u licht. Een effect van de verschillende voederschema’s werd niet 
vastgelegd. 
GAM werd toegediend als een eenmalige SC of PO bolus, aan een dosis van 6 mg/kg LG. Na 
de SC bolus, kon een lichte klinische verbetering waargenomen worden en de dieren 
vertoonden hierbij ook een sneller herstel in vergelijking met de PO en niet-behandelde 
groepen. Door toediening van GAM kon, na zowel SC als PO toediening, de bacteriële titer 
van O. rhinotracheale in trachea en longweefsel worden verminderd. Evenwel, enkel na SC 
injectie van GAM werd de bacteriële titer in longweefsel significant verlaagd. 
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Als CONCLUSIE kunnen we stellen dat de verkregen PK/PD eigenschappen en de resultaten van 
de klinische studies, uitgevoerd in een gestandaardiseerd O. rhinotracheale infectiemodel, 
het mogelijke gebruik van FF en GAM staven bij O. rhinotracheale infectie bij kalkoenen.  
De wateroplosbaarheid van FF is echter vrij laag, waardoor dit geneesmiddel als dusdanig 
momenteel niet toepasbaar is voor drinkwatermedicatie. De ontwikkeling van een geschikte 
farmaceutische formulatie met een hogere wateroplosbaarheid en oplossnelheid dient zich 
dan ook aan. Bovendien werd in deze studies ook een belangrijke invloed van de lichtcyclus 
op de toediening van drinkwatermedicatie bevestigd. In de klinische studies kon door 
toediening van FF O. rhinotracheale duidelijk geïnhibeerd worden ter hoogte van zowel 
trachea als longweefsel, met als gevolg gunstige klinische resultaten. 
Voor GAM waren de PK/PD eigenschappen gunstig om kalkoenen met een O. rhinotracheale 
infectie te behandelen, zeker ter hoogte van het longweefsel. In de klinische studie kon de 
werkzaamheid van GAM tegenover O. rhinotracheale worden aangetoond, maar uitsluitend 
ter hoogte van het longweefsel en enkel na SC toediening. 
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DANKWOORD
  
Als je de tocht aanvaardt naar Ithaka 
wens dat de weg dan lang mag zijn, 
vol wederwaardigheden, vol belevenissen. 
De cyclopen en de Laistrygonen, 
de woedende Poseidon hoef je niet te vrezen, 
zulke ontmoetingen zul je nooit hebben op je weg. 
Wanneer je denken verheven blijft,  
verfijnt de emotie die je hart en lijf beroert. 
De cyclopen en de Laistrygonen, 
de woeste Poseidon zul je niet tegenkomen 
wanneer je ze niet in je eigen geest meedraagt, 
wanneer je geest hun geen gestalte voor je geeft. 
Wens dat de weg dan lang mag zijn. 
Dat er veel zomermorgens mogen komen 
waarop je heel dankbaar, heel blij 
onbekende havens zult binnenvaren. 
Dat je mag pleisteren in Fenicische handelssteden 
om mooie dingen aan te schaffen 
van parelmoer, koraal, barnsteen en ebbenhout, 
en opwindende geurstoffen van alle soorten, 
opwindende geurstoffen zoveel je krijgen kunt. 
Dat je talrijke steden in Egypte aan mag doen 
om veel, heel veel van de geleerden op te steken. 
Blijf wel altijd denken aan Ithaka. 
Daar aan te komen is je doel. 
Maar overhaast de reis in geen geval. 
’t Is beter dat die vele jaren duurt en 
je pas als oude man bij het eiland afmeert, 
rijk door wat je onderweg verwierf, 
zonder verwachting dat Ithaka je rijkdom schenken zal. 
Ithaka schonk je de mooie reis. 
Bestond het niet, dan was je nooit vertrokken. 
Maar meer heeft het je niet te bieden. 
En vind je het armzalig, Ithaka bedroog je niet. 
Zo wijs geworden, met zo veel ervaring 
heb je al wel door waar Ithaka’s voor staan. 
Uit Ilias van Homeros 
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Zoals Homeros beschreef in zijn heldendicht Ilias, is de weg naar Ithaka belangrijker en rijker 
dan de aankomst op het eiland zelf. Zo ook heb ik een fantastische reis meegemaakt de 
afgelopen jaren. Uiteraard bleef deze dag mijn doel, maar de kennis en vriendschappen die 
ik opgebouwd heb, zijn veel meer waard. 
Gedurende de jaren zijn er heel wat mensen met mij meegereisd, voor even of voor de hele 
trip, elk met hun eigen invulling. Zo werd deze reis onvergetelijk! Daarvoor wil ik jullie dan 
ook heel graag bedanken! 
 
Allereerst wil ik mijn promotoren bedanken, zonder hen was er uiteraard geen sprake van 
een doctoraatsthesis.  
Prof. dr. Croubels, Siska, jouw deur staat altijd open, voor een toxicologische vraag, voor 
een zoveelste versie om na te lezen, of gewoon voor een babbel. Na al die jaren aan de 
vakgroep heb ik veel van jou geleerd en heb ik je enorm leren waarderen, voor je 
wetenschappelijke gedrevenheid, je welbekende oog voor detail, maar ook voor je steun en 
optimisme bij moeilijke momenten. Bedankt om er al die jaren te zijn!  
Prof. dr. De Backer, bedankt dat ik aan de vakgroep mocht starten met mijn eigen 
onderzoek. Het heeft wat voeten in de aarde gehad, maar we zijn er uit geraakt. De vele 
historische en culinaire weetjes tijdens de vakgroepuitstappen en congressen zullen me 
altijd bijblijven.  
Prof. dr. Devreese, Mathias… wie had er ooit gedacht dat je zo vroeg in mijn dankwoord 
ging komen. Bedankt om me de laatste jaren bij te staan bij de dierproeven, de analyses en 
het neerpennen van de resultaten! Je was een enorme meerwaarde als promotor van mijn 
thesis. Veel succes nog in je verdere carrière en natuurlijk ook thuis, dat alle wegen mogen 
opengaan . 
 
Ook aan de leden van de examencommissie wil ik mijn oprechte dank betuigen voor het 
kritisch nalezen van dit werk en hun sterk gewaardeerde input in mijn onderzoek. 
Prof. dr. Ducatelle, Rik, de fundamenten voor mijn interesse in diergeneeskunde zijn bij jou 
en Justine gelegd. Bedankt om als voorzitter alles in goede banen te leiden. Prof. Dr. 
Pelligand, Ludo, thank you for making time to come over from the UK and for your 
contributions to the PK/PD integration. Prof. dr. Vanrompay, bedankt om tijd vrij te maken 
voor het lezen van mijn thesis en voor de suggesties. Dr. Boyen, Filip, bedankt voor je tips & 
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trics bij de MIC bepalingen. Dr. Van Hoorebeke, Sebastiaan, door jou wist ik altijd wel 
kalkoenen te vinden. Bedankt voor je advies en om de thesis kritisch na te lezen door de 
ogen van een praktijkdierenarts! 
 
Prof. dr. Meyer, Evelyne, bedankt om mij 7 jaar geleden op te bellen voor de vervanging van 
Heidi en zo mijn carrière aan de vakgroep te laten starten. Na de ommezwaai van mijn 
doctoraat, was de link met de biochemie wat minder, maar toch bedankt voor je blijvende 
interesse in mijn onderzoek. 
Prof. dr. Haesebrouck, Prof. dr. Pasmans en Prof. dr. Martel, bedankt voor de input in het 
realiseren van de dierproeven, en de waardevolle suggesties bij het nalezen van mijn 
artikels. 
 
Een grote dank je wel is zeker op zijn plaats voor de doctoraatscollega’s. Met hen verliepen 
de dierproeven vlotter, ging het labowerk wat sneller vooruit, werd het werk eventjes opzij 
gezet tijdens de lunches en waren er aangename koekjespauzes op donderdagnamiddag. 
Allereerst mijn bureaugenootjes Sophie, Elke en Joske, bedankt voor jullie luisterend oor, 
jullie aanmoedigingen en de aangename vrouwenbabbels. Sophie, mijn assistentenmaatje, 
samen hebben we heel wat cases uitgeklaard en talloze telefoons gepleegd (de een al 
enthousiaster dan de ander ). Bedankt voor de vele fijne jaren, gevuld met chocolade-
shots, caffeïnegeur en gerimpelde appeltjes. Elke G., onze google-madam, niets is voor jou 
te veel! Jij hebt me de laatste jaren met zoveel zaken geholpen, van synoniemen vinden, 
over varkensaangelegenheden tot persoonlijke chauffeur van deze thesis! Bedankt voor al 
jouw hulp en je enthousiasme! Aan jou laat ik ook met plezier mijn taak als vakgroepuitstap-
planner na . Joske, de avonturier die net op tijd terug is . Bedankt voor de gezellige 
momenten en nog veel plezier in de slachthuizen en met de oh-zo-leuke Potter . Meisjes, 
draag zorg voor onze kalender en onze plantjes!!! 
Gunther, jouw pluimveekennis is niet te evenaren! Bedankt voor je weetjes, de oh-zo-
gezellige dierproeven met monsters van beesten  en de plezante congresuitstappen. 
Ook bedank ik graag onze buren, de “jongensbureau”, kwestie van de gender-neutraliteit op 
peil te houden op de vakgroep! Bedankt voor jullie vele hulp! Nathan, veel plezier op je 
wereldreis samen met Marlien, helemaal op jouw ritme “alles kan, niets moet” . Thomas, 
veel succes met het afwerken van je doctoraat en natuurlijk ook in je nieuwe job. Joren, 
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sinds kort mijn stadsgenoot, veel succes nog met de varkentjes en de str*-analyses. We 
komen elkaar wel nog eens tegen in Deinze (in de Colruyt of zo )! 
Wim, een stoere collega met een klein hartje , de naalden zullen wel wennen na verloop 
van tijd! Marianne, beetje bij beetje overwon je je angst voor onze gevederde vrienden en 
voor de kleine roze monstertjes. Bedankt voor je enthousiasme en gulle lach! 
Sandra, de laatste aanwinst van onze vakgroep, veel succes met je onderzoek! Als meter 
maak ik je graag wegwijs op ons labo. 
 
Naast de mededoctoraatsstudenten waren er natuurlijk ook de andere collega’s aan ons 
labo die elk op hun manier bijgedragen hebben tot dit doctoraat.  
Een héél grote dank je wel aan Siegrid! Zonder jouw analytisch vermogen en werkkracht 
waren de analyses van de geneesmiddelen niet gelukt. Ook onze sportieve uitjes op 
donderdagmiddag waren nodig om eventjes stoom (letterlijk en figuurlijk) af te laten. Jelle, 
bedankt om die allerlaatste validaties nog uit te voeren volgens de GLP standaarden (zo was 
alles heel duidelijk voor mij ), maar ook om mij in te wijden in de wondere wereld van de 
toxicologie. Julie, jouw opgewektheid is een plezier om te ervaren in de stal en in het labo. 
Bedankt voor je hulp! An M., onze labo-perfectioniste, jij leerde mij om alles piekfijn uit te 
voeren in het labo. Bedankt voor je opmerkingen (die soms wel nodig waren ) en je advies, 
maar evenzeer voor je luisterend oor! Ann S., een warme persoonlijkheid die we nu wat 
minder zien, maar bedankt voor je gulle lach en de oorbelletjes . Marc, bedankt voor de 
leuke babbels in het labo. Kris, dank je wel voor al jouw pluimvee- en kinetiekkennis, en 
natuurlijk ook voor de overheerlijke honing. Filip, ondanks de stijgende stapels 
aankoopbonnen, facturen, tox-verslagen blijft je enthousiasme enorm groot om steeds klaar 
te staan als administratieve hulp. Merci daarvoor!  
 
Mijn dank gaat ook uit naar de “overkant van de gang”, de collega’s van de Biochemie.  
Kristel, bedankt om mij “in de tijd” de geheimen van flowcytometrie en ELISA mee te geven, 
natuurlijk ook voor jouw enorme gezelligheid en no-nonsense praatjes tijdens de lunch en 
koekjespauze. Jorien, bedankt voor jouw heerlijke chocoladecakes en gezellige babbels over 
zussen en hondjes. Héél veel succes met die soms-vervelende artikels en op naar de laatste 
spurt! Koen en Jonas, het muizenduo van de vakgroep. Veel succes nog met jullie 
baanbrekend kankeronderzoek. En Koen, jouw kennis en doorzettingsvermogen zal mij altijd 
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bijblijven! Femke, helaas geen IWT-beurs, maar hopelijk kan je aan onze vakgroep blijven. 
Veel succes! 
 
A great appreciation to our Italian friends, Elisa and Matteo. Elisa, your work was the start of 
the ORT-subject. Thank you for your contribution to my PhD during your stay in Belgium! 
Matteo, thank you for your help with the FF-analyses and validation on lung tissue! Molto 
grazie per tutti! 
 
Gedurende die 7 jaar, zijn er natuurlijk heel wat mensen de revue gepasseerd. De laatste die 
bij ons wegging was Nathalie, een trouwe kracht als het op administratie aankwam. Bedankt 
voor de vele onkostennota’s, facturen en de gezellige babbels in het secretariaat! Hopelijk 
komen we elkaar nog eens tegen op de sportnamiddag van UGent! Maggy, bedankt om mij 
die eerste jaren altijd een vrolijke morgen te bezorgen en de laatste jaren worden we nog 
steeds verwend met zoetigheden. Sandra, ik heb jouw assistentenplaats, inclusief kippen-
onderzoek, overgenomen. Helaas, of gelukkig? , heb ik het LPS-gedeelte achter mij 
gelaten, toch bedankt voor al jouw kennis. Virginie, onze onderzoeken lagen ver uiteen, 
maar dat deed er niet toe tijdens de lunch/koekjespauzebabbels over de kindjes en onze 
mannen! Nog eens bedankt voor je DGZ-input omtrent ORT! Ann O., bedankt voor de vele 
gezellige uren tussen onze gevleugelde vriendjes, het was TOP! Jouw kipje staat nog steeds 
te blinken op mijn bureau, en het zal ook doorgegeven worden aan de volgende kippen-
onderzoeker! Joline en Anja, de olijke tandem. Ondertussen zijn jullie en onze wegen al wat 
verder uit elkaar, maar ik hoop dat we op tijd en stond tijd vinden voor een brunch of plons-
break. Allebei succes met jullie al-niet-zo-nieuwe job en vele fantastische jaren met jullie 
mannen aan jullie zijde gewenst! Veerle en Nermin, een korte stand-in, maar door jullie hulp 
in het labo, is mijn onderzoek net iets vlotter gegaan, bedankt! En Nermin, probeer je West-
Vlaams te onderhouden tussen die Hollanders daar! De ex-collega’s van de Biochemie, Jella, 
Donna, Bert en Dieter, bedankt voor de aangename samenwerking. Jella en Donna, wij 
komen elkaar nog wel eens tegen, in de Resto of tijdens een AAP-vergadering! Succes met 
jullie onderzoeken! 
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Het bacteriologische luik van deze thesis was niet tot stand gekomen zonder de hulp van de 
diensten Bacteriologie en Pluimveeziekten. In het bijzonder An G., bedankt om mij in te 
wijden in de wereld van de kalkoenen, de trachea-staalnames en om steeds paraat te staan 
om al mijn vragen te beantwoorden. Arlette en Marleen, bedankt voor de hulp in het labo 
met de MIC bepalingen!  
Ook Filip, Wolf en Celine verdienen een woordje van dank. Bedankt voor de gezellige 
uitstapjes in Nantes en Stavanger. Wolf, als je nog eens moeilijk uit je bed geraakt, bel mij 
gerust . 
 
Dan zijn er nog ex-collega’tjes die net iets meer zijn, vriendinnen of zelf “Zusters van de 
DDD”. Eva, jij bent mijn allereerste link met de vakgroep. Als promotor van mijn thesis 
maakte je mij warm om verder in het onderzoek te gaan. Samen hebben we leuke uurtjes 
beleefd binnen en buiten de muren van de Hoogbouw. Voor jou begint er nu een nieuw 
hoofdstuk in jullie nieuwe nest. Maak er samen met Dagmar en Elmer een warme thuis van! 
Heidi, van stille mede-studente, over gezellige zuster, toegewijde mama, ongelooflijk 
gebeten onderzoekster, tot sterke vrouw! Zo heb ik je leren kennen en enorm appreciëren! 
Bedankt voor alle hulp in de stallen en in het labo, de nee-niet-ziek-enkel-nachtelijke-
bloedpunten momenten en de kind-uitstapjes in het weekend. Succes met je job en je 
uitgebreide gezinnetje, en binnenkort komen we wel eens naar het zeetje! Elke P., de 
gedreven wetenschapster voor wie geen enkele tox-vraag te veel was! Bedankt voor je hulp 
met de kippen en kalkoenen, de keuvelmomentjes tijdens de koekjespauze, de tips & trics bij 
de finalisatie van dit doctoraat, en vooral voor je warme aanmoedigende woorden de laatste 
maanden!  
 
Sunny, of is het Prof. dr. Eloot , mijn steun voor de wetenschappelijke publicaties, maar 
ook voor talloze tips voor ontspannende reisjes (met dé Karl!) en gezellige kaas & wijn-
avonden (als het in de agenda staat ). Bedankt voor het nalezen! Nu kan je je volledig 
verdiepen in de PK bij kalkoenen! 
 
Een bijzonder woordje van dank aan Vicky. Zonder jou was het hier thuis niet gelukt! 
Bedankt om al die jaren ons huisje piekfijn te maken! 
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Daniel en Henriette, de liefste buren die we ons konden wensen! Bedankt om ons uit de 
nood te helpen met een patatje, om de kindjes af en toe eens op te vangen en om mijn 
stalbroeken te repareren. Dat we nog lang een babbeltje mogen doen aan “ons hekje”. 
 
En dan de “Moederkes”, Ciska, Marlies, Nele C., Caroline, Lore, Nele D.G. en Lieke. Dat 
blauwe hemd met oranje sjaal bracht ons op een of andere manier bij elkaar. Bedankt voor 
de vele ontspannende momenten! De etentjes, work-outs, cocktailparty’s of filmavonden, ze 
waren allemaal even gezellig en nodig om alles even van mij af te kunnen zetten. Een 
speciaal woordje van dank aan Nele C., mijn sportbuddy, bedankt om er al zoveel jaren te 
zijn, op school, in de KSA en tijdens onze babbelmomentjes in de BBB (sorry Cis ). Onze 
uitdaging voor het komende jaar is de 11 km! 
 
Chloë & Peter, Robbe en Arthur, jullie kan ik niet genoeg bedanken! Jullie staan steeds 
paraat om ons te komen depanneren bij een opvang-probleempje. Bedankt voor de 
zaterdagochtend afspraakjes, de gezellige avondlijke etentjes, de klinkende glazen op 
Nieuwjaar, en zo veel meer. Binnenkort gaan we er weer op uit naar de Ardennen!!! 
 
Lies & Benne, Fé en Cai, ook jullie wil ik bedanken voor de afgelopen jaren! Twintig jaar 
geleden begon onze vriendschap en in al die tijd is er heel wat moois uit voortgevloeid . 
Bedankt voor al die gezelligheid en ik kijk uit naar de komende feestjes!  
 
Mamie en Bonpapa, ook voor jullie een speciaal woordje van dank. Ik denk met veel plezier 
terug aan onze maandagmiddaglunches (met die blonde god ), de verblijfjes aan zee 
tijdens de blok, de verwennerij met verse soep of snoepjes. Dank je wel voor al jullie steun 
en we gaan er samen nog een Duvelke en een Ricardke op drinken (of toch een porto )! 
 
De zusjes… Liesbeth, wij gaan al het langste mee, van ‘malse billetjes’, over een paar 
ruzietjes ;-) tot het uitwisselen van baby-ervaringen. Zus, Nicolas, Juna en Marieke, dank je 
wel voor de steun en de warmte in jullie peperkoekenhuisje! 
Charlotte, onze avonturier. Bedankt voor de no-nonsense babbels, het nalezen van mijn 
artikels en de gezellige onderonsjes bij de kalkoenen. Voor jou is het studentenleven nu ook 
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afgelopen, en trek je er weer op uit. Volg je hart naar waar dan ook, wij komen zeker langs, 
er is slechts 8983.89 km tussen Deinze en San José ! 
Elise, ons jongste zusje. Ook aan jou een dank je wel om mij/ons te steunen de afgelopen 
jaren (nog eens een dikke merci voor al die waterflessen !) en om te komen babysitten 
zodat ik toch eventjes mijn energie kwijt kon tijdens het sporten. Nu is het aan jou om een 
paar jaar (5+…) op die universiteitsbanken te zitten .  
 
Mama en Papa, hier sta ik dan, na 6+6+4+4+6 jaar studeren, met de grootste zelfvoldoening 
! Het lange studeren hebben we alle 4 van niet ver ;-) Dank jullie wel om mij al die kansen 
te geven en om mij en ons gezinnetje te steunen en bij te staan wanneer we het nodig 
hadden. Zonder jullie was dit niet gelukt! 
 
En als laatste, mijn 4 musketiers… een stoere prinses, een sloeber-dondergod, een lieve 
blonde krijger en mijn alles. Amber, ik sluit een lange schoolcarrière af, terwijl jij er net aan 
begonnen bent. Ik weet dat je dat niet goed… maar S PER goed gaat doen! Thor en Finn, 
mijn jongens, jullie kunnen nog even genieten van véél spelen, beetje ruziemaken en de 
wereld ontdekken per fiets of met die kleine voetjes. Dank jullie wel om met een lach en een 
traan ons leven kleur te geven. 
Stijn, in al die jaren hebben we samen vele watertjes doorzwommen (van het 
Grevelingenmeer tot de Rode zee ), knopen (en bomen ) doorgehakt en vele bergen 
verzet. Na 6 jaar hebben we samen deze top bereikt. Het was niet altijd even gemakkelijk, 
maar bedankt om in mij te blijven geloven, om van ons huis een thuis te maken en om er 
gewoon te zijn voor mij! Nu is het aan jou! 
Ik zie jullie graag, helemaal tot aan de maan… en terug! 
 
 
 
 
 
 
